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ABSTRACT
Structure-Function Studies of the Vaccinia Virus Complement Control Protein
Scott Alan Smith
March 27, 2002
The vaccinia virus complement control protein (VCP) is involved in the
modulation of the host inflammatory response during vaccinia virus infection. It
possesses the ability to inhibit both classical and alternative pathways of complement
activation, as well as bind to heparin or heparan sulfate proteoglycans, making it a unique
multifunctional protein with therapeutic potential. VCP is able to block complement
activity through its ability to bind C3b and C4b. Other very novel activities arise from
VCP's ability to bind heparin and heparan sulfate proteoglycans, allowing the protein to
attach itself to cell surfaces. The goal of this research was to fully characterize the
structure and various functions of VCP.
The structural basis for VCP's ability to bind heparin was investigated using
heparin affinity chromatography, surface plasmon resonance analysis, and homology
modeling with well-characterized heparin binding proteins. VCP was found to possess
two regions involved in heparin binding, one involved in weak binding located at the
junction of complement control protein (CCP) modules 1 and 2, and a second involved in
strong binding located at the extreme C-terminal tip of the protein. Additional functions,
involved in blocking molecular interactions with cells, were also identified and
determined to be a result of VCP's ability to bind heparin.
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The structural basis for VCP's ability to bind complement was investigated using
the hemolysis assay, surface plasmon resonance analysis, and homology modeling with
well-mapped complement regulatory proteins. VCP was found to be the smallest
functional unit able to bind and cause factor I cleavage of C3b/C4b, thus inhibiting
complement activity. VCP was also shown to possess the ability to simultaneously bind
and inhibit complement activation, using its entire exposed surface, while remaining
attached to heparin by its C-terminal heparin binding site.
The structure of VCP and its structural and functional stability were determined
using X-ray crystallography, NMR, DSC, and the hemolysis assay. VCP was found to be
an elongated filamentous protein, with defined CCP modular regions with limited
intermodular interfacing, existing as a monomer in solution. VCP was found to possess
the ability to structurally withstand temperatures in excess of 90oC. In addition, VCP was
able to retain functional integrity following exposure to many adverse physical
conditions, which would result in irreversible denaturation of most other proteins.
Lastly, the in vivo pharmacokinetics of VCP was investigated in rats. VCP was
injected as a bolus at different routes and using various concentrations. Continuous and
intermittent intravenous injection strategies were also investigated. In all cases, the
serum CH50 was monitored over time to determine the half-life of VCP activity in the
serum. Traces of intact VCP was detected in urine by SDS-PAGE analysis, giving clues
to its excretion and elimination from the body.
This research has provided greater understanding of the architectural features of a
protein that contribute to heparin and complement binding. In addition, this research may
prove important for the future use of VCP as a novel immunomodulating agent, as well as
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future protein-engineering efforts to design a better treatment for many complement
mediated diseases, such as: Alzheimer's disease, central nervous system (CNS) injury,
systemic lupus erythematosus, and xenograft transplant rejections.
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CHAPTER 1
POXVIRUSES: VACCINIA VIRUS

Introduction
This chapter contains material adapted from the following publications:
Smith S.A., and Kotwal G.J. Virokines: novel immunomodulatory agents. Exp. Opin.
Biol. Ther., 1(3):343-357, 2001.
Smith S.A., and Kotwal G.J. Vaccinia virus. In: Encyclopedia of Molecular Medicine.
John Wiley & Sons Inc., Vol. 5, pp. 3324-3330, 2001.
Smith S.A., and Kotwal G.J. Immune response to poxvirus infections in various animals.
Crit. Rev. Microbiol., In press, 2002.
Vaccinia virus (VV), the most widely studied member of the poxvirus family,
serves as a model to enhance our understanding of this extraordinary family of complex
DNA viruses. Like other poxviruses, which have the largest virions of any animal virus
family, VV virions are substantial in size. They appear as smooth, rectangular sacks,
approximately 350 nm in length by 270 nm in width. Because of its relatively large size,
VV was the first animal virus to have beeen seen microscopically, in 1886. Vaccinia
virus contains a large, linear, double-stranded DNA genome of over 191 kbp. This large
genome is responsible for encoding all the proteins necessary for vaccinia's unique
cytoplasmic lifestyle. Like other members of the poxvirus family, VV replicates almost
entirely independent of the infected cell nucleus. Therefore, being unable to utilize the
host cell's machinery to synthesize RNA or replicate DNA, VV must encode these

important proteins in its own genome. Another interesting feature of the vaccinia
genome is the presence of terminal hairpin loops. The ends of the double-stranded DNA
are covalently linked to form a continuous single-stranded polynucleotide chain (figure
1). This unique telomeric structure seems to be very important in replication.
Upon entry into the host cell, the VV life cycle is naturally divided into three
stages according to gene expression: early, intermediate, and late. Early genes are
expressed via transcriptional regulatory proteins packaged within the infecting virion. It
is during this time that the genome is replicated to high numbers in cytoplasmic factories
(virosomes) through the formation of large concatemers, utilizing many proteins
produced during this early stage of gene transcription. The intermediate stage of vaccinia
replication is defined by a strong spike in gene expression, falling shortly after the
initiation of DNA replication and before the expression of the more abundant late genes.
Late gene expression is responsible for production of the major virion components,
including those that are structurally important and those necessary for early stage gene
expression upon entry into a new host cell. Late gene expression continues to produce
structural proteins that accumulate in large amounts in the cytoplasm, allowing for viral
assembly and maturation for at least 48 hours after infection.
In addition to those viral proteins encoded by VV required for transcription,
replication and virion assembly, there are several nonessential proteins utilized by VV to
establish a suitable habitat. Vaccinia virus encodes a growth factor that, when secreted
from infected cells, results in the proliferation of neighboring cells, increasing the number
of local cells that can be infected by viral progeny. Other interesting nonessential
proteins encoded by vaccinia virus include: complement control protein (VCP),
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Figure 1. Vaccinia virus genome organization. The vaccinia virus genome is a very
large double stranded DNA. The end 5% of the genome is made up of inverted terminal
repeats and the very ends are covalently closed by terminal hairpin loops. The genome is
divided into three main areas: variable left end, conserved central region, and variable
right end. Listed are many of the important proteins coded by these areas of the vaccinia
virus genome.
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interleukin one receptor (IL-1R) homologue, tumor necrosis factor receptor (TNFR)
homologue, and interferon receptor (IFNR) homologue. Although not all of the
nonessential proteins have been studied, each is presumed to play an important role in
modulating the host's immune response to infection, thereby maintaining the viral habitat.
Vaccinia virus also played an important role in the eradication of the deadly
variola virus. Edward Jenner, in 1796, started immunizing individuals with a very close
relative of VV, cowpox virus (CPV). Eventually, VV replaced CPV as the chosen
vaccine, and the World Health Organization (WHO) launched its extremely successful
eradication campaign. Interestingly, the exact origin of VV still remains a mystery today.
It is postulated that VV arose in the 19th or early 20th centuries from all the mixing of
vaccine strains (or possibly variola and cowpox), since the nature of viruses was still quit
unknown at that time. Therefore, it is still believed that the lack of a natural host
reservoir and broad host range exhibited by vaccinia virus is due to its creation in a
laboratory.
As mentioned earlier, the poxvirus family, Poxviridae, has the largest virions of
any animal virus family. They appear oval or brick shaped, approximately 350 nm in
length and 270 nm in width. Poxviruses contain a large, linear, double-stranded DNA
genome of 130-280 kbp. This large genome is responsible for encoding all the proteins
necessary for their unique cytoplasmic lifestyle. Members of the poxvirus family
replicate almost entirely independent of the nucleus of the infected cell. Unable to utilize
the host cell's enzymes to synthesize RNA or replicate DNA, they encode these essential
proteins in their own genome. In addition to those proteins encoded by poxviruses
required for transcription, replication and virion assembly, there are several nonessential
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proteins employed to establish a suitable habitat. Several interesting nonessential
proteins encoded by poxviruses include: complement control protein, IL-1R homologue,
TNFR homologue, and IFNR homologue (Kotwal, 1997). These nonessential proteins,
and several others, play an important role in modulating the host's immune response to
the infection, thereby maintaining the viral habitat (Howard et al., 1998).
The family Poxviridae is divided into two subfamilies, Chordopoxvirinae, which
are vertebrate poxviruses, and Entomopoxvirinae, which are insect poxviruses – we will
only discuss the Chordopoxvirinae (Moss, 1996). There are eight genera of vertebrate
poxviruses – see table 1. Poxviruses have been found to infect vertebrates ranging from
birds to humans. Some of these infections can be highly fatal; smallpox virus (variola),
which replicates only in humans, has killed more people than any other infectious
disease. In addition, myxoma virus, which infects rabbits, can have as high as a 99%
mortality rate. Much of the success of poxviruses as pathogens is due to the immune
evasion strategies they employ (Kotwal, 1997).
The poxvirus infection generally follows one of two courses, a localized infection
resulting in benign skin lesions, or a systemic infection resulting in viral dissemination
and usually death. Local pathogenesis of molluscum contagiosum virus (MCV) and
Shope fibroma virus (SFV) infection has been well documented. Although the
pathogenesis and host response to infection is quite different, both poxvirus diseases are
self-limiting and remain localized to the skin. The generalized infections, however, are
characterized by several stages, ending in an explosion of viral lesions. Ectromelia virus
infection of mice starts with an infection of the skin, usually via the footpad. After some
replication, the virus spreads through the local lymphatics to the bloodstream, resulting in
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Table 1. Poxvirus classification. The family Poxviridae, subfamily Chordopoxvirinae
is composed of eight genera. Listed are the most studied members of each genus.
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primary viremia. The virus then replicates to high titers in the spleen and liver before
reentering the blood, resulting in a secondary viremia. Finally, the virus spreads to the
skin and a severe rash of ulcerating lesions very rapidly overcomes the mouse. The
disease progression of variola virus infection in humans occurs similarly, with high
mortality rates – see figure 2.
The immune response to poxvirus infection is very complex. Each arm of the
immune system plays a vital role in the segregation and elimination of a poxvirus
infection. Early in the infection, the innate immune response attempts to keep the
infection under control, while the acquired immune response is mounted. Complement,
interferon (IFN), NK and inflammatory cells help control the early infection. Within a
few days, a very strong humoral immune response is mounted, and poxvirus-specific
antibodies are produced. The antibodies can then help control the infection through a
variety of mechanisms, including virus neutralization and complement activation,
opsonization, and ADCC. In addition, a cell-mediated immune response is mounted a
few days into the infection. Poxvirus-specific CTLs are generated and attack virusinfected cells, ultimately resulting in clearance of the poxvirus infection.
Animal models have been used quite extensively for the study of poxvirus disease
pathogenesis and exploring the therapeutic potential of poxvirus immunomodulatory
proteins. To gain a better understanding of the infection processes and genes involved in
interactions with the host, several animal models have been developed to study various
poxvirus diseases and recombinant mutant poxviruses. Animal infection models are
important for testing the efficacies of new anti-viral drugs or to explore new treatment
strategies. Models have been developed to study the inflammatory response generated by
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Figure 2.

Smallpox virus pathogenesis.

Smallpox virus infection occurs via the

respiratory route or direct skin-to-skin contact with a lesion. An incubation period of
approximately 10 to 12 days follows while the virus replicates in the draining lymph
node(s).

After this incubation period, the virus enters the blood and disseminates

throughout the body, causing fever, malaise, headache and backache; these are the first
signs of sickness. For the next 3 to 6 days, the virus can be recovered from the patient's
blood. An eruptive exantham then ensues, starting as small macular lesions of the mouth
and pharynx, face and forearms, before spreading to the trunk and legs.

The rash

becomes popular, then pustular and often protrudes from the skin before scabbing over on
the eighth or ninth day of the rash. If the individual recovers, permanent damage to the
skin (pockmarks) becomes evident. Overall there is a 20-50% mortality rate associated
with smallpox infection, however, in the rapidly progressing type of infection, mortality
may be as high as 95%.
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Scabs

poxvirus infection, analyzing the degree of inflammation and cellular infiltration both
quantitatively and qualitatively. This allows for a better understanding of the genes
associated with poxvirus pathogenesis and results in better characterization of mutant
strains. Understanding pathogenesis assists in the generation of more attenuated vaccine
strains and poxvirus vectors for use in live vaccines, in hopes of reducing complications
associated with traditional vaccines. Animal models have also been instrumental in the
study of poxvirus immune modulating proteins. Several poxvirus immunomodulatory
proteins have been investigated extensively for their potential use as therapeutic agents.
These immune blocking proteins have very powerful anti-inflammatory properties that
may be employed for treatment of many injuries or diseases that involve excessive
inflammation. Animal model systems have been used to test the value of these proteins
for use in transplantation, vascular injury, CNS injury, sepsis, arthritis, and restenosis.
The therapeutic effects of these proteins, revealed by these model systems, are often quite
fascinating.
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Virus Structure
Several methods utilizing electron microscopy have been used to visualize viral
particles. Thin section electron microscopy (often using immunostaining) and
cryoelectron microscopy are widely used and have played a very important role in
deciphering both VV morphology, as well as the various intracellular stages of its life
cycle. Vaccinia virus virions appear as large, smooth surfaced rectangles (350 nm by 270
nm) when their surface is viewed by cryoelectron microscopy. When fixed, stained, and
viewed as thin sections, the vaccinia virions appear much more elliptical. The dumbbellshaped virion core (within which resides the large double-stranded DNA genome and
essential proteins) can also be seen through this method along with the lateral bodies
(unknown function) lying adjacent, within its cavities. This characteristic shape is now
believed to be an artifact caused by dehydration during section preparation. Regardless
of the method used, however, a 30 nm external surface membrane can be clearly seen
surrounding the entire virion.
One very interesting feature of the VV is how it makes many intracellular and
extracellular morphological forms, two of which are infectious. During virion
maturation, several structurally unique forms can be discerned by electron microscopy:
the immature virus (IV), the infectious intracellular mature virus (IMV), the intracellular
enveloped virus (IEV), the cell-associated enveloped virus (CEV), and the infectious
extracellular enveloped virus (EEV) – see figure 3. The immature virus (IV) occurs early
and is characterized by a single outer membrane and incompletely formed core. The
intracellular mature virus (IMV) also contains a single outer membrane; however, its core
is completely formed, allowing the virus to be infectious when released by cell lysis
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Figure 3. Life cycle of the vaccinia virus. (1) Either of the two infectious forms of vaccinia
virus (IMV or EEV) may bind a receptor on a host cell, allowing for membrane fusion, and viral
core entry into the cytoplasm of the cell. (2) Essential viral core proteins are then able to initiate
early gene transcription from the viral genome (completely independent of the host cell's
nucleus). (3) Early viral mRNA is translated by host cell ribosomes into early proteins (many are
involved in inhibition of the host's immune response).
replication of the vaccinia virus genome.

(4) Many early proteins aid in the

This replication involves the formation of large

concatomeric structures. (5) After the genome is replicated to high numbers, transcription factors
(early protein) and a cellular protein (Vitf2), relocating from the nucleus, allows for transcription
of intermediate genes from the newly synthesized genomes. (6) These intermediate mRNAs are
then translated to proteins by host cell ribosomes. (7) Transcription factors produced during the
intermediate stage then lead to late gene transcription.

(8) Again, the host cell ribosomes

translate the late vaccinia virus mRNAs into late proteins. (9) Late structural proteins and mature
genomes assemble on intracellular membranes and form immature virus particles (IV). (10)
Cleavage of core proteins occurs and the IV becomes an intracellular mature virus (IMV). (11)
The IMV may escape the host cell by lysis and infect a neighboring cell. (12) Alternatively, the
IMV may bud through the golgi network and acquire two additional membranes and becomes an
intracellular enveloped virus (IEV). (13) The IEV can then polymerize actin and push to the cell
membrane, where it fuses and becomes known as a cell-associated enveloped virus (CEV). The
CEV may bud free of the host cell, losing one of its three membranes and becoming known as an
extracellular enveloped virus (EEV). This form of vaccinia virus is also infectious and may be
important in dissemination.
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(Hollinshead et al., 1999). After acquiring two additional membranes, the IMV becomes
known as the intracellular enveloped virus (IEV), possessing three membranes in total.
The IEV can move to the plasma membrane (through actin polymerization), fusing to
become known as the cell-associated enveloped virus (CEV). This morphological form
may be released by further budding through the membrane, losing one of its membranes,
and is known as the extracellular enveloped virus (EEV). This form of VV is also
infectious and is responsible for cell-to-cell transmission as well as dissemination
throughout the host.
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Genome Organization
The complete sequence of VV, Copenhagen strain, has been known for many
years now. This large linear, double-stranded genome was found to be 191,636 bp,
possessing 263 open reading frames, 65 of which are contained within a larger open
reading frame (ORF) (Johnson et al., 1993). The genome as a whole is roughly divided
into three general regions: variable left end, variable right end, and conserved central
region – see figure 1. The variable left and right ends of the genome, for the most part,
contain nonessential ORFs responsible for encoding proteins used in host specificity and
modulating host defense. Some of these are close homologues of host immune proteins,
clearly indicating that genes were derived and adapted from the host cell. The conserved
central region of the genome contains ORFs that encode all the essential proteins required
for replication in cell culture. This includes those proteins necessary for RNA synthesis,
DNA replication, and virion assembly. The extreme ends of the VV genome are
composed of identical, but oppositely oriented, inverted terminal repeats. Contained
within the 12 kbp inverted terminal repeats found at either end of the genome are several
tandem repeating sequences of approximately 70 bp in length.
As mentioned earlier, the far ends of vaccinia virus's DNA are covalently linked
hairpin loops, which form a continuous polynucleotide chain. These terminal hairpin
loops are composed of highly A+T rich sequence that do not fully base-pair. This
telomeric structure allows DNA replication to occur through a continuous simple
elongation step, creating large concatemers, resulting in large numbers of replicated
genomes. Just adjacent to the terminal loop lies an extremely conserved 100 bp region.
This region contains the resolution sequence – see figure 4 - responsible for the precise
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cleavage of these large concatemeric DNA structures into individual genomes, which are
complete and ready to be packaged to form an infectious virion.
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Figure 4. Important sequences for transcription and concatemer resolution. Listed
are the important nucleotides involved in early, intermediate, and late promoter function.
An important spacer region between the core promoter and initiation site, responsible for
proper positioning of the polymerase, in noted. The early termination signal, which is
highly conserved among early genes, results in termination of the mRNA 20-50 base
pairs downstream of this sequence. The efficiency of termination is about 80%. The
concatemer resolution site is highly conserved and located at the far end of the genome.
Cleavage of large concatemers into genome length fragments occurs specifically at this
site.
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Virus Life Cycle
Vaccinia virus replicates exclusively within the cytoplasm of host cells in three
stages temporally regulated by viral transcriptional activating proteins (Beaud, 1995).
The various stages of replication - early, intermediate, and late – are summarized in
figure 3. Infection is initiated through attachment of the virion, followed by entry of the
core into the host cell. The cellular receptor responsible for VV attachment and entry has
recently been shown to be heparan sulfate proteoglycan (Chung et al., 1998). A protein
present on infectious VV binds this very common cell surface component, allowing for
membrane fusion and ultimately core entry. The ubiquitous nature of this receptor helps
explain the broad host range exhibited by this virus. As soon as the VV core enters the
cytoplasm of the host cell, early transcription is initiated.
Early viral mRNAs, synthesized by the transcription system packaged in the core,
are detectable in the cytoplasm within 20 minutes and reach a maximum level between
one and two hours after entry. Approximately one hour after entry, intermediate viral
mRNAs are detected and reach a maximum level in two hours. In addition, two hours
after infection, late viral mRNAs can be detected and will continue to be expressed until
the end of infection, approximately 48 hours after initial entry. Various transcriptional
activating proteins control the temporal regulation of these various stages of gene
expression. Early gene expression occurs through the specific promoter binding (figure
4) of early transcription activating proteins, produced and packaged into infectious
virions during the late stage of infection. Intermediate gene expression occurs similarly
through the specific promoter binding of intermediate transcription activating proteins,
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produced during the early stage of gene expression. Late genes are expressed through the
binding of transactivating proteins produced in the intermediate stage of infection.
During early transcription, all of the necessary proteins required for DNA
replication are synthesized and immediately utilized to replicate the genome. Large
concatemers of DNA are thereby synthesized within cytoplasmic foci often referred to as
factory areas or virosomes. The process occurs with very little help from the host cell
nucleus. This has been demonstrated through various experiments using enucleated cells.
Genome replication occurs very rapidly and results in around 10,000 new genomes per
cell (only half of which will be packaged into virions). The speed at which new DNA
can be synthesized is greatly enhanced by several viral enzymes involved in synthesizing
deoxyribonucleotides, increasing the cytoplasmic precursor pools. The large
concatemers that result are then cleaved into genome length segments by a specific
enzyme that recognizes a region of DNA located near the terminus of the mature genome.
The specific enzyme responsible for this is still not known. The most likely candidate,
however, seems to be the virally encoded DNA topoisomerase I enzyme, known for sitespecific cleavage of DNA (Berger, 1998).
Once late transcription has been initiated, and structural proteins accumulate in
the cytoplasm, mature genomic DNA can be packaged along with proteins required for
early gene transcription. The assembly process probably occurs in association with an
internal host cell membrane, presumably the Golgi network. After acquiring a double
membrane through association with the Golgi network, an immature virus (IV) is formed.
Further maturation from this immature state then results in the development of an
intracellular mature virus (IMV) that is fully capable of binding and infecting other cells,
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but only through lysis of the host cell. Alternatively, this IMV may acquire two
additional double membranes via the golgi network (three double membranes total),
becoming an intracellular enveloped virus (IEV) (Hollinshead et al., 1999; Wilton et al.,
1995). By polymerizing cellular actin, the IEV is able to force itself to the cell surface,
allowing the outermost membrane to fuse with the plasma membrane, where it becomes
known as a cell-associated enveloped virus (CEV). The CEV is now capable of escaping
the host cell and disseminating, or may pass directly into a neighboring cell. The
extracellular enveloped virus (EEV) that results from budding out of the host cell still
retains two double membranes and is capable of binding and infecting a new host cell.

22

Poxvirus Immunomodulation
In order to defend themselves from the many arms of the immune system,
poxviruses must constantly evolve new, more powerful methods of modulating the host
immune response. Being large DNA viruses, poxviral genomes have enough capacity to
encode proteins not directly involved in replication. Therefore, they often encode a
repertoire of proteins involved in habitat formation and immune evasion – see figure 5.
These proteins cover a wide range of activities, reflecting the scope and complexity of the
immune response that they counter in their host. The survival of the virus depends on its
ability to create and perfect strategies to conceal itself from this much larger and more
sophisticated opponent. The creativity and potency of the resulting proteins is fascinating
and cover both intracellular and extracellular processes. Thus far, most of the proteins
that have been discovered are secreted and extracellular. The term "virokine" was coined
and used to describe virally encoded proteins that are secreted from the infected host cell.
Most virokines are powerful viral immune modulating proteins created by capturing and
modifying genes responsible for regulating the host immune response. These viral
proteins therefore share many structural and functional features similar to that of the host
proteins. However, since there is limited room within the viral genome, only those genes
very useful to the virus are possibly maintained and constantly adapted to make them
smaller and more potent. There have been virokines discovered and shown to modulate
many important aspects of the immune response. Many cytokine (IL-6, IL-10) and
cytokine receptor (TNFR, INFγR, IL-1βR) homologues (also referred to as viroceptors or
virokines that mimic receptors) have been shown to significantly disrupt cytokinesignaling pathways. This often results in the masking of the host immune system from
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Figure 5. Poxvirus immune modulation: (1) Poxvirus binds the host cell, allowing for core
entry and early gene transcription to initiate. At this time, many viral proteins are produced to
interfere with the host's immune response, in order to establish a suitable habitat for optimal
growth. (2) Vaccinia virus complement control protein (VCP) is produced and secreted from
infected cells. VCP can block the activation of complement through its ability to bind C3b and
C4b complement components. VCP can also bind heparan sulfate proteoglycans on the cell
surface, blocking many molecular and cellular interactions with the cell, like chemokine and
antibody binding. (3) Poxviruses also produce a soluble interleukin one receptor homolog (vIL1βR) that is secreted from the cell, binding up soluble IL-1β before it has a chance to reach the
cell's receptor. (4) Chemokine binding proteins, such as T1 and T7, inhibit chemokine binding to
heparan sulfate proteoglycans on the cell surface. (5) Soluble viral interleukin ten (vIL-10) is
secreted from the cell, binds to IL-10 receptors on inflammatory cells, blocking cell activation.
(6) Soluble poxvirus interferon gamma receptor homologue (vIFN-γR) is also secreted from
infected cells, binding and preventing host IFN-γ from binding the cellular receptor. (7) Another
poxvirus early protein that is responsible for immune modulation, soluble tumor necrosis factor
receptor (vTNFR) homologue, binds host TNF and prevents its interaction with the cellular
receptor.

(8) Poxvirus interleukin eighteen binding protein (vIL-18BP) is secreted form the

infected host cell and binds soluble IL-18, inhibiting its pro-inflammatory functions. (9) Orf
virus encoded granulocyte-macrophage colony stimulating factor-inhibitory factor (GIF) is
secreted and binds to granulocyte-macrophage colony-stimulating factor (GM-CSF), blocking its
ability to stimulate the production and secretion of IFNα. (10) Myxoma virus SERP-1, which is
the only secreted poxvirus serpin, blocks several serine proteases, leading to reduction of
inflammation. (11) The intracellular poxvirus serine protease inhibitor proteins, such as SPI-2,
serp-2, and crmA, block the conversion of pre-caspase to active caspase one, thereby blocking its
ability to convert pro-IL-1β to IL-1β and the cell's ability to undergo programmed cell death.
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the viral infection, allowing the virus to replicate to high titers. Chemokine homologues
and chemokine inhibitors (some of which are chemokine receptor homologues) were
found to have a dramatic effect on leukocyte chemotaxis. These virokines have been
shown to either help the virus evade immune detection, in some cases by blocking the
influx of leukocytes into the area of infection, or in other cases, actually cause the
recruitment of leukocytes to increase the pool of new host cells to allow for better
dissemination. Chemokine inhibitors have been identified and shown to block cellular
influx into the areas of infection. There are also virokines that block one of the most
important aspects of the innate immune system, the complement system. These proteins
are very powerful; they not only prevent the formation of the membrane attack complex
(MAC), but also block the complement cascade at multiple sites upstream to block the
formation of proinflammatory factors. They are therefore also able to greatly reduce the
migration of leukocytes into the area of viral infection.
In addition to those proteins encoded by poxviruses that are secreted from the host
cell, there are also proteins that act intracellularly. The most studied group of
intracellular poxvirus immune modulating proteins are the serine proteinase inhibitors
(serpins) (Kettle et al., 1997). Many poxviruses have been found to encode serpins that
modulate programmed cell death, apoptosis. By blocking the cysteine proteinase
interleukin-1β-converting enzyme (ICE), and the serine proteinase granzyme B, the
cowpox cytokine response modifier A (CrmA), vaccinia virus SPI-2, and myxoma virus
Serp-2, all have been shown to inhibit apoptosis (Nash et al., 1999). By blocking these
intracellular enzymes, the poxvirus serpins are able to prevent TNF- and IFN-induced, as
well as T-lymphocyte-mediated, Fas-induced apoptosis (Tewari et al., 1995). By
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protecting the infected cell from programmed cell death, the virus is able to replicate to
higher titers and continue host evasion.

Complement Regulatory Proteins:
Many poxviruses encode proteins that mimic components of the host complement
system in order to block the activation of complement and thereby modulate the
inflammatory response mounted by the host (Kotwal, 2000). See the section below for
information on the vaccinia virus complement control protein, the best-studied poxvirus
complement regulatory protein.

Cytokine Homologues:
The parapoxvirus, Orf virus, which often infects sheep and goats (sometimes
humans), has very recently been shown to encode a viral homologue of IL-10 (vIL-10)
(Fleming et al., 2000). This protein shows the greatest degree of homology, 80%, to
sheep IL-10. Endogenous IL-10 plays many important roles in down regulating the
immune system. One very important function is to suppresses activation of macrophages,
thereby blocking their ability to act as accessory cells to activate T-cells (especially TH1)
or natural killer (NK) cells via IL-12 production and secrete cytokines. Thus, IL-10 acts
as a potent anti-inflammatory agent and a powerful immunosuppressor. Because of this
activity, it is believed that the Orf virus produces vIL-10 in order to inhibit expression of
various cytokines that regulate the immune response against viral infection, suppressing
activation of macrophages. The benefits of vIL-10 production for the virus are thereby to
mask viral infection from the immune system long enough to replicate to high titers.
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Very recently, a new virokine, having homology to human interleukin-18 binding
protein (hIL-18BP), was uncovered in molluscum contagiosum virus (MCV) (Xiang and
Moss, 1999). Since this time, it has also been found in other poxviruses, including
ectromelia, vaccinia, and cowpox (Smith et al., 2000). IL-18 is a proinflammatory
cytokine important in activating natural killer (NK) cells, inducing a T-helper 1 response,
and inducing the production of interferon gamma (IFNγ). The MCV vIL-18BP has been
shown to bind to both human and murine IL-18 and inhibit the production of IFNγ in a
dose dependent manner (Xiang and Moss, 1999). Deletion of the gene encoding vIL18BP in VV was shown to dramatically attenuate the virus (Smith et al., 2000). In
addition, the ectromelia virus vIL-18BP was shown to block IL-18 induced NF-κB
activation and induction of IFNγ. This strategy of viral evasion therefore also acts to
indirectly block the strong antiviral effects of IFNγ.

Cytokine Receptor Homologues (Viroceptors):
Many members of the poxvirus family, including myxoma, vaccinia, and cowpox,
encode homologues of the tumor necrosis factor receptor (TNFR). This viral tumor
necrosis factor receptor (vTNFR) was originally described in myxoma virus where it is
known as T2, and in Shope fibroma viruses (SFV), and the term viroceptor was proposed
to describe them (Upton et al., 1991). TNF is a very important cytokine for the early
response to viral infection. It is a very powerful proinflammatory agent, triggering
numerous immunological events, including apoptosis of virally infected cells. In order to
block the effects of this powerful cytokine, these poxviruses have captured and modified
the host gene for TNFR so that it may be secreted in large amounts from the infected cell.
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The vTNFR can bind soluble TNF present in the nearby area, preventing its binding to
the cellular TNFR, thereby blocking the action of this cytokine. Many poxviruses encode
several copies of this gene; cowpox virus, for example, contains three separate copies,
showing its importance to viral replication (Loparev et al., 1998). In addition, when
vTNFR (T2) was deleted from myxoma virus the virulence was significantly reduced.
Interestingly, vTNFRs show a great deal of host specificity. Myxoma virus vTNFR, T2,
will only bind to rabbit TNF (not at all to human), while the vTNFR encoded by vaccinia
and cowpox viruses will bind human, mouse, and rat TNF effectively.
Many poxviruses, including variola, ectromelia, vaccinia, cowpox, and camelpox,
also encode an additional interesting cytokine receptor homologue, viral IFNγ receptor
(vIFNγR). These proteins greatly resemble the N-terminal, ligand-binding (extracellular
domain) region of their mammalian counterparts. As with vTNFR, these cytokine
receptor homologues are also very species specific. The first and most extensively
studied of these proteins comes from the myxoma virus and is known as T7 (Upton et al.,
1992). T7 is a 37 kDa N-glycosylated protein that is the most abundantly secreted
protein of myxoma virus. Exhibiting great species specificity, T7 was shown to bind and
block the effects of rabbit IFNγ, but had no effect in blocking human or murine IFNγ. In
contrast, vaccinia virus, which has a broad host range, can bind and block a number of
mammalian IFNγs. The importance of this encoded protein to myxoma virus virulence is
evident, not only because it is the most abundantly secreted protein, but also because
deletion of the gene eliminates the 99% mortality rate exhibited by the virus, and all
infected rabbits recover. Therefore, the T7 protein represents the major virulence factor
of myxoma virus. The importance of this protein to viral virulence is due to IFNγ's
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powerful antiviral effects. IFNγ serves numerous functions, including switching on many
intracellular antiviral activities, and giving the signal to nearby cells that a viral infection
is occurring. Another cytokine receptor homologue, produced most notably by the
orthopox members, vaccinia and cowpox viruses, is viral interleukin 1 receptor (vIL-1R).
This 33 kDa protein was first identified with vaccinia virus, and found to have the ability
to bind murine IL-1β in 1992 (Alcami and Smith, 1992). A similar ORF was later
identified in cowpox virus and the protein product was found to bind murine IL-1β.
Interestingly, supernatants taken from vaccinia virus-infected cells were found to inhibit
IL-1 induced murine lymphocyte proliferation. In addition, recombinant vaccinia, unable
to express vIL-1R, showed remarkable attenuation in vivo, compared to the wild type
(Spriggs et al., 1992). This demonstrates how the protein plays a critical role in the
pathology of vaccinia virus infection. The importance of IL-1 in combating viral
infection is large, and was demonstrated many years ago (Vacheron et al., 1990).
Expression of IL-1 is induced early on in many viral infections, and results in a broad
spectrum of inflammatory responses. NK cells and B-cells proliferate in response to IL1, neutrophils degranulate, and T-cells produce IL-2 and proliferate.
Another very recently identified virokine was found encoded by the parapoxvirus,
Orf (Deane et al., 2000). The Orf virus produces a secreted protein, termed granulocytemacrophage colony stimulating factor-inhibitory factor (GIF), which was shown to bind
to and block the activity of GM-CSF, as well as IL-2. Both of these cytokines are very
important in host antiviral immunity; IL-2 is essential for its role in the activation of Tcells, and GM-CSF for its ability to stimulate the production and secretion of IFNα. This
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remarkable virokine plays a very novel role in modulation of host defense as a means of
preserving viral habitat.

Chemokine Homologues:
Many poxviruses encode proteins that inhibit chemokines; the CC (β) chemokine
homologue encoded by the molluscipoxvirus, molluscum contagiosum virus (MCV),
designated as molluscum contagiosum chemokine homologue (MCCH) or MC148, was
only recently discovered (Senkevich et al., 1996). This human disease-causing virus
presumably utilizes this virokine to block leukocyte trafficking to the site of infection.
MC148 is highly homologous to members of the CC or β chemokine family; however, it
is truncated in the N-terminus of the protein. The N-terminal portion of the chemokine is
required for proper binding and activation of the cell (Senkevich et al., 1996). Therefore,
the MC148 chemokine homologue of MCV acts by binding to the chemokine receptor,
identified as being specifically CCR8, thereby blocking endogenous chemokine binding.
The overall result of this protein is reduced cellular influx and therefore reduced
inflammation. This protein seems to be geared toward specifically blocking monocyte
infiltration and dendritic cell function.

Chemokine Inhibitors:
Many poxviruses encode a protein that blocks the effects of chemokines.
Collectively these virokines have been termed the T1/35kDa family, all of which possess
eight conserved cysteine residues, and are shown to interact with members of the CC
and/or CXC classes of chemokines (Graham et al., 1997). The myxoma virus T1 and T7
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proteins are the most widely studied members of this group. T1 shows no homology to
any host chemokine or chemokine receptor and binds strongly (specifically) to members
of the CC class of chemokines, but only weakly (nonspecifically) to CXC chemokines
(Kettle et al., 1997). Because of this ability, T1 has been shown to block human
monocyte migration, in the presence of MIP-1α, in vitro. Deletion of the coding
sequence for T1 resulted in a pronounced increase in infiltrating monocytes and
macrophages in the site of infection in vivo (Graham et al., 1997). However, the loss of
T1 had no significant effect on mortality, indicating that this gene does not play a critical
role in the pathogenesis of the infection. T7, on the other hand, has been shown to inhibit
the activity of members of C, CC, and CXC classes of chemokines in a nonspecies
specific manner. This protein, which is most noted for its anti-IFNγ activity, has been
shown to nonspecifically bind to the heparan sulfate proteoglycan binding domain of the
chemokine, preventing gradient formation along the vascular wall, and inhibiting
chemotaxis (Lalani et al., 1997). Addition of excess soluble heparin completely prevents
this activity of the T7 protein, supporting this hypothesis. Since the T7 protein also
exhibits no homology to any known chemokine, this strategy of chemokine inhibition is
quite novel.

Serine Protease Inhibitors:
Several poxviruses have been shown to encode proteins that are able to prevent
apoptosis, programmed cell death. The cowpox cytokine response modifier A (CrmA),
vaccinia virus SPI-2, and myxoma virus Serp-2 have all been shown to inhibit apoptosis
through the ability to block both, the cysteine proteinase interleukin-1β-converting
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enzyme (ICE), and the serine proteinase granzyme B (Nash et al., 1999; Quan et al.,
1995; Turner et al., 1999; Kettle et al., 1997; Turner et al., 1999). By blocking these
intracellular enzymes, these poxvirus serine protease inhibitor (serpins) proteins are able
to prevent TNF and IFN-induced, as well as T-lymphocyte-mediated (Ca+2-independent),
Fas-induced apoptosis (Nash et al., 1999; Tewari et al., 1995; Kettle et al., 1997).
Therefore, these proteins prevent destruction of infected cells, even if they are recognized
as being infected, thus maintaining a habitat conducive to virus replication.
Many members of the poxvirus family encode proteins that inhibit serine
proteases intracellularly, but only myxoma virus encodes one that acts as a serine
protease inhibitor (serpin) and is secreted extracellularly. First identified in 1990, this
secreted glycoprotein, Serp-1, has structural features that place it in the serpin family of
serine protease inhibitors (Upton et al., 1990). Before its discovery, intracellular serpins
were found with VV (Kotwal and Moss, 1989). Serpins have many functions in
maintaining homeostasis of eukaryotic systems, from complement activation and blood
clotting, to the inflammatory response. In addition, mutations in serpins have been linked
to over 90 human diseases. Given the importance of these proteins, many pathogens have
evolved to carry their own serpins to disrupt host processes. Myxoma virus Serp-1, for
example, has been shown in vivo to weaken the inflammatory response to viral infection.
When this gene is deleted from the virus, a much greater inflammatory process is
observed and the infection is resolved much more rapidly. Purified recombinant Serp-1
has been shown to bind a variety of proteases, including plasmin, thrombin, tissue-type
plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA), although
the exact target has not been found (Lomas et al., 1993). This protein acts as a
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pseudosubstrate for these serine proteases, forming a stable complex, preventing the
protease from binding its true substrate. Due to the role of Serp-1 in modulating
inflammation, it was recently tested in a restenosis model system to evaluate its
therapeutic value.
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Vaccinia Virus Complement Control Protein (VCP)
The vaccinia virus complement control protein (VCP) was the first soluble
microbial protein shown to have complement binding activity and postulated to have a
role in evasion of host complement (Kotwal and Moss, 1988). In the years since its
discovery, VCP has become one of the best studied and the best characterized virokine.
Structurally, it is composed of four complement control protein (CCP) modules [also
called short consensus repeats (SCR)], making it and other homologous proteins
members of the regulators of complement activation (RCA) superfamily. VCP exhibits
functional similarity to factor H (fH), membrane cofactor protein (MCP), decayaccelerating factor (DAF), complement receptor one (CR1), and is structurally most
similar to human complement 4b binding protein (C4b-BP). Purified bioactive VCP has
been shown to inhibit both the classical and alternative pathways of complement
activation through its ability to bind C3 and C4 and act as a cofactor for factor I cleavage
of C3b and C4b (Sahu et al., 1998). VCP, secreted from virally infected cells, is believed
to protect the cell and the released viral progeny from host complement attack. In
addition, by blocking complement activation at multiple sites, there is a large reduction of
C3a, C4a, and C5a proinflammatory chemotactic factors, resulting in reduced cellular
influx and inflammation. VCP has also been shown to possess the ability to bind heparin,
as well as, heparan sulfate proteoglycans (heparin-like molecules) on the surface of
human endothelial cells. Because of this activity, VCP has been shown to exhibit many
properties that all other complement control proteins are lacking. In vivo studies have
indicated that FITC-labeled VCP, when injected intravenously, becomes localized in the
endothelium. This very interesting property of VCP has been shown in vitro to reduce
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chemotactic migration of leukocytes in the presence and absence of the chemokine MIP1α (Reynolds et al., 2000). This suggested that VCP could interfere with molecular
interactions with infected cells, and possibly prevent antibody-dependent cell-mediated
cytotoxicity (ADCC) as well as other cytotoxic cell interactions with target cells.
Amazingly, VCP was shown to block interactions between pig aortic endothelial cells
(PAECs) and naïve neutrophils and NK cells, preventing cell killing (Al-Mohanna et al.,
2001). In addition, cell culture studies demonstrate that VCP blocks complementmediated killing of PAECs by human serum, in a dose-dependent manner. VCP is
further discussed in chapters 2-6.
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CHAPTER 2
EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF VCP

VCP from VV Infection of Mammalian Cell Culture
This chapter contains material adapted from the following publication:
Smith S.A., N.P. Mullin, J. Parkinson, S.N. Shchelkunov, A.V. Totmenin, V.N. Loparev,
R. Srisatjaluk, D.N. Reynolds, K.L. Keeling, D.E. Justus, P.N. Barlow, and G.J.
Kotwal. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on
poxvirus complement control proteins serve as putative heparin binding sites and
contribute to inhibition of molecular interactions with human endothelial cells: a
novel mechanism for evasion of host defense. J. Virol. Jun. 74(12):5659-66, 2000
[Cover of J. Virol. Oct. 74(20), 2000].
Natural VCP, produced by VV during a natural infection process of cultured cells,
was produced in large quantities with technical assistance. Briefly, RK-13 cells were
grown to confluency in large cell factories before infecting with VV WR strain. After 48
hours the media was harvested, filtered through a 0.22 µm filter, and concentrated to ~50
ml using an Amicon stirred-cell (with 10 kDa molecular size cut-off). Heparin HiTRAP
(Pharmacia) chromatography was then performed on the media for specific purification
of VCP. A NaCl step gradient (100 mM – 1 M) was used to rinse and elute VCP from
the column. Finally, the fractions were examined by SDS-PAGE and Coomassie blue
staining. VCP eluted from the heparin column and was primarily located in the 400 mM
NaCl elution fraction. All fractions containing VCP were then pooled, the protein
concentration was estimated using a Bio-Rad protein assay kit, and the protein's activity

estimated using the hemolysis assay (described in chapter 4) (Kotwal and Moss, 1988).
Natural VCP was frequently isolated at greater than 90% purity (using SDS-PAGE
analysis) by this method.

38

Pichia pastoris Yeast Expression System
Nick P. Mullin from the Edinburgh Center for Protein Technology, University of
Edinburgh, UK expressed VCP and fragments of VCP in Pichia pastoris using the
secretory expression vector pPIC9, see figure 6. The fragments corresponded to amino
acids 18-146 (rVCP~1,2), 82-204 (rVCP~2,3), 145-263 (rVCP~3,4) and 18-262
(rVCP~1-4). Genomic DNA from vaccinia virus was used as template for the
amplification of the DNA fragments encoding the above protein fragments by PCR. In
all cases except for VCP~3,4 the oligonucleotides used introduced a 5’ Eco RI site and a
3’ Not I site which were used for cloning the fragments into the expression vector. For
VCP~3,4, cloning was carried out as described earlier (Wiles et al., 1997).
Selection of clones and expression of rVCP~3,4 has been described previously
(Wiles et al., 1997). For rVCP~1,2, rVCP~2,3 and rVCP~1-4 clones transformed with
the expression vectors described above where selected on the basis of their ability to
grow on histidine deficient medium. Small-scale expression screening was performed by
inoculating 5 ml of buffered minimal glycerol (BMG) and incubating at 30 oC until the
OD600 reached between 6 and 10. The cells were harvested and resuspended in 2 ml (for
KM71 cells) or 15 ml (for GS115 cells) of buffered minimal methanol (BMM). Cells
were grown with vigorous shaking for 4 to 5 days with daily addition of methanol to
reach a concentration of 0.5% [for activation of gene expression (see figure 5)]. Media
from these inductions was analysed by SDS-PAGE and the highest-level expressers
selected. For rVCP~1,2, ~2,3, and ~1-4, the KM71 cell line proved to produce the most
protein. For large-scale growth of rVCP~1,2 and rVCP~1-4, 100 ml of BMG was
inoculated with 5 ml of an overnight culture and grown at 30oC with vigorous shaking
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Figure 6. Pichia pastoris yeast expression system. Listed are the steps used for cloning
and growth using the Pichia pastoris yeast expression system by Invitrogen.

Also

shown, is the pPIC9 expression vector used in the cloning of VCP and the various VCP
truncations. Special features of the pPIC9 vector are depicted in the diagram.

1)
2)
3)
4)
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5)
6)
7)
8)
9)
10)
11)

Select the appropriate expression vector.
Clone your desired gene into vector.
Transform E. coli, select ampicillin-resistant transformants,
and confirm presence and orientation of desired gene.
Linearize constructs with appropriate restriction enzymes to
generate His+ Muts recombinant strain.
Transform and select for His+ transformants.
Screen His+ transformants for His+ Muts strains
Confirm integration of your gene in His+ Muts strain by PCR.
Grow recombinants in 100-200 ml of buffered glycerol medium
(BMGY) to an OD600 = 2-6.
Harvest cells and resuspend to an OD600 of 10 with methanol
medium (BMMY) and place in 250 ml flask.
Incubate at 300C with shaking and take samples for analysis at
0, 24, 48, 72, 96, 120, and 144 hours.
Analyze medium for protein via PAGE/Coomassie Blue staining,
western blot, activity, ELISA, or immunoprecipitation.

overnight. This culture was then used to inoculate several liters of BMG. The cultures
were grown for 48 hours until the OD reached approximately 20. The cells were spun
down, resuspended in the same volume of BMM, and grown for 4 to 5 days with
vigorous shaking. Cells were fed methanol to a concentration of 1% every 24 hours. For
rVCP~2,3, BMG media was inoculated with an overnight culture and grown at 30oC with
vigorous shaking until an OD of approximately 6 had been attained. The pellet was then
harvested by centrifugation, resuspended in BMM media (40% of the total BMG volume)
and grown for 5 days with daily addition of methanol to a concentration of 0.5%.
Purification of rVCP~3,4 has been described previously (Wiles et al., 1997). For
purification of rVCP~1,2, media was concentrated down to a small volume using a
combination of a Millipore Prep/Scale-TFF cartridge (3 kDa molecular size cut-off) and
Amicon stirred-cell (with 3 kDa molecular size cut-off). The sample was exchanged into
50 mM Tris-HCl (pH 9.0) using a Pharmacia PD-10 column and loaded onto a Pharmacia
Mono-Q column, equilibrated in the same buffer. The protein was then eluted with a
NaCl gradient of 0 to 100% over twenty minutes. Fractions containing rVCP~1,2 were
collected and concentrated using Amicon stirred-cell ultrafiltration and then loaded onto
a Brownlee Aquapore C4 reverse-phase column and the protein eluted with an
acetonitrile gradient. Fractions containing pure rVCP~1,2 were collected and
lyophilized. For purification of rVCP~2,3, media was concentrated to approximately 50
ml using an Amicon concentrator (3 kDa cut-off) before being centrifuged at 20,000 x g
for 1 hour and the pellet discarded. The sample was exchanged into 5 mM sodium
acetate (pH 4.0) using a PD-10 column and applied to a Mono-S cation exchange column
(Amersham Pharmacia, Uppsala, Sweden), equilibrated in the same buffer. Protein was
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eluted with a NaCl gradient and fractions corresponding to pure rVCP~2,3 were pooled
and lyophilized. For purification of rVCP~1-4, media was concentrated to a small
volume by the same means as rVCP~1,2. The protein was exchanged into 20 mM
phosphate pH 6 using a PD-10 column and dried.
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Growth and Affinity Purification
BMGY –versus- BMMY:
The various rVCP yeast clones described previously were stored in 10% glycerol
and frozen to –80oC. When growth is desired, the frozen stock was plated on minimal
methanol histidine media (MMH) for selecting and maintaining a pure culture of the
clone. Optimal growth on MMH was achieved through incubation at 30oC for several
weeks. A single colony was then used for inoculation of starter culture.
Using sterile technique, a single colony was removed from the MMH plate and
inoculated into 1 ml buffered minimal-complex glycerol medium (BMGY). One liter of
BMGY consists of: 750 ml peptide base (30 g YEP in one liter H2O, autoclaved), 100 ml
10X glycerol (100 ml glycerol in 900 ml H2O, autoclaved), 100 ml phosphate buffer pH
6.0 (~132 ml 1 M K2HPO4 and ~868 1 M KH2PO4, autoclaved), 50 ml yeast nitrogen
base (1.7 g YNB in 100 ml H2O, sterile filtered), and 2 ml 500X biotin (sterile filtered).
The 1 ml starter culture was grown at 30oC overnight. The starter culture was then used
to inoculate the remaining 999 ml BMGY in a large 4 L Erlenmeyer flask, the mouth
covered with cheesecloth. The culture was then incubated at 30oC with vigorous shaking
(200 rpm) for 2-3 days. The cells were then removed by swing bucket centrifugation
(3,000 rpm) for 30 min using 250 ml polypropylene bottles. Being careful to prevent
contamination, the cells were then resuspended in 500 ml (50% of the total BMGY
volume) buffered minimal-complex methanol medium (BMMY). BMMY consists of:
250 ml peptide base (30 g YEP in one liter H2O, autoclaved), 500 ml autoclaved H2O,
100 ml 20% methanol (200 ml methanol in 800 ml H2O, autoclaved), 100 ml phosphate
buffer pH 6.0 (~132 ml 1 M K2HPO4 and ~868 1 M KH2PO4, autoclaved), 50 ml yeast
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nitrogen base (1.7 g YNB in 100 ml H2O, sterile filtered), and 2 ml 500X biotin (sterile
filtered). The culture was then incubated at 30 oC with vigorous shaking (200 rpm) for 2
days. Additional methanol was added to a final concentration of 2% (10 ml) after the
first day. After two days of incubation, the cells were then removed by high-speed
centrifugation (12,000 rpm) for 45 min using 250 ml polycarbonate bottles. The media
was then carefully decanted and passed through a 0.22 µm bottle-top filter. The media
was then concentrated using an Amicon stirred-cell with 10 kDa molecular weight cut-off
membrane to ~50 ml.

Affinity Purification and Endotoxin Removal:
Recombinant VCP (rVCP = rVCP~1-4) was purified from the concentrated
BMMY media by using heparin HiTRAP (Pharmacia) affinity chromatography. BMMY
was first pumped at a rate of 1 ml/min through a sterile filter (0.22 µm syringe filter) into
a series of five heparin HiTRAP columns run in tandem. The unbound material was
collected and the column was washed with 50 ml sterile H2O. A NaCl 30 ml step
gradient ranging from 250 mM to 550 mM, increasing in 50 mM increments, was then
applied to the column to elute the bound protein. Finally, the column was washed with
50 ml 2 M NaCl to remove any remaining proteins. The fractions were then visualized
by SDS-PAGE and coomassie blue staining, see figure 7. The fractions containing rVCP
were then pooled, the protein concentration was estimated using a Bio-Rad protein assay
kit, and the protein's activity estimated using the hemolysis assay (Kotwal and Moss,
1988). The purity of the recovered rVCP was frequently greater than 95% by this
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Figure 7. Heparin purification of rVCP (rVCP~1-4). Coomassie blue stained SDSPAGE gel shows fractions following heparin affinity chromatography. Fractions shown
are from a NaCl elution step gradient ranging from 250 mM to 550 mM (by 50 mM
increments) and a 2 M wash. S.M. = starting material, Unb. = unbound fraction.

Heparin Purification of rVCP

2M
550mM
500mM
450mM
400mM
350mM
300mM
250mM
Unb.
S.M.
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method. This procedure can be used for purification of rVCP~1-4, rVCP~1,2, rVCP~3,4,
and rVCP~2,3,4, but cannot be used to purify rVCP~2,3.
rVCP~2,3 was purified most effectively by affinity chromatography using
HiTRAP ANX (high sub) sepharose fast flow (Pharmacia). ANX sepharose is a weak
anion exchanger, similar to DEAE, with a high degree of cross-linking. This allows for
better purification of rVCP~2,3 and higher yields. Similar methodology was used for
chromatographic purification of rVCP~2,3 as compared to the other rVCP clones, with
the exception of the step gradient. A NaCl step gradient ranging from 50 mM to 350
mM, increasing in 50 mM increments, was applied to the column to elute the bound
protein. Visualization and characterization of the protein was the same as above.
If contamination of the yeast culture does not occur, samples of rVCP will contain
only trace amounts of endotoxin and do not need further purification. However, if
contamination occurs, and endotoxin is present (BioWhittaker Limulus Amebocyte
Lysate endotoxin detection assay), endotoxin removal can be carried out as follows.
Twenty milliliters of endotoxin removal gel, polymyxin B sepharose, was seeded into a
30 ml all-purpose HPLC column, washed with endotoxin free water, and activated using
the appropriate activation buffer. Keeping in mind that the matrix has an endotoxin
binding capacity of 5,000 EU/ml, the appropriate amount of rVCP was then passed
through the column at a 0.5 ml/min flow rate. The column was then rinsed with a column
volume of endotoxin free water and a NaCl gradient (H2O to 1 M) was used to elute the
rVCP that was nonspecifically bound. Fraction collection was continually monitored at
280 nm, and two rVCP peaks are visible; the first peak was rVCP which flowed directly
through the matrix, and the second was rVCP which had a nonspecific interaction with

48

the matrix and was eluted with low NaCl, see figure 8. Fractions were then visualized by
SDS-PAGE and coomassie blue staining, the fractions were pooled, and the protein
concentration estimated using a Bio-Rad protein assay kit. Finally, the final
concentration of endotoxin was estimated using the BioWhittaker Limulus Amebocyte
Lysate endotoxin detection assay and compared with the original estimate to determine
the endotoxin reduction, see figure 9.
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Figure 8. Endotoxin removal using Polymyxin B HPLC.

A representative graph of

the 280 nm scan and fractions following endotoxin removal of rVCP using Polymixin B
chromatography is shown. The 280 nm scan is shown in blue, the NaCl gradient shown
in red, and peaks one and two are labeled. rVCP elutes from the column as two peaks
because of a low affinity which some rVCP exhibits toward Polymixin B.

Polymyxin B Gel Chromatography

Peak 1

Peak 2

NaCl
Gradient
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Figure 9. Endotoxin removal of rVCP. The concentration of endotoxin in a sample of
rVCP is shown before and after each step of purification.

Heparin affinity

chromatography was performed as described in the "Growth and Affinity Purification"
section of chapter 2, protein concentrations were estimated using the Bio-Rad protein
assay kit, and endotoxin was estimated using the BioWhittaker Limulus Amebocyte
Lysate endotoxin detection assay.
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W a t e r Us e d

Assays and Characterization
Hemolysis Assay and Activity Units:
The hemolysis assay was developed to test the activity of VCP quickly and easily
using a microtiter plate reader (Kotwal and Moss, 1988). At the heart of the assay is the
sensitized sheep red blood cell (sSRBC) (Diamedix). In the presence of serum, the
classical complement pathway will be activated on the surface of the erythrocyte,
resulting in its lysis. In the presence of VCP, however, the complement pathway
activation will be inhibited and the erythrocyte will not be lysed. The assay was
performed in 0.65 ml general-purpose polypropylene Eppendorf tubes on ice, see figure
10 for diagram. First, half of the sSRBC buffer (1.5 ml) was removed to obtain the
correct concentration for the assay (OD of 5.0 @ 405 nm). The VCP sample was then
serially diluted in 20 µl of the buffer. Next, 30 µl of diluted serum (~1:70) was added
(must be able to only lyse 95% of the sSRBCs). Finally, 150 µl of sSRBCs was added to
each tube to give a final volume of 200 µl. A positive control was made by adding no
VCP, and a negative control was made by adding no serum. The tubes are incubated for
one hour at 37oC, and then centrifuged at 7,000 rpm for 20 seconds. Directly after
centrifugation, 150 µl of the supernatant was then pipetted into a 96 well flat-bottomed
microtiter plate. The plate was then read at 405 nm, and the activity units are derived
from the percent lysis inhibition which was calculated using the formula {[(O.D. sample
– O.D. negative control)/(O.D. positive control – O.D. negative control) X 100] – 100}.
Specific activity for VCP can be determined using the hemolysis assay. Specific
activity units are defined as the quantity of VCP required to inhibit hemolysis to 50% in
the hemolysis assay. To determine the total activity units of the VCP sample, the
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Figure 10.

Hemolysis assay.

Illustrated are the procedures used to perform the

hemolysis assay to measure the activity of VCP. After serially diluting the sample of
VCP, enough serum is added to lyse 95% of the sSRBSs. Lastly, the sSRBCs are added
and the tubes are incubated at 37 oC for 1 h. After incubation, the tubes are centrifuged
for 20 sec and the supernatant pipetted into a 96 well flat-bottomed microtiter plate. The
absorbance is read at 405 nm using a microtiter plate reader (ELX800 BIO-TEK
Instruments, Inc.) and the activity of the sample is calculated, as indicated in the "Assay
and Characterization" section of chapter 2.

Hemolysis Assay
20 µl

20 µ l

20 µ l

20 µ l
Dilution 5
or Discard

(-) Control
150 µ l sSRBCs
50 µ l Buffer

(+) Control

Sample 1

150 µ l sSRBCs
150 µ l sSRBCs
20 µ l Buffer
40 µ l (Sample + Buffer)
30 µ l Diluted Serum 30 µ l Diluted Serum

Sample 1
Dilution 2

Sample 1
Dilution 3

Sample 1
Dilution 4

20 µ l Buffer
30 µ l Diluted Serum

20 µ l Buffer
30 µ l Diluted Serum

20 µ l Buffer
30 µ l Diluted Serum

Incubate @
37oC for 1 hour

Centrifuge
10,000 rpm
30 Sec
sSRBCs
Plate 150 µl
Supernatant

Read Absorbance
@ 405 nm
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appropriate dilution (producing 50% lysis inhibition) is multiplied by the total volume of
the sample. In most cases, one activity unit equates to approximately 0.25-0.50 µg of
VCP.

Protein Estimation Assay:
Accurate estimation of the amount of purified rVCP and rVCP fragments can be
done quickly and easily using the Blue Bio-Rad protein assay. Bovine serum albumin
was used as a standard for accurate concentration estimates. A microtiter plate reader
was used for this assay, which reduces the quantity of protein required (5 µl) to do the
estimation. This was far superior to the Red Bio-Rad protein assay, which uses a
spectrophotometer and 100 µl of sample.
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VCP Production for NMR, X-Ray Crystallography, and Antibodies
Labeling for NMR:
In order to obtain an NMR structure of VCP, all amino acids of the protein must
be labeled with N15 non-radioactive isotope. Typically, the best way to achieve this is by
growing the yeast in the presence of N15 labeled ammonium sulfate. Due to the great
expense of this labeled compound, optimal growth and labeling conditions were first
established using unlabeled ammonium sulfate. Yeast were first grown under normal
conditions in 500 ml BMGY, as described above. After removing the medium by
centrifugation, the yeast were starved for 6 hours in ammonium sulfate media. This
media consisted of the following: 2.5 g ammonium sulfate, 225 ml sterile H2O, and 25 ml
10X glycerol. This medium is designed to replace the unlabeled amino acid reserves in
the yeast with what would normally be N15 labeled amino acids, from the ammonium
sulfate. As a control, the same experiment was done without ammonium sulfate, to test
the turnover of the amino acid reserves, see figure 11A. Finally, the yeast were growth
for 3 days, with daily addition of methanol (to a final concentration of 2%), in
ammonium sulfate methanol medium. This media consisted of the following: 2.5 g
ammonium sulfate, 225 ml sterile H2O, and 25 ml of 10% methanol. After removing the
yeast by high-speed centrifugation, the media was filtered and the protein was purified by
heparin affinity chromatography, see figure 11B. Yeast grown without ammonium
sulfate produced only a small amount of protein (no nitrogen source), indicating that the
vast majority of rVCP produced by yeast growing in the presence of ammonium sulfate
was the result of this compound being present. The fractions containing rVCP were then
pooled and the protein concentration was estimated. Using this technique, 1 mg of
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Figure 11. Heparin affinity chromatography of ammonium sulfate rVCP. In order to
determine the amount of rVCP that can be produced, for use in NMR, by growing the
Pichia pastoris yeast clone in minimal media, yeast were grown by two methods, with
and without ammonium sulfate.

A)

rVCP produced after heparin chromatography

following growth in minimal media containing no ammonium sulfate.

B)

rVCP

produced after heparin chromatography following growth in minimal media containing
ammonium sulfate. In both cases, rVCP was purified using a NaCl elution step gradient
ranging from 100 mM to 500 mM (increasing increments of 50 mM). The starting
material, unbound material and rVCP marker are also shown.

Heparin Purification of Ammonium Sulfate rVCP

A
Without
Ammonium
Sulfate

B
With
Ammonium
Sulfate

500 mM

450 mM

400 mM

350 mM

300 mM
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Unbinding

Start Mat.

VCP Marker
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greater than 95% pure rVCP can be made using 5 g of ammonium sulfate. Due to the
great cost required, N15 labeled ammonium sulfate was never used.

Large Scale Purification for X-Ray Crystallography:
In order to produce large quantities of highly purified rVCP for X-ray
crystallography, the above procedure was scaled up to 2 liters. After heparin purification
was repeated a second time, the purity of rVCP was found to be approximately 98%, see
figure 12. The protein concentration was estimated to be approximately 12.5 mg, and the
activity units estimated to be approximately 5 x 105. The sample was then sent for
crystallization as 10% glycerol at 4oC. Crystals were produced and the structure of rVCP
was obtained, discussed in chapters 3-5.

Anti-VCP Production, Purification, and Characterization:
In order to obtain antibodies to rVCP, for use in immunohistochemisty and
Western blot analysis, purified protein was mailed to Washington Biotec (Baltimore,
Maryland) for immunization of a chicken and a rabbit. Both the rabbit and chicken
received three immunizations. In order to obtain antibodies to linearized epitopes on
rVCP to be used for Western blotting, the second immunization given to the rabbit was of
denatured rVCP. After running several milligrams of rVCP on SDS-PAGE with
reducing agent, the protein was purified by gel extraction. Immunization of the chicken
and purification of IgY from hen eggs was done by Washington Biotech, Inc. Due to the
high concentration of non-specific antibodies in the samples, further purification of antirVCP antibodies was desired. Purification was achieved using a Peirce Amino-link Plus
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Figure 12. Purity of rVCP used in X-Ray crystallography. Various amounts of
purified rVCP are shown by SDS-PAGE and Coomassie blue staining. Also shown is the
total volume, number of milligrams, and total activity units of the sample. This sample
contained 10% glycerol (total volume) and was sent to Dr. Krishna Murthy for
crystallization studies, which ultimately resulted in the crystal structure of rVCP,
described in chapters 3-5.

rVCP for X-ray Crystallography

0.25 µl

0.125 µl

0.5 µl

Sample: 1,863 µl
12.5 mg
476,928 Units

Total activity:
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1 µl

2 µl

protein immobilization kit. Using this kit, 20 mg of purified rVCP was covalently
immobilized to 2 ml activated sepharose beads for use in chromatography. Using this
column, rVCP specific antibodies could be purified from the immunoglobulin samples.
After passing 5 ml of purified IgY through the column, a NaCl step gradient was used to
elute the bound antibodies, see figure 13A. As can be seen, different strengths of
antibody affinity are evident. Only the higher NaCl fractions were then pooled and
concentrated. Similar techniques were used in an attempt to purify rabbit anti-rVCP IgG,
but were unsuccessful due to very low concentrations of specific antibodies. The low
concentration of specific IgG antibodies against VCP found in the immunized rabbit sera
was most likely the result of VCP being only mildly immunogenic in mammals. This is
due to the great structural similarity between VCP and the mammalian complement
regulatory proteins.
To better characterize the affinity-purified anti-rVCP IgY, a Biacore X instrument
(University of Western Cape, Cape Town, SA), utilizing surface plasmon resonance
technology, was employed. With rVCP covalently immobilized to a CM-5 sensor chip,
10 mM anti-rVCP IgY was injected. As can be seen in figure 13B, strong binding
occurs. To test the specificity of this antibody, 10 mM pre-immune (non-affinity
purified) IgY was injected. Figure 13C shows that no binding was evident, indicating
that binding antibodies arose after immunization. Finally, anti-rVCP was pre-incubated
with 50 nM rVCP before injecting. As can be seen in figure 13D, the binding to the chip
(with rVCP immobilized) was completely abolished, compared to that seen in figure 13B.
The results obtained in these experiments demonstrated the specificity of the anti-rVCP
IgY; this antibody was then available for many future immunohistochemistry studies.
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Figure 13. Purification and characterization of anti-rVCP IgY. IgY anti-rVCP was
obtained from Washington Biotech through multiple immunization of a single chicken.
A)

rVCP affinity purification of ant-rVCP IgY using an rVCP column, made by

immobilizing rVCP to a Pierce Amino-Link Plus column. Anti-rVCP IgY was eluted
using a NaCl step gradient ranging from 50 mM to 2 M. IgY with various affinities can
be seen eluting from the column at different NaCl concentrations.

Only the higher

affinity antibodies were pooled and concentrated for use in immunohistochemistry and
Biocore studies. B) With rVCP immobilized to a CM5 Biacore sensor chip, 10 nM of
anti-rVCP IgY was injected and binding was observed. The kinetics of this binding are
very strong, as indicated by the extended disassociation time.

C)

With rVCP

immobilized to a CM5 Biacore sensor chip, 10 nM of pre-immune IgY was injected and
binding was monitored. No binding was observed, indicating that no anti-rVCP IgY was
present. D) With rVCP immobilized to a CM5 Biacore sensor chip, 10 nM of anti-rVCP
IgY and 50 nM rVCP was mixed together, injected, and binding was monitored. Again,
no binding was observed, indicating that the antibody was specific to the immobilized
protein, rVCP.
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CHAPTER 3
HEPARIN BINDING ACTIVITY OF VCP

Introduction to Heparin Binding
This chapter contains material adapted from the following publications and manuscript:
Smith S.A., N.P. Mullin, J. Parkinson, S.N. Shchelkunov, A.V. Totmenin, V.N. Loparev,
R. Srisatjaluk, D.N. Reynolds, K.L. Keeling, D.E. Justus, P.N. Barlow, and G.J.
Kotwal. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on
poxvirus complement control proteins serve as putative heparin binding sites and
contribute to inhibition of molecular interactions with human endothelial cells: a
novel mechanism for evasion of host defense. J. Virol. Jun. 74(12):5659-66, 2000
[Cover of J. Virol. Oct. 74(20), 2000].
Murthy K.H., Smith S.A., Ganesh V.K., Judge K.W., Mullins N., Barlow P.N., Ogata
C.M., and Kotwal G.J. Crystal structure of a complement control protein that
regulates both pathways of complement activation and binds heparan sulfate
proteoglycans. Cell. Jan. 26, 104:301-11, 2001.
Smith S.A., Arjunwadkar S., Krishnasamy G., Judge K., Murthy K.H., Pugh D.R., and
Kotwal G.J. Mapping of regions within the vaccinia virus complement control
protein involved in binding to key complement components and heparin using surface
plasmon resonance. Submitted to Virology, 2002.
The most recently identified property of the multifunctional VCP is its ability to
bind heparin. It has been shown in previous studies, as well as this one, to exhibit
lysozyme-like heparin binding activity. Because of this activity, VCP can be taken up by
mast cells and possibly persist in the tissue for extended periods of time, helping to
preserve the viral habitat (Kotwal et al., 1998b). In vivo studies have indicated that
FITC-labeled VCP injected intravenously becomes localized along the endothelium. It
has also been shown to reduce chemotactic migration of leukocytes in the presence and

absence of the chemokine MIP-1α (Reynolds et al., 2000). This suggests that VCP can
bind to heparin-like (heparan sulfate proteoglycans, see figure 14) molecules lining the
surface of endothelial cells, blocking chemokine binding and thereby blocking the
chemotactic signal.
It is clear that the ability to bind polyanions, such as heparin, is crucial for the
function of many immune-regulating proteins. Factor H (fH), for example, binds to the
polyanion sialic acid on the surface of mammalian cells, preventing activation of the
alternative pathway (Meri and Pangburn, 1994). Like VCP, fH is made up of SCRs,
three of which have been shown to have heparin binding abilities (Blackmore et al.,
1998). It is postulated that these heparin-binding domains are responsible for binding
sialic acid, thereby preventing alternative pathway activation. The heparin binding
regions of many other proteins exhibiting heparin binding activity have been mapped
(Cardin and Weintraub, 1989; Cardin et al., 1991; Marino et al., 1999; Sendak and
Bensadoun, 1998; Wong et al., 1995; DuBose and Haugland, 1993). VCP, fH, and C4bBP are the only complement control proteins found to possess this ability (Blom et al.,
1999; Blackmore et al., 1998). In most cases (including ours), binding is the result of
dense regions of positively charged amino acids. These arginine and/or lysine rich
regions vary in sequence and length among heparin binding proteins. Interestingly, the
heparin binding sequences used by VCP and its homologues are short and relatively
conserved.
We have attempted to further characterize the biological significance of VCP's
ability to bind heparin. Using flow cytometry, the amount of specific antibody binding to
human endothelial cells - in the presence and absence of VCP - was measured. It was
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Figure 14. Heparan sulfate proteoglycans. Heparan sulfate proteoglycan structure is
illustrated, along with their location and the monomers that make up the large
polysaccharide chains. Heparan sulfate proteoglycans are present on many cell surfaces.
The main body, or peptide core, possesses a short intercellular domain, membrane
anchoring region, and extracellular peptide core to which the polysaccharide,
glycosaminoglycan, chains are attached. Heparan sulfate proteoglycans are named by the
number of sulfate groups per disaccharide unit of the glycosaminoglycan chain; for
example, heparan monosulfate contains one sulfate group per disaccharide unit. Also
shown are the monomers that can make up the glycosaminoglycan chain. Depending on
the degree of sulfation, heparan sulfate proteoglycans may have varying degrees of
electronegative charge.
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found that VCP was able to inhibit antibody binding to MHC class I molecules on human
endothelial cells. This suggests that VCP can interfere with molecular interactions with
infected cells and could prevent antibody-dependent cell-mediated cytotoxicity (ADCC)
as well as other cytotoxic cell interactions with target cells. The ability of VCP to bind
heparin-like molecules suggests that it plays many roles and therefore may have a variety
of applications. It is for these reasons that we have been interested in obtaining a better
understanding of the molecular basis for the VCP-heparin interaction. Through
examination of several recombinant VCP fragments, it has now been determined that the
percentage of positively charged amino acids, overall charge, and the number of putative
heparin binding sites, are all important factors governing the heparin binding ability of
rVCP. In addition, the heparin binding ability of rVCP and the various truncated rVCP
molecules was tested using surface plasmon resonance (SPR) binding analysis (Biacore
X ®) with heparin immobilized to the sensor chip. Positive binding was determined by
subtraction of ligand channel readings from the readings of the control channel, and each
experiment was repeated several times to confirm results. Next, in order to test whether
the putative heparin binding site, K/R-X-K/R, was actually involved in this interaction,
synthetic peptides (tri-peptides) were designed to resemble the putative heparin binding
sites present on rVCP, and competition assays were performed. The presence of this
synthetic heparin binding site resulted in a stronger binding between rVCP and heparin,
which was believed to result from the bridging of the protein's central net negative
charge. With the results of these assays in hand, attempts were then made to purify
rVCP~2,3 using this technique. Finally, due to the extreme cost of heparin
chromatography, dextran sulfate chromatography was also investigated. As a result of
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the similar high degree of sulfation, rVCP was found to bind very effectively to sulfated
dextran beads.
Utilizing the data collected in the above experiments, an NMR model of rVCP
was created and the positions of the heparin binding sites highlighted. Two areas, located
at each end of the protein, were identified as being involved in binding. In addition, with
the X-ray crystal structure in hand, an accurate model of the electrostatic field
distribution across rVCP could be predicted and illustrated. Finally, spatial homology
with other well-characterized heparin binding domains was investigated for comparison.

72

Materials and Methods
Flow Microfluorimetric Analysis:
Ratchapin Srisatjaluk and David Reynolds, Department of Microbiology and
Immunology, aided in all experiments involving flow microfluorimetric analysis. Human
umbilical cord vascular endothelial cells (HUVECs) were obtained from the American
Type Culture Collection (ATCC, Rockville, MD) at passage thirteen. Monolayer cultures
were maintained using F12K Ham’s media supplemented with 10% fetal bovine serum,
30 µg/ml endothelial cell growth supplement (Sigma), and 100 µg/ml heparin (Sigma), at
37oC in humidified air containing 5% CO2. Cells were cultured to approximately 80%
confluency in 75 cm2 vented flasks coated with 1.5% gelatin in phosphate buffered
saline. Cells were trypsinized (0.25% trypsin, 1 mM EDTA, Sigma), and 4 x 105 cells/ml
were placed in a 6-well flat-bottom culture plates (3.5 cm diameter, Falcon, Lincoln Park,
NJ), coated with 1.5% gelatin, and incubated for 24 h in F12K media without growth
factor (Lian et al., 1996). In order to determine the ability of rVCP, rVCP~3,4, and HBP
to bind HUVECs, duplicate wells (2 ml each) were trypsinized and rinsed with FTA
hemagglutination buffer (Becton Dickinson) and stained for 30 min on ice with either 20
µg of FITC-labeled rVCP, 30 µg of FITC-labeled rVCP~3,4, or 30 µg of FITC-labeled
HBP. For analysis of antibody interaction with cell surface class I HLA-ABC molecules,
triplicate wells (2 ml each) were trypsinized and rinsed with FTA hemagglutination
buffer and stained for 30 min on ice with 0.25 µg of phycoerythrin-conjugated mouse
antihuman HLA-ABC mAb (Caltag, Burlingame, CA), or a mouse IgG2a mAb (an
isotype-match negative control) in the presence or absence of 2 or 5 µg of VCP – 90-98%
pure from natural infection. After incubation, cells were rinsed three times in FTA
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buffer, and then fixed in Hank’s balanced salt solution (HBSS) containing 2%
paraformaldehyde. Before staining, cell cultures were assessed for viability by trypan
blue dye exclusion, and the cells were found to be >95% viable. The percentage of
positively stained cells was determined using a flow cytometer (Becton Dickinson
FACScan, San Jose, CA) equipped with a single 15-mW argon laser tuned to 488 nm,
technical assistance and use of the FACS facilities was provided by Dr. Sam Welhausen
of the J. Graham Brown Cancer Center. Forward and 90o angle light scatter, integrated
log phycoerythrin and FITC fluorescence signals were collected and analyzed.
Variability between duplicate samples was less than 10%. To compensate for any
background fluorescence, the control threshold was set less than 1% binding of control
mAbs. Data were acquired from analysis of >3000 events. A single homogenous cell
population was indicated as detected by forward and 90o light scatter.

Heparin Binding Ability:
In order to establish a basis for comparing heparin binding ability, 10 µg each of
bovine serum albumin (BSA), heparin binding protein (HBP)[described earlier
(Flodgaard et al., 1991)], lysozyme, and MIP-1 α were pooled, dissolved in 1 ml of
ultapure water, and passed through a 1 ml HiTRAP heparin column and the unbound
material collected. The bound proteins were rinsed with 1 ml of ultrapure water and then
eluted with increasing sodium chloride concentrations ranging from 250 mM up to 4.0 M.
Next, 20 µg of purified rVCP~1,2, rVCP~2,3, rVCP~3,4, rVCP or 10 µg of wild type
VCP (from VV infection of cell culture) were each dissolved in 1 ml of ultrapure water
and passed through separate 1 ml HiTRAP heparin columns and the unbound materials
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collected. After washing the column with 1 ml of ultrapure water, the proteins were
eluted with sodium chloride concentrations ranging from 250 mM to 2.5 M. The
fractions were then separated using SDS-PAGE and silver stained. Densitometric
readings were taken using the AlphaImager 2000 software system. Finally, 0.5 ml of the
fraction containing the protein was concentrated by ultrafiltration and its activity tested
using the hemolysis assay.

Sequencing of the VCP Homologue in MPV:
Sequencing was done by Alexei Totmenin, from the Department of Molecular
Biology of Genomes, State Research Center of Virology and Biotechnology Koltsovo,
Novosibirsk Region, Russia, as described previously (Shchelkunov et al., 1998).

Biacore Instrumentation:
Instruction and use of the Biacore X ® facilities was provided by David Pugh and
Jasper Rees from the Department of Biochemistry, University of Western Cape, Cape
Town, South Africa. Carboxylated dextran sensor chip CM5 was chosen for amine
coupling. Chip was docked and primed in a Biacore X ® instrument. Hepes-buffered
saline (HBS) (Biacore, Biagrade) was used as the running buffer throughout the study.
Standard amine coupling was used to immobilize heparin to the sensor chip – see figure
15 for amine coupling procedure. First, channel one was selected with a flow rate of 10
µl/min. The surface of the sensor chip was then activated by injecting 35 µl of a freshly
prepared 1:1 mixture of N-hydroxysuccinimide (NHS) to N-ethyl-N'(dimethylaminopropyl)-carbodiimine (EDC). Directly following surface activation, 30 µl
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Figure 15.

Standard amine coupling procedure for Biacore instrument.

carboxylated dextran sensor chip (CM5) was chosen for amine coupling.
docked and primed in a Biacore X

®

The

Chip was

instrument. The surface of the sensor chip was then

activated by injecting a freshly prepared 1:1 mixture of N-hydroxysuccinimide (NHS) to
N-ethyl-N'-(dimethylaminopropyl)-carbodiimine (EDC).

Directly following surface

activation, a mixture of streptavidin (the ligand) (1 mg/ml) and coupling buffer 3 (0.1 M
glycine pH 4.8) was injected. The surface was then deactivated (unreacted groups were
blocked) by injecting 20 µl ethanolamine HCl (1M, pH 8.5).
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of a mixture of 5 µl streptavidin (1 mg/ml) and 95 µl coupling buffer 3 (0.1 M glycine pH
4.8) was injected. The surface was then deactivated (unreacted groups were blocked) by
injecting 20 µl ethanolamine HCl (1M, pH 8.5). Surface regeneration was frequently
achieved by injecting 10 µl of Biacore regeneration solutions 1, 2, or 3. In order to arrive
at satisfactory regeneration in studies testing heparin binding of rVCP, 1-10 µl injections
of 50-70 mM NaOH were used. If regeneration was not adequate after the first injection,
more than one injection was tried. Care was taken not to damage ligand on chip surface.
BiaEvaluation 3.0 software was used to evaluate all data collected. For comparison, data
is presented by displaying both ligand channel and control channel for all binding studies.
In order to test the interaction between heparin and rVCP, heparin was
immobilized to a CM5 sensor chip in the following manner. Using standard amine
coupling, streptavidin (Sigma) was immobilized to channel one of the sensor chip. Next,
heparin-albumin-biotin (Sigma) was passed over the streptavidin, resulting in binding of
this heparin coated albumin molecule (albumin with heparin and biotin covalently bound)
to the sensor chip. Finally, the interaction between rVCP and heparin could be measured.
The interaction of various fragments of rVCP with heparin was also tested.

Tri-peptide Studies:
To test the hypothesis that synthetic peptides resembling the putative heparin
binding sites could interfere with binding of rVCP to heparin by competitive inhibition,
three tri-peptides were purchased from Bio-Synthesis Incorporated. The KRR tri-peptide
was synthesized to act as the competitive inhibitor and both negatively charged (DID)
and neutral (GSS) tri-peptides were used as a control. In the presence and absence of

78

various concentrations (300 µg – 3 mg) of each tri-peptide, heparin chromatography of
rVCP was performed. The tri-peptide was suspended in water in the presence of 300 µg
rVCP. This starting material was then passed through a 1 ml HiTRAP heparin column
and the unbinding material was collected. The column was then washed and the protein
was eluted with a NaCl step gradient ranging from 100 mM to 500 mM. The fractions
were then visualized using SDS-PAGE and coomassie blue staining. The rVCP
containing fractions were then compared between tri-peptides in order to determine the
effect that they had on the heparin binding ability of rVCP.

Model of rVCP:
The structure of the two unknown VCP modules (VCP SCR 1 and VCP SCR 2)
were modeled by homology with the four known VCP module structures: VCP SCR 3,
VCP SCR 4, fH SCR 15 and fH SCR 16, using the program MODELLER (Sali and
Blundell, 1993). Five models of each module were created. The model which was
closest to the average structure was used in the construction of the rVCP~1-4 model.
Construction of the rVCP~1-4 was undertaken using the molecular visualization package,
InsightII (Msi Inc. San Diego, Ca). This was achieved by simply bonding the two
modeled VCP structures to the NMR derived structure of the rVCP~3,4 module pair
(Wiles et al., 1997). No attempt was made to accurately model the junctions between
modules 1 and 2 and modules 2 and 3. Rather, torsion angles in the two residues linking
the module pairs were set to give a relatively extended conformation.
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X-Ray Crystallography:
Dr. Krishna Murthy from the Center for Biophysical Science and Engineering,
University of Alabama at Birmingham performed the X-ray crystallography of rVCP.
Two crystal forms, form I and form II, of rVCP expressed in yeast were grown. Both
were obtained using a protein concentration of 5-12 mg/ml in 20 mM TRIS, pH 7.5 (form
I) and 8.3 (form II), 100 mM NaCl. Form I crystals were grown using 10% PEG 6000
and form II crystals using 8-12% PEG 8000 in hanging drop vapor diffusion experiments
over 7-10 days at 20oC.
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Results
Specific Antibody Blocking to HUVECs:
In order to determine the biological consequences of heparin binding by VCP, we
tested whether VCP was able to block functional molecular interactions with human
umbilical cord vascular endothelial cells (HUVECs). First, the ability of FITC-labeled
rVCP to bind heparin was tested by chromatography. As can be seen in figure 16, the
heparin binding ability of rVCP is diminished due to labeling. However, approximately
~25% of the labeled material retains functional heparin binding ability. The ability of
rVCP, rVCP~3,4, and HBP to bind the surface of HUVECs was then tested using flow
cytometric analysis. As shown in figure 17A and B, all three proteins possess the ability
to bind strongly to HUVECs. A 3.0, 2.9, and 5.4 fold increase in mean fluorescent
intensity (MFI) over the control was observed when 20 µg FITC-labeled rVCP, 30 µg
FITC labeled rVCP~3,4, or 30 µg FITC labeled HBP (respectively) was added to the
suspension of HUVECs. Next, using flow cytometric analysis of HUVECs treated with
mouse monoclonal antibodies to human MHC class I molecules – in the presence and
absence of VCP – VCP was shown to be capable of modulating antibody binding in a
dose-dependent manner. As shown in figure 17C, addition of 5 µl (2 µg) of VCP to
antibody treated HUVECs, reduced antibody binding from 91.5% down to 75.4%. An
additional 15 µl (5 µg total) of VCP reduced antibody binding from 91.5% to 61.0% suggesting that it is blocking in a dose-dependent manner.
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Figure 16. Heparin binding of FITC-labeled rVCP. Heparin purification of rVCP
labeled with FITC. Most of the FITC rVCP sample passed through the HiTRAP heparin
column with out binding. Only ~25% of the sample bound heparin with the same affinity
as the unlabeled protein, see figure 7 for comparison. This observation may be due to
FITC masking of the heparin binding sites on rVCP.
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Figure 17. Representative histograms showing that VCP is able to reduce mouse
antihuman HLA class I antibody binding to HUVECs.

The results of flow

microflourimetric analysis are as follows: A1) No treatment control A2) Binding of
FITC-labeled rVCP to HUVECs B1) No treatment control B2) Binding of FITC-labeled
rVCP SCR (3,4) to HUVECs B3) Binding of FITC-labeled HBP to HUVECs C1)
Nonspecific mouse monoclonal antibody (isotype-matched mouse IgG2a mAb) binding
to HUVECs cells (negative control) C2) Mouse monoclonal antihuman HLA-ABC
antibody binding to HUVECs (positive control) C3) Mouse monoclonal antihuman HLAABC antibody binding to HUVECs in the presence of 5 µl (2 µg) of VCP C4) Mouse
antihuman HLA-ABC antibody to HUVECs in the presence of 20 µl (5 µg) of VCP.
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Heparin Binding of rVCP and rVCP Fragments:
To calibrate the HiTRAP heparin column, several proteins having different
binding affinities for heparin were passed through the column and eluted with increasing
sodium chloride concentrations. SDS-PAGE analysis of the eluted fractions containing
these proteins of various heparin-binding activities can be seen in figure 18. Analysis
suggests that bovine serum albumin (BSA) does not bind heparin, since it is present only
in the unbound and wash fractions. Lysozyme and MIP-1 α, which bound heparin with
moderate and equal affinity, were contained within the 500 mM and 750 mM sodium
chloride fractions. HBP, showing the highest affinity for heparin, was eluted by a sodium
chloride concentration of 2.0 M.
In order to better characterize the heparin binding ability of the VCP molecule,
VCP, recombinant VCP, and various recombinant segments of VCP were passed through
HiTRAP heparin columns and analyzed using SDS-PAGE, shown in figure 19. The
results suggest that the full-length natural and recombinant proteins bind heparin with
close to or equal affinity as lysozyme and MIP-1 α; both VCP and rVCP were
concentrated primarily in the 500 mM and 750 mM sodium chloride fractions. PAGE
analysis of the various recombinant VCP segments revealed data that are even more
interesting. Recombinant rVCP~1,2 and rVCP~3,4 bound heparin with the same strength
as the full-length protein, eluting once again at 500 mM and 750 mM. In contrast,
recombinant rVCP~2,3 did not bind heparin at all and was found primarily in the
unbound and wash fractions. The activity of the purified proteins was then tested using
the hemolysis assay. The results indicate that only the full-length protein inhibits lysis of
sensitized sheep red blood cells - anywhere from 60 to 90% inhibition. The rVCP
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Figure 18. PAGE analysis of the heparin binding activity of BSA, HBP, lysozyme,
and MIP-1 alpha. In order to calibrate the HiTRAP heparin column, various proteins
(BSA, HBP, lysozyme, and MIP-1α) with differing affinities for heparin were passed
through the column and eluted with sodium chloride concentrations ranging from 250
mM to 4.0 M. M = molecular weight marker, S.M. = starting material, Unb. = unbound
fraction, W = wash.
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Figure 19. PAGE analysis of the heparin binding activity of VCP and rVCPs. VCP
and various rVCPs were passed through separate HiTRAP heparin columns and eluted
with sodium chloride concentrations ranging from 250 mM to 2.5 M. The fractions were
collected, run on SDS PAGE, silver stained, and the band densities measured. The
results are shown as follows: A) recombinant rVCP SCR (1,2) B) recombinant rVCP
SCR (2,3) C) recombinant rVCP SCR (3,4) D) recombinant rVCP E) VCP from the
natural infection process. For gels A-E, M = molecular weight marker, S.M. = starting
material, Unb. = unbound fraction, W = wash, VCP = VCP from natural infection. F)
Densitometric scanning of above gels A-E.

segments showed no inhibition of lysis, suggesting that the whole protein is needed to
block complement activation. The naturally truncated VCP homologue produced by
monkeypox virus (MPV)(shown in figures 20 and 21), which lacks almost the entire
fourth SCR, has been shown to inhibit hemolysis of sensitized sheep red blood cells.
Thus, this indicates that it is blocking the classical pathway of complement activation.

Conserved K/R-X-K/R Sites:
To more precisely identify the molecular basis behind the VCP-heparin
interaction, the amino acid sequences were analyzed using the MacVector software
system. Putative heparin binding sites (K/R-X-K/R) were first identified – shown in
figure 20 along with the sequence alignment of different poxvirus VCP homologues –
and predicted to be located on the surface of the protein. The amino acid sequences were
then scanned to determine the total number of positive amino acids (K+R), the percentage
made up of these positively charged amino acids (% K+R), and the overall pI of the
protein – the results are summarized in figure 21. All of the proteins shown to bind
heparin had an overall pI of greater than 7.0, and more importantly, were made up of
greater than 9% positively charged amino acids. The results also suggest that SCR 1 and
SCR 4 contribute the most to this interaction. Although the results show there is no
simple answer to how VCP binds heparin, it is clear that the overall positive charge,
number of putative binding sites, and the percentage of positive amino acids making up
the protein, have a significant effect on its ability to interact with and bind heparin.
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Figure 20. Sequence alignment including termini of rVCP constructs and putative
heparin binding sites. Multiple alignment of the four short consensus repeats (SCR)
from orthopoxviruses VAC-COP (vaccinia virus, Copenhagen strain), VAC-WR
(vaccinia virus, western reserve strain), CPV-GRI (cowpox virus, Russian isolate from
human patient), CPV- BRI (cowpox virus, Brighton strain), VAR-BSH (variola virus,
Bangladesh strain), VAR-IND (variola major virus, Indian strain), VAR-GAR (variola
minor virus, alastrim Garcia strain), and MPV-ZAI (monkeypox virus, isolated from a
human patient from Zaire in 1996). The putative heparin binding sites (K/R-X-K/R) are
marked with solid bars, arrows indicate the termini of the rVCP constructs, and the
cysteines are highlighted. See figure 57 for disulphide bonding pattern.
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Figure 21.
rVCPs.

Structure-function summary table of VCP, VCP homologues, and

VCP/IMP/SPICE, MPV homologue of VCP, recombinant VCP, and four

overlapping recombinant segments of VCP with 2 or 3 SCRs are shown along with their
ability to inhibit hemolysis of sensitized sheep red blood cells and/or bind heparin. Also
listed are the number of positively charged amino acids (K+R) found in the protein,
percentage of positively charged amino acids (% K+R) making up the protein, pI of the
protein, and number of putative heparin binding sites found on the surface of the protein.

Inhibition of
Hemolysis

Heparin Binding
Activity

K+R

% K+R
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# of Putative
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(K/R X K/R)

+

+
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4
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+
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3

rVCP

+
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4

rVCP SCR (2,3,4)

+

16
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rVCP SCR (1,2)

+

12
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1
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VCP/IMP/SPICE

rVCP SCR (2,3)

rVCP SCR (3,4)

+

Short Consensus Repeats (SCR)

---C--P--------------------YF-C---C--------C---G-W----A/P-C-

Biacore Heparin Binding:
To map the heparin binding site(s) on VCP using SPR, heparin was immobilized
to a CM5 sensor chip and rVCP, or rVCP fragments, was injected and their ability to bind
measured. As shown in figure 22, both rVCP and rVCP~3,4 bound strongly to the
immobilized heparin. Surprisingly, rVCP~1,2, although the protein was purified using
heparin affinity chromatography, did not show the ability to interact with heparin
immobilized to the sensor chip. The chromatography data suggests that two sites on
rVCP, that are highly homologous to the well-characterized heparin binding site of
fibroblast growth factor protein, may be involved in heparin binding. The two sites are
located at the junction between CCP modules 1 and 2 (KRR), and at the far end of
module 4 (KQK). These sites were first identified when mutant proteins rVCP~1,2 and
rVCP~3,4 were shown to bind and be purified using heparin affinity chromatography.
The second heparin binding site found at the junction of CCP modules 1 and 2 may
possess a much weaker affinity, and without the presence of the remaining half of the
protein is unable to bind heparin using SPR. This region may therefore double as a
heparin/C3b-C4b binding site, binding weakly to heparin only in the absence of
complement.

Tri-peptide Studies:
Small tri-peptides were ordered from Bio-Synthesis Incorporated (Lewisville,
Texis) to determine whether the heparin binding of rVCP could be inhibited in the
presence of a high concentration of putative, K/R-X-K/R, binding sites. The putative
heparin binding site, KRR, as well as control tri-peptides DID (negatively charged) and

96

Figure 22. Heparin binding of rVCP fragments. The ligand and control channel
responses are shown for the binding between rVCP, or rVCP fragments, and heparin
immobilized to the sensor chip. Control channel response represents only bulk effects;
no protein is immobilized. All proteins were tested at different concentrations to confirm
the presented results.
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GSS (neutral), were each tested in various concentrations to see what effect they would
have in rVCP's ability to bind heparin. As can be see in figure 23, rVCP binding to
heparin was actually enhanced with increasing concentrations of the KRR tri-peptide.
This effect was also seen, though to a lesser extent at higher concentrations, with the DID
and GSS tri-peptides – see figures 24 and 25. These results suggested that the KRR tripeptide might bridge the central negatively charged region of rVCP, and thus increase its
interaction with heparin by increasing its positive electrostatic field. If this hypothesis
were true, rVCP~2,3 (normally unable to bind heparin due to strong negative charge), in
the presence of high concentrations of KRR, would bind heparin. As can be seen in
figure 26, this was not the case. rVCP~2,3 did not bind heparin even in the presence of
high concentrations of the KRR tri-peptide.

Dextran Sulfate Affinity Chromatography:
As an alternative to heparin chromatography, in an attempt to reduce expense and
increase binding capacity, dextran sulfate matrix was purchased from Sigma. Using a
disposable 20 ml Bio-Rad column, 20 ml of sulfated dextran matrix was seeded and
rinsed with water. Figure 27 shows the results obtained using a NaCl step gradient to
elute rVCP. rVCP was found to bind dextran sulfate with a higher affinity (500 mM
elution) than heparin (400 mM elution). In addition, its binding capacity seemed to be
greater than that observed for heparin matrices. Unfortunately, however, the dextran
sulfate matrix expanded too much to use for large-scale purification of rVCP.

99

Figure 23. Heparin binding of rVCP in presence of KRR tri-peptide.

Heparin

affinity chromatography was performed on rVCP in the presence of varying amounts of
the positively charged tri-peptide KRR. rVCP was eluted from the column using a NaCl
gradient ranging from 100 mM to 2 M. rVCP eluted in the 300 mM NaCl fraction in the
absence of KRR, but eluted as high as 500 mM in the presence of large concentrations of
KRR. It is not known why the KRR tri-peptide was stained while the DID and GSS tripeptides (figures 24 and 25) were not.
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No Tri-peptide
(KRR)
rVCP

300 µg rVCP
300 µg Tri-peptide
(KRR)

Tri-peptide
(KRR)

300 µg rVCP
600 µg Tri-peptide
(KRR)

300 µg rVCP
1.5 mg Tri-peptide
(KRR)

300 µg rVCP
3.0 mg Tri-peptide
(KRR)
2M

500 mM

450 mM

400 mM

350 mM

300 mM

250 mM

100 mM

Unb

S.M.

101

Figure 24. Heparin binding of rVCP in presence of DID tri-peptide. Heparin affinity
chromatography was performed on rVCP in the presence of varying amounts of the
negatively charged tri-peptide DID. rVCP was eluted from the column using a NaCl
gradient ranging from 100 mM to 2 M. rVCP eluted in the 300 mM NaCl fraction in the
absence of DID, and eluted as high as 450 mM in the presence of large concentrations of
DID.

Although DID resulted in rVCP having an increased affinity for heparin, this

affinity was significantly lower at higher concentrations of tri-peptide than that observed
in the presence of the KRR tri-peptide.
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Figure 25. Heparin binding of rVCP in presence of GSS tri-peptide. Heparin affinity
chromatography was performed on rVCP in the presence of varying amounts of the
neutrally charged tri-peptide GSS. rVCP was eluted from the column using a NaCl
gradient ranging from 100 mM to 2 M. rVCP eluted in the 300 mM NaCl fraction in the
absence of GSS, and eluted as high as 450 mM in the presence of large concentrations of
GSS. Although GSS resulted in rVCP having an increased affinity for heparin, this
affinity was also significantly lower than that observed in the presence of the KRR tripeptide at the 1.5 mg tri-peptide concentration.
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Figure 26. Heparin purification of rVCP~1,2, rVCP~2,3 (using KRR), rVCP~2,3,4.
Purification of rVCP~1,2, rVCP~2,3, and rVCP~2,3,4 using heparin affinity
chromatography. rVCP~1,2 and rVCP~2,3,4 are easily purified by this method due to
their strong affinity for heparin, however, rVCP~2,3 does not show this affinity and must
be purified by other means. Attempts were made to use the tri-peptide KRR to purify
rVCP~2,3 by heparin affinity chromatography, but failed. Proteins were eluted using a
NaCl step gradient ranging from 100 mM to 2 M.

Heparin Purification of rVCP (1,2),(2,3),(2,3,4)
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Figure 27. Dextran sulfate chromatography of rVCP. Do to the similarity between
dextran sulfate and heparan sulfate, attempts were made to purify rVCP by dextran
sulfate chromatography. rVCP was eluted using a NaCl step gradient ranging from 300
mM to 1 M. Interestingly, rVCP eluted from the dextran column at a significantly higher
NaCl concentration (500 mM as compared to 350–400 mM) than seen using heparin
chromatography. This indicates that rVCP possesses a higher affinity toward dextran
sulfate than heparin. This may be due to the greater degree of sulfation present on the
dextran sulfate molecule.
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NMR Modeled Structure:
In order to better visualize the positioning of heparin binding sites in the VCP
molecule, a model was developed using four known VCP module structures: VCP SCR
3, VCP SCR 4, factor H (fH) SCR 15 and fH SCR 16 – see figure 28. As can be seen in
this model, heparin binding exists primarily at the ends – SCRs one and four. The middle
of the molecule therefore does not contribute any to the binding (hence rVCP~2,3
showed no ability to bind).

Electrostatic Charge Distribution:
Using the X-ray crystal structure of rVCP, the electrostatic field distribution was
predicted. An extreme positively charged field over the fourth domain is very evident.
In addition, concentration of basic residues [Lys (K) and Arg (R) residues] at the junction
of modules 1 and 2 makes a second highly positively charged patch – see figure 29. Most
of the residues with carboxylic acid side chains are clustered in modules 2 and 3 with
those two modules carrying a net negative charge.

X-Ray Crystal Structure Homology:
Other than VCP, only the serum complement regulatory proteins C4b-BP and fH
have heparin binding activity. Binding sites for heparin on CCP modules 1 and 2 on the
α chain of C4b-BP (Blom et al., 1999; Hessing et al., 1990) and on CCP modules 7, 20
and 13 for fH (Blackmore et al., 1998; Sharma and Pangburn, 1996) have been identified.
The above experimental results suggest the possible presence of two heparin binding sites
on modules 1 and 4 of rVCP.
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Figure 28. VCP model showing the heparin binding sites. Front (A) and back (B)
views of the modeled structure of VCP SCR (1-4) showing the heparin binding sites
(differentially colored). In order to differentiate the extents of the individual modules,
they are shaded appropriately.

SCR 4

SCR 3

SCR 3

SCR 2

SCR 2

SCR 1

SCR 1

112

SCR 4

A)

B)

Figure 29. Electrostatic attributes of VCP. Domain 1 is at the top and domain 4 at the
bottom in all panels. a-d) Electrostatic potential mapped on to the molecular surface of
molecule A of form I crystals.

Dark blue represents 10.2 electrons per Å and red

represents –4.3 electrons per Å. e) Representation of the ±2kT contour of the potential
field around the molecule calculated and displayed by GRASP using program defaults for
all parameters, α-carbon trace is shown in yellow. f) Expanded views of the two positive
patches between domains 1 and 2 (top) and domain 4 (bottom). The top half of the panel
is in approximately the same orientation as panel a; the bottom panel represents a view as
seen from the bottom of panel a looking up at module 4. K and R residues contributing
to each patch are labeled. For the primary structure of rVCP, see figures 20 and 57.
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The structure of VCP confirms that there are two spatially distinct putative
heparin binding sites in the molecule. rVCP, in the crystal structures, appears to be a
long molecule with large positively charged domains at its two ends; a large patch of
positive charge is located at the tip of domain 4 and a second positive patch straddles
domains 1 and 2. Negatively charged groups on heparin and positively charged groups
on proteins dominate heparin-protein interactions. Heparin binding sequence motifs in
proteins consisting of suitably spaced K and R residues have been proposed (Margalit et
al., 1993) and such motifs have been identified in VCP. Structures of acidic (DiGabriele
et al., 1998; Schlessinger et al., 2000) and basic (Faham et al., 1996) fibroblast growth
factors (FGFs) complexed with heparin have offered insights into details of binding of
heparin by proteins. Modeling of heparin binding to rVCP employing FGF as a template
and using Insight II (Biosym-Technologies, 2000) shows that α carbon atoms of K
residues, 214, 216, 220 and 241, in a flexible region of module 4, can be superimposed
on corresponding basic residues, K113, R119, R112 and K128 in acidic FGF (DiGabriele
et al., 1998; Schlessinger et al., 2000). All the ligands in module 4 are either end
residues of β strands or are in flexible loops between strands – see figure 30. Similarly,
residues K64, R65 and R66 in module 1 and the linker connecting modules 1 and 2 can
be superimposed on residues K122, K118 and R119 of FGF. These two putative heparin
binding regions are separated by about 80 Å. Figure 30 shows a stereo view of the model
for the site at the tip of module 4. It is significant that the model for rVCP interactions
with heparin resembles that in the FGFs closely, an unrelated protein, indicating heparinprotein recognition mode of wide applicability.
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Figure 30. Stereo view of interaction of VCP with Heparin. An Cα trace of residues
213-242 of VCP is shown in orange. Carbohydrate is shown with carbons colored gray,
oxygen, red, nitrogen blue and sulfur yellow. Sidechains of the four basic residues of
acidic and basic FGF and VCP that were superimposed are shown in red, magenta and
cyan respectively. VCP sidechains are labeled. The figure was composed using a rigid
body transformation of VCP mainchain on to the basic FGF heparin binding segment.
The sidechains of the K residues in VCP have been rotated to point towards the heparin
fragment. The side chain of K 214 is beyond hydrogen bonding distance from heparin as
currently modeled.

Mainchain movements of 1-2 Å will be required to bring its

sidechain within interacting distance.
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Discussion
The ability of VCP to bind heparan sulfate proteoglycan molecules adds a new
dimension to its role in modulating the host immune response. In previous studies, the
ability of VCP to bind heparin was found to permit uptake by mast cells – possibly
allowing for tissue persistence over an extended time. In addition, earlier studies have
shown that binding to heparin-like molecules on the surface of endothelial cells can block
chemokine adherence, resulting in reduced chemotactic signaling. The next step was to
determine if VCP, bound to the endothelial cell surface, could interfere with antibody
binding. In this study, flow cytometry was used to demonstrate that VCP is able to bind
the surface of endothelial cells, interfering with antibody binding. More importantly, this
study demonstrates that addition of VCP significantly decreases the amount of antibody
able to attach to HUVECs in a dose-dependent manner. It is postulated that VCP,
binding to heparin-like molecules on the surface of endothelial cells, prevents antibody
adherence. This binding may therefore block antibody attachment through steric
interference, and block both molecular and cellular interactions - which are dependent on
target cell adhesion molecules binding to cytotoxic cells. Furthermore, this novel
mechanism can enable virus-infected cells or the antigen presenting cell from destruction
by host defense mechanism. Interestingly, it was estimated that the amount of VCP
required for inhibition of roughly 5 x 105 cells is approximately the same as that
produced by 2 x 105 infected cells, and therefore each infected cell can protect itself and
one or two surrounding cells. Thus, VCP enables orthopoxviruses, all of which encode
homologues of VCP, to evade the immune system by multiple mechanisms, e.g. by
blocking complement pathways, blocking antibody-dependent cytotoxic cell activity

118

(ADCC) or by interfering with attachment of cytotoxic T cells to virus infected cells.
This observation is further strengthened by recent studies by Al-Mohanna et al. (2001),
who showed that rVCP was able to block interactions between pig aortic endothelial cells
(PAECs) and naïve neutrophils and NK cells, preventing cell killing (Al-Mohanna et al.,
2001). In addition, cell culture studies demonstrate that VCP blocks complementmediated killing of PAECs by human serum, in a dose-dependent manner.
Due to the apparent importance heparin binding has in many of the biological
activities exhibited by VCP, we became interested in better characterizing the molecular
reasons for this interaction. Recombinant segments of VCP - each representing two of
the four SCRs - were generated by genetic engineering vaccinia virus DNA, encoding
VCP, into the Pichia pastoris expression system. The ability of these recombinant
segments to bind heparin was then tested. It was determined that recombinant proteins
rVCP~1,2 and rVCP~3,4 retained the same binding affinity as the full-length native
protein. While recombinant protein rVCP~2,3 retained no heparin binding ability at all.
In order to explain this, the amino acid sequences of the recombinant protein segments
were more closely examined. It was determined that the number, and more importantly,
the percentage of positively charged amino acids making up the protein contributed
greatly to its ability to interact with heparin. In addition, the overall charge and number
of putative binding sites (K/R-X-K/R) making up the protein, appears to play a role in
heparin binding. For the most part, the ability of VCP to bind heparin lies in its first and
fourth SCR. These two short consensus repeats possess within them the highest
percentage of positive amino acids, the greatest number of putative binding sites, and
have a very strong overall positive charge (data not shown).
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Using SPR, Biacore binding analysis, the ability of rVCP and rVCP fragments
was tested in order to confirm the locations of the heparin binding sites. The two sites are
located at the junction between CCP modules 1 and 2, and at the far end of module 4.
These sites were first identified in the above experiments where mutant proteins
rVCP~1,2 and rVCP~3,4 are found to bind and be purified using heparin affinity
chromatography. With heparin immobilized to the sensor chip, rVCP and the various
mutant rVCP truncations were injected and their interaction measured. rVCP and
rVCP~3,4 was found to bind strongly to the immobilized heparin. Surprisingly,
rVCP~1,2 did not show the ability to interact with heparin immobilized to the sensor
chip. The second heparin binding site found at the junction of CCP modules 1 and 2,
may possess a much weaker affinity and without the presence of the remaining half of the
protein is unable to bind heparin using SPR. It is now believed that this region may
double as a heparin/C3b-C4b binding site, binding weakly to heparin only in the absence
of complement.
In order to better visualize the positioning of heparin binding sites in the VCP
molecule, a model was developed using four known VCP module structures: VCP SCR
3, VCP SCR 4, factor H (fH) SCR 15 and fH SCR 16. As can be seen in this model,
heparin binding exists primarily at the ends – SCRs one and four. The middle of the
molecule therefore does not contribute any to the binding (hence rVCP~2,3 showed no
ability to bind). This model was confirmed when the crystal structure was resolved.
Using the crystal structure, an accurate assessment of charge distribution could be used to
authenticate the heparin binding site locations. Indeed, strong positive charge can be
seen surrounding the locations of the heparin binding sites at the junction between CCP
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modules 1 and 2, and at the far end of module 4. In addition, using spatial modeling,
both of these regions showed a considerable degree of homology with the heparin
binding site of acidic and basic fibroblast growth factor (FGF) protein. The small heparin
binding sequence of FGF is often used to define heparin binding sites on other proteins.
Due to the very close alignment of critical basic amino acid residues on rVCP with FGF,
it is almost certain that these two putative heparin sites are responsible for VCP's ability
to interact with heparin.
Using synthetic tri-peptides to mimic the short conserved sequences (K/R-X-K/R)
suspected to be involved in the heparin binding of rVCP, competition analysis was
performed. The ability of rVCP to bind heparin was actually enhanced in the presence of
increasing concentrations of the predicted heparin binding site sequence. This did not
prove that these sequences were not involved in heparin binding, although it suggested
that the sequences were not this size. Previously published heparin binding sites are
much longer than three amino acids and containing spacer regions to spatially position
the basic amino acids in alignment with the negatively charged heparin. All of the above
data suggests that the K/R-X-K/R binding motif is, in fact, part of the heparin binding
sites of rVCP, but is not the entire site required for the interaction. It is now believed that
the heparin binding site at the junction between CCP modules 1 and 2 does consist of
amino acids K64, R65, and R66, (and possibly R40, K41, and K43) but does however
involve the linker region between CCP 1 and 2 as well. Likewise, a series of K residues,
214, 216, 220 and 241, which also incorporates a K/R-X-K/R binding motif, makes up
the second heparin binding site on a flexible region at the tip of module 4 – see figure 31.
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Figure 31. Residues involved in binding heparin in VCP. Spatial relationship of two
heparin binding sites on VCP. Residues K64, R65, and R66 (cyan) between modules 1
and 2 are believed to be involved in weak heparin binding in the absence of complement,
image A. In the presence of complement, these basic residues are thought to double as a
ligand for C3b/C4b, image B. Residues K214, K216, K220, and K241 (cyan) at the Cterminus of VCP are thought to bind heparin strongly, contributing significantly to VCP's
heparin binding abilities. Heparin hexasaccharide (carbon, white; oxygen, red; nitrogen,
blue; and sulfur, yellow) is modeled in A and B, with the four lysine residues which
likely act as ligands.

B.

A.
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The importance of heparin binding to the function of soluble complement control
proteins is becoming more evident. Studies of factor H (fH) show that heparin binding is
very important in distinguishing activator surfaces from host cell surfaces (Pangburn et
al., 2000). In addition, both C3b decay acceleration and co-factor activities of fH are
enhanced in the presence of heparin (Meri and Pangburn, 1994). This may add strength
to the hypotheses that VCP binds heparan sulfate on the surface of vaccinia virus infected
host cells to protect the cell from complement activation, cell lysis, and thus preserves the
viral habitat.
In summary, by examining the heparin-binding ability of VCP, we have gained a
better understanding of the molecular basis by which this interaction occurs. In addition,
the data presented here further enhances our understanding of this truly unique, yet
compact, multifunctional viral protein. It resembles in structure and function giant
complex human complement regulatory proteins human C4b binding protein (C4b-BP)
and the complement receptor 1 (CR1), respectively. Not only is VCP a miniature version
of these large molecules, it has retained all the complement modulating functions, and as
we have described here, added a number of additional functions to its repertoire due to its
ability to bind heparin-like molecules. This better understanding may some day help in
the exploitation of VCP’s possible therapeutic properties in the treatment of
inflammatory conditions such as Alzheimer’s Disease (Daly and Kotwal, 1998), CNS
injury, systemic lupus erythematosus, and xenograft transplant rejections.
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CHAPTER 4
COMPLEMENT BINDING ACTIVITY OF VCP

Introduction to Complement Binding
This chapter contains material adapted from the following publications and manuscript:
Smith S.A., N.P. Mullin, J. Parkinson, S.N. Shchelkunov, A.V. Totmenin, V.N. Loparev,
R. Srisatjaluk, D.N. Reynolds, K.L. Keeling, D.E. Justus, P.N. Barlow, and G.J.
Kotwal. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on
poxvirus complement control proteins serve as putative heparin binding sites and
contribute to inhibition of molecular interactions with human endothelial cells: a
novel mechanism for evasion of host defense. J. Virol. Jun. 74(12):5659-66, 2000
[Cover of J. Virol. Oct. 74(20), 2000].
Murthy K.H., Smith S.A., Ganesh V.K., Judge K.W., Mullins N., Barlow P.N., Ogata
C.M., and Kotwal G.J. Crystal structure of a complement control protein that
regulates both pathways of complement activation and binds heparan sulfate
proteoglycans. Cell. Jan. 26, 104:301-11, 2001.
Smith S.A., Arjunwadkar S., Krishnasamy G., Judge K., Murthy K.H., Pugh D.R., and
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In order to modulate the inflammatory response mounted by the host, many
poxviruses encode proteins that mimic components of the complement and chemokine
systems (Kotwal, 2000). Our lab has been interested in the many properties of the
vaccinia virus complement control protein (VCP). Functionally, VCP is very similar to
factor H (fH), membrane cofactor protein (MCP), decay-accelerating factor (DAF), and
complement receptor one (CR1). Structurally, it is composed of four complement control
protein (CCP) modules, also known as short consensus repeats (SCR) or Sushi domains,

making it along with homologous proteins members of the complement control protein or
regulators of complement activation (RCA) family – see figure 32 (Kotwal and Moss,
1988). VCP has been shown to inhibit the classical and alternative pathways of
complement activation, through its ability to bind C3b and act as a cofactor for factor I
cleavage, preventing the formation of the alternative pathway C3 and classical pathway
C5 convertase (McKenzie et al., 1992; Kotwal et al., 1990; Sahu et al., 1998). VCP is
also able to bind C4b, allowing it to block early steps in the classical pathway of
complement activation – see figure 33. By blocking complement activation at multiple
sites, VCP down-regulates C3a, C4a, and C5a proinflammatory chemotactic factors,
resulting in reduced cellular influx and inflammation. Experimental support for this
comes from in vivo experiments using BALB/c mice injected in the footpad with cowpox
virus (CPV) expressing or lacking the VCP homologue in CPV, termed the inflammation
modulatory protein (IMP) (Miller et al., 1997). A significantly greater influx of
inflammatory cells into the tissue was observed when the footpad was infected with CPV
lacking IMP as compared to that found in IMP expressing CPV. Another experiment,
using BALB/c congenically matched C5-sufficient and C5-deficient mice injected in the
footpad with CPV, showed that C5-deficient mice exhibited a significantly greater
swelling response that persisted longer and also showed signs of hemorrhage, edema, and
ulceration (Miller et al., 1995). In addition, the presence of IMP drastically diminished
the inflammatory response elicited by CPV (Kotwal et al., 1998a; Howard et al., 1998).
As mentioned in chapter 1, the origin of vaccinia virus remains unknown. Since
VCP is secreted from the infected host cell in order to establish a suitable habitat for viral
replication, it seems likely that VCP may have evolved to be host specific. This means
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Figure 32.

Several members of the complement control protein (CCP) family.

Illustrated are the cartoon structures of VCP, C4b-BP, and CR1. These are examples of
proteins that belong to the family of SCR containing proteins, also known as the CCP
family.

These proteins are made of repeating units, SCRs, which have a common,

relatively conserved sequence, which results in two disulfide bonds and a characteristic
sushi structure. The size of VCP, and the MPV homologue, is compared to that of C4bBP, which it shares the highest degree of sequence homology, and CR1, which it shares
the greatest functional homology.
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Figure 33. Complement cascade and points of VCP inhibition. Illustrated are the two
main pathways of complement activation, the classical pathway, initiated by antibody
fixation, and the alternative pathway, initiated by an activator surface. VCP possesses the
ability to block both pathways of complement activation by binding C3b and C4b
(depicted by red Xs), resulting in their cleavage and inactivation by factor I.

This

prevents the formation of the classical and alternative pathway C3 convertase, ultimately
blocking activation at an early step. In addition, VCP blocks the formation of the C5
convertase in the classical pathway.

By blocking multiple steps of complement

activation, VCP is also able to prevent the release of proinflammatory chemotactic
factors, such as, C4a, C3a, and C5a.
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that VCP's affinity and/or activity for binding and inhibiting complement activation may
be stronger for one animal species as compared to another. The animal species that
vaccinia virus most commonly infects would be most susceptible to the complement
inhibiting action of VCP. To initially test this hypothesis, the activity of VCP and rVCP
was tested against various animal sera, including: pig, dog, rabbit, rat, human, horse, and
baboon. Interestingly, VCP and rVCP possessed different activities against many of
these sera.
To determine whether full-length rVCP is needed for hemolysis inhibition, factor
I cofactor activity, or if one or more of the rVCP constructs retains this activity, each of
the constructs purified and described in chapter 3 were tested in the hemolysis assay. In
addition, V.N. Loparev, from the Poxvirus Section, Viral Exanthems and Herpesvirus
Branch, Division of Viral and Rickettsial Diseases, National Center for diseases, Centers
for Disease Control and Prevention, Atlanta, GA, used the hemolysis assay to test the
activity of the monkeypox homologue of VCP. This VCP homologue is naturally
truncated at its C-terminus, missing 75% of the fourth CCP module (figures 20 and 21).
In order to determine whether full-length rVCP is required to bind complement,
various rVCP constructs were created using the Pichia pastoris expression system and
subjected to plasmon resonance binding analysis (Biacore X ®) with C3b. With C3b
immobilized to the sensor chip, recombinant VCP or truncated rVCP molecules,
consisting of CCP modules 1 and 2 (rVCP~1,2), 2 and 3 (rVCP~2,3), 3 and 4
(rVCP~3,4), and 2-4 (rVCP~2,3,4), were injected to determine whether they possessed
the ability to bind C3b. In addition, with rVCP immobilized to a CM5 sensor chip,
methylamine treated C3 or C4 (C3-MA, C4-MA) was injected and binding was observed.
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In all cases, positive binding was determined by subtraction of ligand channel readings
from the readings of the control channel (nothing immobilized). Each experiment was
repeated several times to confirm results.
The ability of rVCP to perform both of its functions simultaneously, binding
complement and heparin, was tested using a modified hemolysis assay. This modified
assay tests the ability of rVCP to inhibit hemolysis of sheep red cells in the presence of
various concentrations of heparin or heparan sulfate. The results of these preliminary
experiments suggest that rVCP is in fact able to bind complement while remaining bound
to heparin by the C-terminus. To conclusively demonstrate this ability, Shrihari
Arjunwadkar, from the Division of Medical Virology, University of Cape Town, Cape
Town, South Africa, used plasmon resonance binding analysis (Biacore X ®). With
heparin immobilized to the sensor chip (described in chapter 3), rVCP was injected and
binding to heparin was observed. Shortly after injection of rVCP stopped, without
regeneration, methylamine treated C3 or C4 (C3-MA, C4-MA) was injected to test for
binding to rVCP. As a control, C3-MA and C4-MA were injected in the absence of
rVCP, to test whether they possessed the ability to interact with heparin (data not shown).
The results suggest that C3-MA and C4-MA do interact with heparin, but only slightly.
The interaction was very small in comparison to that seen in the presence of rVCP. Each
experiment was repeated three times to confirm the results and positive binding was
observed by channel subtraction.
Using the results obtained by the above experiments, results obtained in chapter 3,
and homology found between rVCP and other complement control proteins, a model of
the putative heparin and/or complement binding residues was created. These putative
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binding domains were visualized using the X-ray crystal structure of rVCP. The residues
involved in complement binding were predicted using rVCP's homology with the wellcharacterized MCP. A recent study subjected MCP to extensive alanine-scanning
mutagenesis and epitope mapping, which revealed the residues involved in cofactor
activity and involved in binding C3b and/or C4b (Liszewski et al., 2000). The homology
between VCP and MCP is so great that these residues could very confidently be projected
upon VCP and thought to contribute the same function.

133

Materials and Methods
Hemolysis Assay:
The hemolysis assay was performed as described in chapter 2 with a few
modifications. Serial dilutions of rVCP were mixed with various amounts of heparan
sulfate (HS) (Sigma) before addition of serum and sSRBCs. In assays using heparin
sepharose, 10 µl of slurry, made from 1ml heparin sepharose (Pharmacia) and 1 ml water,
were added to a series of rVCP dilutions and incubated for 30 min on ice. After the
incubation, the samples were centrifuged and the supernatants tested for hemolysis
activity. The heparin sepharose beads were then washed with buffer before serum and
sensitized sheep red blood cells were added. After the assay was performed, reaction
supernatants and the pelleted heparin sepharose beads were analyzed by SDS-PAGE for
the presence of rVCP. Supernatants were concentrated and the heparin beads
resuspended in 600 mM NaCl, to strip off rVCP, and concentrated. In all cases, both
positive and negative controls received the same amount of heparin/heparan as all of the
samples, in order to compensate for lysis inhibition caused by the heparin/heparan.

Preparation of rVCP and rVCP Truncations:
The cloning of VCP and fragments rVCP~1,2; rVCP~2,3; rVCP 3,4; rVCP~2,3,4
in the Pichia pastoris yeast expression system (Invitrogen) was described in chapter 2.
rVCP; rVCP~1,2; rVCP~3,4; rVCP~2,3,4 were all purified from media using heparin
(Pharmacia) affinity chromatography, described in chapter 2. rVCP~2,3 was purified by
ion exchange chromatography using a 1 ml DEAE HiTrap fast flow (Pharmacia) column.
All proteins were visualized by SDS-PAGE (4-12% gel) with coomassie blue staining.
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Complement Component Purification:
Initial purification of C3 and C4 was performed by Gunasekaran Krishnasamy,
from the Center for Biophysical Science and Engineering, University of Alabama at
Birmingham, AL. Three milliliter of inhibitor solution containing 330 mM KH2PO4 (pH
7.3), 66 mM EDTA, 66 mM benzamidine-HCl and 1 g of Lysine (free base) was added to
the 20 ml of blood plasma. The resultant treated plasma was added to polyethylene
glycol 4000 D (PEG4K) for precipitation. The final concentration of PEG in the solution
was 5%. After removing the precipitate, the plasma solution was further made 21%
PEG4K. The solution was stirred in cold room at 4oC for about 2 hrs. The precipitate
formed was dissolved in 7 ml of DEAE starting buffer [3 mM KH2PO4 (pH 7.3), 6.5 mM
EDTA, 6.5 mM benzamidine-HCl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 40 mM
EACA and 30 mM NaCl]. The sample was applied on a 100 ml DEAE column, and after
washing with two column volumes of starting buffer, a gradient was developed from 30
mM to 150 mM NaCl. Those fractions containing C3 were dialyzed against a buffer
containing 25 mM Tris (pH 7.8), 50 mM EACA, 2 mM EDTA, 2 mM benzamidine-HCl
and 50 mM NaCl. The dialyzed sample was applied on a 5 ml Blue Sepharose column
and eluted with a gradient of 50-500 mM NaCl (Gresham et al., 1986).
To produce C3b, purified C3 was further purified by perfusion chromatography
using BioCAD 20HQ column – see figure 34. C3b was prepared by limited trypsin
digestion of C3 with sequencing grade trypsin (Roche). C3 was incubated with 5%
trypsin (w/w) for 2 min at 37 oC, before adding 5% (w/w) soybean trypsin inhibitor
(SBTI) (Sigma) to stop the reaction. C3 and C3b were visualized by SDS-PAGE (4-12%
gel) with coomassie blue staining.
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Figure 34. C3 Purification using BioCAD 20HQ Column. Purification of C3 was
achieved using BioCAD 20HQ ion exchange chromatography. The top panel shows the
first passage, with a large amount of unbound material. The absorbance is shown in red
and the NaCl gradient shown in blue. As can be seen in this panel, the C3 peak appeared
half way through the NaCl gradient (SDS-PAGE analysis of this peak is shown in figure
39), indicating strong binding. The bottom panel shows a rerun of the unbinding material
from the top panel, showing that all of the initial unbound material passed through the
column without binding a second time.

C3 Purification using BioCAD 20HQ Column

0.05
0.045
0.04
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0

160
Abs 280nm

140

NaCl (mS)

120
100
C3

80

Unbinding

mS

60
40
20
837
881

397
441
485
529
573
617
661
705
749
793

221
265
309
353

0
1
45
89
133
177

Abs.

1st Run

Seconds

0.005
0.0045
0.004
0.0035
0.003
0.0025
0.002
0.0015
0.001
0.0005
0

160
Abs 280nm

140

NaCl (mS)

120
100
No C3

80
60

Unbinding

40
20

Seconds

137

883

841

799

715
757

673

631

589

505
547

463

421

337
379

295

253

211

127
169

85

43

1

0

mS

Abs.

Unbinding Rerun

To isolate C4, 5 mM PMSF, 5 mM EDTA and 2.7 mM iodoacetamide were added
to 20 ml of plasma and the pH was adjusted to 7.4. After 5% PEG precipitation, the
resultant supernatant was made 26% PEG. The precipitate obtained was dissolved and
diluted to a conductivity of 2.9 mS in 20 mM phosphate buffer (pH 7.0) with 5 mM
EDTA, 5 mM PMSF and 10 mM NaCl. The sample was applied to a DEAE-cellulose
(DE-52 cellulose) column and eluted with the same buffer. The eluted fractions
containing C4 were applied to a DE-52 cellulose column a second time and eluted with a
gradient of 30-200 mM NaCl (Reboul et al., 1979; Press and Gagnon, 1981).
The purified C3 and C4 were dialyzed against 20 mM KH2PO4, 2 mM EDTA,
100 mM NaCl, 20 mM EACA (pH 7.5). The C3 or C4 was treated with 20 mM, 50 mM
and 100 mM methylamine in steps for a period of 3 hrs at 4°C (Tack et al., 1980). Then,
the solution was allowed to stand in the same temperature for about 10 hrs. The resultant
methylamine-treated C3 or C4 was dialyzed against 20 mM KH2PO4, 2 mM EDTA and
100 mM NaCl (pH 7.5) and concentrated.

Primary and Secondary Antibody Binding Analysis:
The binding between a mono-specific anti-rVCP IgY 1o antibody (Washington
Biotec, described in chapter 2) and rVCP was visualized using BiaEvaluation 3.0
software system. With rVCP amine coupled to a CM5 sensor chip, 40 µl of 10 nM
purified mono-specific IgY was diluted in HBS, and injected with a flow rate of 10
µl/min at 25oC. The wash was delayed for 600 seconds. The binding between a 2o antichicken IgG (Vector Laboratories) and the 1o mono-specific anti-rVCP IgY was
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visualized by the same method. The 1o antibody was immobilized and the 2o antibody
was used as the analyte.

Simultaneous Heparin and Complement Binding:
Hemolysis assays were performed as described in chapter 2, with a few
modifications. Serial dilutions of rVCP were mixed with various amounts of heparan
sulfate (HS) (Sigma) before addition of serum and sensitized sheep red blood cells. In
assays using heparin sepharose, 10 µl of slurry, made from 1ml heparin sepharose
(Pharmacia) and 1 ml water, was added to a series of rVCP dilutions and incubated for 30
min on ice. After the incubation, the samples were centrifuged and the supernatants
tested for hemolysis activity. The heparin sepharose beads were then washed with buffer
before serum and sSRBCs were added. After the assay was performed, reaction
supernatants and the pelleted heparin sepharose beads were analyzed by SDS-PAGE for
the presence of rVCP. Supernatants were concentrated and the heparin beads
resuspended in 600 mM NaCl, to strip off rVCP, and concentrated. In all cases, both
positive and negative controls received the same amount of heparin/heparan as all of the
samples, in order to compensate for lysis inhibition caused by the heparin/heparan.

X-Ray Crystallography:
The procedures for the X-ray crystallography are described in chapter 3.
Homology with MCP was obtained using a BLAST search and through comparison with
the study by Liszewski et al., 2000.
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Results
Hemolysis Assay of Various Animal Sera:
The ability to block the activity of complement in various animal species was
tested using the hemolysis assay. The outcomes of experiments using VCP and rVCP are
presented in figure 35. VCP was found to behave very similarly to rVCP with most
animal sera tested – see figure 36. For rat sera, the results very strongly suggest that VCP
has the greatest degree of activity against rat sera. Melanie Scott, from the Department of
Microbiology and Immunology, University of Louisville, obtained very similar results
using mouse sera (personal communication). In addition, VCP clearly possesses very
limited activity against rabbit sera. Most importantly, however, is the moderate activity
that VCP exhibits against human sera. This activity was also found to be identical in
baboon (data not shown). Therefore, VCP was found to have very strong activity against
rat, moderate activity against human, and little activity against rabbit sera.

Hemolysis Assay of rVCP Constructs:
The activity of the purified recombinant protein constructs was tested using the
hemolysis assay. The results indicate that only the full-length protein inhibits lysis of
sSRBCs - anywhere from 60 to 90% inhibition. The rVCP segments showed no
inhibition of lysis, suggesting that the whole protein is needed to block complement
activation. Although, the naturally truncated VCP homologue produced by monkeypox
virus (MPV) (shown in figure 37), which lacks almost the entire fourth SCR (figures 20
and 21), has been shown to inhibit hemolysis of sSRBCs. This indicates that it is
blocking the classical pathway of complement activation.
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Figure 35. Hemolysis assay of various animal sera. The ability of VCP and rVCP to
block the activation of complement in various animal sera was tested. A) Silver-stained
SDS-PAGE gel showing the concentration of VCP and rVCP used in the experiment. B)
The ability of VCP, produced by the natural infection of mammalian cells, to inhibit the
activation of complement in dog, horse, human, pig, rabbit, and rat sera was tested. The
results clearly indicate that VCP possesses the greatest activity against rat sera (and pig)
and the lowest activity against rabbit sera. C) The ability of rVCP, produced by the
Pichia pastoris yeast expression system, to inhibit the activation of complement in dog,
horse, human, pig, rabbit, and rat sera was tested. Again, the results clearly indicate that
rVCP possesses the greatest activity against rat sera and the lowest activity against rabbit
sera.
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Figure 36. Hemolysis assay of rat sera using VCP and rVCP. The activity of VCP
and rVCP against complement activation using rat sera is shown – data taken from figure
35. The concentration of VCP and rVCP were estimated to be the same and the activity
exhibited against rat serum complement is shown to also be the same. This demonstrates
that the activity of VCP and rVCP are identical against rat sera.
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Figure 37.
rVCPs.

Structure-function summary table of VCP, VCP homologues, and

VCP/IMP/SPICE, MPV homologue of VCP, recombinant VCP, and four

recombinant segments of VCP are shown along with whether they are able to inhibit
hemolysis of sSRBCs, bind C3b using SPR, or bind heparin using chromatography or
SPR. Also listed is the number of putative heparin binding sites found on the surface of
the protein.

# of Putative C3b Binding Heparin Binding
Inhibition of Heparin Binding
Sites
Activity
Activity
Hemolysis
Activity
(K/R X K/R) Using SPR
Using SPR
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Biacore Complement Binding:
As a control to determine whether the Biacore instrument was functioning
properly, rVCP was immobilized on a CM5 sensor chip by standard amine coupling. 10
nM of purified mono-specific chicken anti-rVCP IgY, primary antibody, was injected
across the surface of the sensor chip and very strong binding was observed, see figure
38A. In addition, this primary anti-rVCP antibody was immobilized to a CM5 sensor
chip by standard amine coupling procedures. 10 nM of biotinylated goat anti-chicken
IgG (Vector Laboratories), secondary antibody, was passed across the immobilized antiVCP antibody and extremely strong binding was observed, see figure 38B.
To better understand the binding of rVCP to C3b, C3 was subjected to incomplete
trypsin digestion, followed by amine coupling to a CM5 sensor chip. Using
recombinantly expressed rVCP and fragments of rVCP, the location for C3b binding on
rVCP was mapped – see figure 39 for the protein reagents. Interestingly, none of the
recombinant proteins, representing nearly all combinations of two and three CCP
modules found in rVCP, had the ability to bind. As can be seen in figure 40, rVCP is the
only protein found to bind C3b immobilized to the sensor chip. By comparing the ligand
channel response to the control channel response, it is very clear that all segments of
rVCP are unable to bind the immobilized C3b. In all cases, the analyte was injected at
different concentrations to confirm the results. The amplitude of binding was found to be
low due to the incomplete cleavage of C3 to C3b, resulting in less immobilized C3b on
the surface of the sensor chip. In addition, the best line fitting was obtained using the
heterologous ligand model, due to a mixed population of C3 and C3b (data not shown).
This data suggests that rVCP has a very weak ability to interact with native C3 and a
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Figure 38. Control 1o and 2o antibody binding. A) Analysis of anti-VCP IgY (1o
antibody) binding to VCP. Subtracted ligand channel and control channel is shown. B)
Analysis of anti-chicken IgG (2o antibody) binding to anti-VCP IgY 1o antibody.
Subtracted ligand channel and control channel is shown.
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Figure 39. Coomassie blue stained SDS-PAGE of C3, C3b, and rVCP constructs. A)
(1) Purified C3α and β chains before trypsinization. (2) C3b after trypsinization. Note
that incomplete trypsinization resulted in approximately 80% of the C3 being converted
into C3b, leading to a mixed ligand.

B)

Purified rVCP and rVCP fragments

(approximately 20 µg) are shown as: (1) rVCP; (2) rVCP~1,2; (3) rVCP~2,3; (4)
rVCP~3,4; and (5) rVCP~2,3,4.

A

1

2

Uncleaved
C3

C3α
α

C3b
C3β
β

B

62kDa

1

28kDa
18kDa
14kDa

151

2

3

4

5

Figure 40. C3b binding of rVCP fragments. The ligand and control channel responses
are shown for the binding between rVCP, or rVCP fragments, and C3b immobilized to
the sensor chip. Control channel response represents only bulk effects; no protein is
immobilized. All proteins were tested at different concentrations and with multiple C3b
coupled chips to confirm the presented results.
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much stronger ability to interact with C3b. This ability of rVCP to bind, at least weakly,
to C3 is in agreement with data obtained earlier (Sahu et al., 1998). In addition, the
ability of rVCP to bind methylamine treated C3 or C4 (C3-MA, C4-MA) was tested.
With rVCP immobilized to the sensor chip, 80 nM C3-MA or 80 nM C4-MA was
injected and binding was recorded. As can be seen in figure 41, rVCP binds strongly to
both C3-MA and C4-MA. This demonstrates the ability of rVCP to bind the activated
forms of the third and fourth components of the complement system. Taken together,
these results suggest that VCP is the smallest unit required for binding C3b and
facilitating factor I cofactor function, thus blocking activation of complement.

Simultaneous Heparin and Complement Binding:
Since rVCP is an extended molecule, and given the probable location of a heparin
binding site at the extreme C-terminal end and putative regions involved in binding
complement spread throughout the remainder of this extended molecule, it might be
expected that C3b/C4b interactions and heparin binding are not mutually exclusive.
Participation of common residues in heparin binding and complement inhibition in rVCP
is not supported by the observation that rVCP is able to inhibit hemolysis of sSRBCs and
bind heparin simultaneously (figure 42 and 43). Addition of varying amounts of soluble
heparin (figure 42) or heparan sulfate to a hemolysis assay containing rVCP had no effect
on the protein’s ability to inhibit hemolysis (figure 43a). The hemolysis inhibition seen
in the cases when only heparin or heparan sulfate is present in high concentrations is
likely due to its slight ability to bind C3/C4, thus inhibiting hemolysis on its own. A
similar experiment employing heparin sepharose beads, used to carry rVCP into the
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Figure 41. rVCP binding to activated C3 and C4. rVCP was immobilized to a CM5
sensor chip. A) 80 nM C3-MA was injected and binding was observed. B) 80 nM C4MA was injected and binding was observed. In both cases, the results are shown as the
subtraction of the control channel from the ligand channel.
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Figure 42. Simultaneous heparin binding and hemolysis inhibition by rVCP. Results
of hemolysis assays performed on serially diluted samples of rVCP each containing 0.01,
0.03, 0.05 Units of soluble heparin (filled squares, filled triangles and open circles,
respectively) are compared to the sample without heparin (control, shown as filled
diamonds). The degree of hemolysis inhibition caused by heparin alone is shown as
asterisks.
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hemolysis assay, revealed that rVCP can still inhibit complement activation while
remaining bound to insoluble heparin, although to a much lesser extent (figure 43b). The
reaction mixture was further examined after the assay was performed in order to
determine whether rVCP inhibits hemolysis while bound to heparin, or is pulled off by
C3 and C4 during the reaction. Figure 43c clearly demonstrates that the hemolysisinhibiting activity could be attributed to rVCP that remained bound to the heparin
sepharose beads and was not detached from the beads in the process.
To confirm the above results using SPR technology, heparin was immobilized to a
CM5 sensor chip, 80 nM of rVCP was injected, and binding was observed. Shortly after
the injection of rVCP stopped, 100 nM of C3-MA or C4-MA was injected to test if
binding to rVCP could occur. As can be seen in figure 44, rVCP is able to bind
complement while remaining bound to heparin immobilized to the sensor chip. These
results demonstrate the ability of rVCP to perform both functions at once. With both C3MA and C4-MA, strong binding was observed, indicating that rVCP is able to
simultaneously bind both heparin, via its C-terminus, and complement, using the rest of
its exposed surface. Using the data obtained in the above experiments, along with
sequence homology data described below, a model for heparin binding and complement
component binding was developed and shown in figure 45.

X-Ray Crystal Structure Homology:
Putative sites on rVCP, which are suspected to interact with C3b/C4b, are
suggested by comparison with other complement control proteins for which extensive
mutagenesis data are available. A recent study employing synthetic peptides,
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Figure 44. Simultaneous binding to heparin and complement by rVCP. A) Analysis
of rVCP binding to heparin, followed by binding of methylated C3 to rVCP. Results are
represented by subtraction of the ligand channel and the control channel. The experiment
was repeated to confirm results. B) Analysis of rVCP binding to heparin, followed by
binding of methylated C4 to rVCP. Results are represented by subtraction of the ligand
channel and the control channel. The experiment was repeated to confirm results.
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Figure 45.

Model for simultaneous heparin and complement binding.

Spatial

relation of C3b/C4b binding and heparin binding in rVCP is shown. The positive patch
between modules 1 and 2 is shown with contributing basic residues labeled. Side chains
of residues of putative importance for C3b and C4b binding by rVCP are shown as
spheres on a α-carbon trace (light blue) of rVCP. Color-coding is the same as in figure
46A. Heparin hexasacchride (carbon, brown; oxygen, red; nitrogen, blue and sulfur,
yellow) derived from the complex with acidic FGF is also shown below with the four
lysine residues (cyan) that modeling suggests are likely ligands.
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mutagenesis and epitope mapping of MCP is one of the most comprehensive (Liszewski
et al., 2000). An alanine-scan of MCP from residues 94-103 (figure 46) proves to be
particularly useful. The mutations Y97A, Y98A, L99A and E103A each abolished
cofactor activity for C4b but not binding of C4b, while N94A, E95A, G96A and E102A
decreased both C4b binding and cofactor activity, and C3b binding was affected only by
E102A. The equivalent residues in VCP, also 94-103, are close in sequence (figure 46)
and lie in module 2 near the interface with module 3. Thus, by homology with the rVCP
structure, it is likely that residues 94, 95, 98, 102 and 103 of MCP are involved directly,
and N94, E95 and E102 directly contact C4b. It is reasonable to propose that N94, H98
and E102 (figures 45 and 46, red) play a similar role in rVCP. The same study
(Liszewski et al., 2000) determined that residues in the region 191-196 of MCP were
very important for C3b-binding. Substitutions of K193, R195 and F196 by alanine
interfered with both C3b-binding and cofactor activity for C3b. In VCP, the equivalent
region is 184-189 and lies at the C-terminus of module 3 with K186 and H189 exposed.
Since K193 and F196 of MCP contact C3b, it is reasonable to propose that K186 and
H189 of VCP (figures 45 and 46, magenta) play a similar role. Finally, in MCP, residues
in the region 206-212, G207A, F208A, K210A, K211A and F212A are involved in C3bbinding since the mutations each significantly reduce affinity for C3b, but not C4b, F208
and K210 (figure 45, yellow) are likely to be contact points for C3b. In rVCP these
residues lie within the sequence 199-205 of module 4 with F201 and R203 exposed at the
surface. Although it is not unreasonable to invoke F201 and R203 (figures 45 and 46,
yellow) as C3b-binding residues in rVCP, most of this module, including residues 208
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and 210 are missing from its MPV homologue and do not appear to be pivotal for this
function.
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Figure 46. Putative C3/C4 binding residues in rVCP. A) Alignment of the sequences
of rVCP and MCP in regions identified as potential C3b/C4b binding sites are shown.
The three sets of residues in MCP shown to decrease C4b binding (red), C3b binding
(magenta and yellow) when mutated. rVCP residues in the three positions corresponding
to those in MCP, which appear to be accessible for complement binding, are also shown
in matching colors. B) Putative C3b and C4b binding regions of VCP are shown in
alignment with a well-characterized C3b/C4b binding site on human MCP CCP 1 (shown
outlined), along with other complement regulating proteins from different species. Noted
in red are important residues, shown to be necessary for C3b binding by MCP. Colored
green are highly conserved cysteine residues. The locations of each site are shown for
comparison.
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Discussion
Results obtained by testing VCP's ability to inhibit the activation of complement,
using various animal sera, demonstrate a significant difference in specificity. VCP was
found to have very limited activity against rabbit complement, possessing 250 fold less
activity than it has against rat sera (and possibly pig). It was also shown to possess
moderate activity against human and baboon (data not shown) sera, having 4 to 8 fold
less activity than against rat sera. Clearly, VCP shows the greatest activity against rat
complement. This study does not suggest the reason for this significant difference in
specificity. VCP may have a greater affinity for rat C3b/C4b, or its cofactor activity may
be enhanced. The mechanism by which VCP blocks the activation of rat complement
greater than human complement can be investigated further in the future by using Biacore
(SPR) binding analysis. The affinity and kinetics of VCP with human or rat C3b/C4b can
be studied to help answer this question. The idea that VCP may be specific for rat,
suggesting that a rat/rodent host coevolved with vaccinia virus, is further strengthened by
studies done by Ariella Rosengard, University of Pennsylvania, on the variola virus
homologue of VCP she termed SPICE, for smallpox inhibitor of complement enzymes.
These studies suggest that the variola virus homologue inhibits complement activation of
human sera fourfold more effectively than VCP. This suggests that SPICE is more
specific for human complement due to it coevolving in a human host. This hypothesis is
quite interesting considering that the difference between VCP and SPICE is only twelve
residues.
In an attempt to map the location of C3b/C4b binding and cofactor activity on
rVCP, various truncated proteins consisting of nearly all combinations of 2 and 3 CCP
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module fragments [CCP modules 1 and 2 (rVCP~1,2), 2 and 3 (rVCP~2,3), 3 and 4
(rVCP~3,4), and 2-4 (rVCP~2,3,4)] were tested in the hemolysis assay. The results
suggest that only full-length rVCP is able to inhibit complement activation in the
hemolysis assay. To confirm these results using surface plasmon resonance (SPR), the
recombinant truncated versions of rVCP were used to map the regions involved in C3b
binding. Only full-length rVCP was able to bind C3b. These results help to confirm
previous data showing that none of the mutant proteins were able to inhibit complementmediated lysis of sSRBCs in the hemolysis assay. The results of both studies suggest that
VCP is the smallest functional unit, and, therefore, most of the exposed surface is
required for binding complement, cofactor activity, and ultimately blocking complement
activation. This was also suggested by previously published studies using truncated
membrane bound versions of rVCP (Rosengard et al., 1999). With the origin of VCP in
mind, it is easy to understand why this protein is the smallest functional unit. The size of
the vaccinia virus genome, though it is quite large for a virus, is very limited in size.
VCP was most likely pirated from the host, possibly as C4b-BP or MCP, and reduced to
its minimal functional unit to conserve valuable genomic space. VCP does not represent
the smallest CCP known to bind C3b, only the smallest CCP able to bind C3b and inhibit
complement activation. Surface plasmon resonance studies of fH have shown that a two
CCP module fragment, SCR 19-20, was able to bind C3b (Jokiranta et al., 2001).
Although this small fragment was able to bind both C3b and C3d, it does not retain
cofactor or decay accelerating activity (personal communication). The notion that a two
CCP module fragment of fH is required to bind portions of C3, while all four CCPs of
VCP are required, suggests that differing mechanisms of action are involved. The idea
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that VCP and fH may have different mechanisms of action to inhibit complement
activation has been suggested by previous data (Sahu et al., 1998).
In order to investigate the hypothesis that VCP may inhibit complement activation
while remaining bound to heparin/heparan sulfate, several experiments were employed.
Various concentrations of heparan sulfate was added to a serially diluted sample of rVCP
and then tested using the hemolysis assay. The ability of rVCP to inhibit complement
activation was unchanged. This experiment was repeated using various concentrations of
heparin with the same results. In order to be sure that rVCP was binding and remaining
bound to heparin while being tested in the hemolysis assay, heparin sepharose beads were
also used. rVCP bound to heparin sepharose beads was tested in various concentrations
in the hemolysis assay. The results obtained by all experiments suggest that VCP is able
to inhibit complement activation while remaining bound to heparin/heparan sulfate.
These results were later confirmed using SPR analysis. With rVCP immobilized to the
sensor chip, C3-MA or C4-MA was injected and binding between the proteins was
confirmed. Next, with heparin immobilized to the sensor chip, rVCP was injected and
allowed to bind before C3-MA or C4-MA was injected. Clear binding was observed
between rVCP bound to heparin on the surface of the sensor chip and both C3-MA and
C4-MA. These experiments imply that the protein, in addition to its ability to strongly
inhibit complement activation while in soluble form, may also inhibit complement while
bound to heparan sulfate proteoglycans lining the endothelial cell layer. rVCP would
therefore be able to protect the infected host cell, and neighboring cells, from not only
host complement attack, but also antibody binding and cell death caused by NK cells.
The ability of rVCP to perform both functions at once has significant implications in our
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understanding of viral habitat formation. VCP may act in two states, the cell bound state,
where it utilizes heparan sulfate to tether itself to the cell surface, and the soluble state,
where it is free to diffuse into the surrounding local tissue. Therefore, VCP acting in the
cell bound state may not only be involved in protecting the infected cell from the
molecular and cellular interactions of the immune system, but also cell surface activation
of complement. In addition, the soluble form of VCP may be able to diffuse locally,
blocking complement activation in the surrounding tissue, and preventing the release of
chemoattractant compounds. All together, the two states of VCP may create a habitat
better suited for local spread of viral progeny and growth.
With the X-ray crystal structure of rVCP in hand (see chapter 5), the data
obtained in the above experiments, as well as homology studies with other well
characterized complement regulatory proteins, was used to map the locations of the
complement binding regions and project them onto the structure of rVCP. MCP, whose
residues involved in C3b/C4b binding are well mapped, aligns very closely with rVCP.
Therefore, it was used to accurately predict the residues on rVCP involved in C3b/C4b
binding without requiring alanine-scanning mutagenisis of VCP. Taken together, the
above experiments and homology data suggest that most, if not all, of the surface of
rVCP is needed to bind C3b/C4b, as well as cofactor activity for their cleavage by factor
I. VCP, made up of 4 CCP modules, would represent the smallest functional unit
required for binding and inhibiting complement activation. This knowledge could be
important in the bioengineering of new therapeutic proteins capable of blocking
complement activation.
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CHAPTER 5
VCP STRUCTURE AND STABILITY

Introduction to CCP Structure
This chapter contains material adapted from the following publication and manuscript:
Murthy K.H., Smith S.A., Ganesh V.K., Judge K.W., Mullins N., Barlow P.N., Ogata
C.M., and Kotwal G.J. Crystal structure of a complement control protein that
regulates both pathways of complement activation and binds heparan sulfate
proteoglycans. Cell. Jan. 26, 104:301-11, 2001.
Smith S.A., Krishnasamy G., Murthy K.H., Cooper A., Bromek K., Barlow P.N., and
Kotwal G.J. Vaccinia virus complement control protein is monomeric, and retains
structural and functional integrity after exposure to adverse conditions. Biochim.
Biophys. Acta., In press, 2002.
As previously mentioned in chapter 4, VCP exhibits sequence and functional
similarity to the mammalian complement regulators, such as, factor H (fH), membrane
cofactor protein (MCP), decay-accelerating factor (DAF), complement receptor type one
(CR1), and complement 4b binding protein (C4b-BP). VCP is most similar in terms of
sequence to the N-terminus of the α-chain of C4b-BP, sharing 24, 33, 35 and 29 identical
or conservatively replaced residues, out of about 60, in modules 1, 2, 3 and 4,
respectively (figure 32). VCP is the smallest, only 244 amino acids, and least complex of
the complement control proteins, with no glycosylation or transmembrane domains,
making it an excellent candidate for structural analysis. Structures of fragments of MCP
with, two out of four CCP modules (Casasnovas et al., 1999) and fH with, one (Barlow et

al., 1991; Barlow et al., 1992) or two (Barlow et al., 1993) out of 20 CCP modules have
been published. The NMR structures of two pairs of modules of rVCP, modules 3 and 4
(rVCP~3,4) (Wiles et al., 1997) or 2 and 3 (rVCP~2,3) (Henderson et al., 2001), have
also been published. None of these fragments shows complement inhibition activity or
factor I cofactor activity. The structure of b2-glycoprotein I (b2-GPI or apolipoproteinH), a molecule with four CCP modules, has been reported, however, b2-GPI is not a
complement inhibitor (Bouma et al., 1999; Schwarzenbacher et al., 1999). Thus, to date
there has been no three-dimensional structure available of a protein or protein fragment
that is able to regulate complement activation.
In all published structures of CCP modules, each folds into a compact 6-8
stranded β-structure that has a conformation similar to that originally observed in the
structure of fH16 (Barlow et al., 1991). Between each module are "linkers" of varying
lengths, which connect one module to another. The relative orientations of neighboring
modules seem to differ from one module-pair to another quite significantly and in a
manner that is not predictable from differences in primary sequences (Barlow et al.,
1993; Casasnovas et al., 1999; Henderson et al., 2001; Gaboriaud et al., 2000). Despite
this, bi-modular orientation preferences have been used in building structures containing
three or more CCPs. Such models have been used to fulfill the need to provide a threedimensional context for functional and mutational studies of RCA proteins. Examples
include models for the structures of rVCP and MCP (Liszewski et al., 2000). Similarly,
homology modeling has been used to develop C3dg-binding bi-modular fragments of
CR2 based on those identified on fH (Molina et al., 1995; Nagar et al., 1998; Prodinger et
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al., 1998). However, without the structure of a functional stretch of CCP modules, such
models are only speculative.
The crystal structure of rVCP that is fully active both in complement inhibition
and in binding heparin (in soluble form) was resolved in two different crystal forms by
Dr. Krishna Murthy from the Center for Biophysical Science and Engineering, University
of Alabama at Birmingham. This structure, for the first time, offers a picture of the threedimensional positioning of all the CCP domains necessary for a well-characterized
complement inhibitory activity. Unlike studies of CCP protein fragments, this structure
is not susceptible to the criticism that deletion of modules might alter orientations at
inter-modular junctions. The high level of sequence similarity between VCP and the
mammalian RCAs, as well as complement receptor type 2 (CR2) means that the rVCP
structure will provide the richest and most reliable source of information yet. This
information may be invaluable for modeling other functional stretches of three to four
CCPs using homology, or for the design and interpretation of mutagenesis experiments
aimed at understanding the structural basis of complement control. The structure of a
fully active, complete four-domain rVCP presented here will significantly contribute to
our understanding of viral and mammalian complement regulatory proteins, and
ultimately many complement-mediated diseases.
Knowledge of the oligomerization state of VCP and its stability are crucial for
understanding the durability of the evasion of host response mediated by VCP.
Understanding the stability of VCP is also important for administration, shipping,
storage, and dosage purposes. rVCP has now been shown, using gel filtration, to be a
monomeric protein in solution. In order to test its thermal stability, the protein was
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examined by NMR over a range of temperatures and analyzed by differential scanning
calorimetry. These studies demonstrate that the 3D structure of rVCP is robust and able
to tolerate extreme temperatures. It was very important, however, to assess the extent to
which functional activity is able to withstand high temperatures. Therefore, rVCP was
subjected to a variety of harsh conditions, after which the specific activity was measured
to determine whether the protein had retained its functional conformation. These
included exposure to multiple freeze-thawing events and strong acids. rVCP was found
to be functionally stable after exposure to severe conditions, remaining active even after
boiling. The shelf-life of rVCP was also investigated and the protein was found to retain
full activity at the longest time point tested.
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Materials and Methods
Production and Purification of rVCP:
Samples of rVCP were produced using the Pichia pastoris yeast expression
system (Invitrogen) and purified to greater than 95% using heparin affinity
chromatography (Pharmacia), described in chapter 2).

X-Ray Crystal Structure of rVCP:
The procedures for X-ray crystallography are described in chapter 3.

Shelf-life:
Aliquots of 50 µl of rVCP (2.75 µg/µl) were placed in 0.65 ml microcentrifuge
tubes and stored at room temperature. At various time points, 2 µl (5.5 µg) samples were
tested for complement inhibition in the hemolysis assay. The experiment was performed
on aliquots of a single rVCP sample.

Freeze-thawing Sensitivity:
A 0.5 ml sample of rVCP (2.75 µg/µl) was repeatedly frozen to –20oC for 30 min
and then rapidly thawed to room temperature. After various numbers of freeze-thaw
events, 8 µl was removed, serially diluted, and its activity tested in the hemolysis assay.
The experiment was performed on a single rVCP sample.
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Temperature Sensitivity:
Aliquots of 50 µl of rVCP (2.75 µg/µl) were placed in 0.65 ml microcentrifuge
tubes and incubated in a heat block at various temperatures for 30 min. After incubation,
4 µl (11 µg) was taken from the sample and tested in the hemolysis assay. The
experiment was performed on aliquots of a single rVCP sample.

pH Sensitivity:
Several 100 µl aliquots of rVCP (3.0 µg/µl) were sealed in dialysis tubing and
placed into flasks containing 150 ml of water adjusted to various pHs. After vigorous
stirring for 30 min, the dialysis tubing containing the sample of rVCP was removed and
placed into a beaker with 800 ml of water, to equilibrate the sample to a neutral pH.
After vigorous stirring for 1 h, the sample was removed from the dialysis tubing and 4 µl
(12 µg) was then tested by hemolysis assay. Several sentinel samples were removed
early from the dialysis tubing and tested using litmus paper to ensure that the desired pH
was achieved. The experiment was performed on aliquots of a single rVCP sample.

Hemolysis Assay:
The hemolysis assay was performed as described in chapter 2.

Gel Filtration:
A 50 x 0.7 cm glass column was packed with 19 ml Superdex 75 (Pharmacia) and
equilibrated with either water or 100 mM NaCl. Using blue dextran (Sigma), the column
exclusion volume was determined. The positions of various gel filtration standards (4 mg
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each) (Sigma) were then determined individually by collecting numerous 100 µl
fractions, visualized by SDS-PAGE stained with coomassie blue, and quantitated by
densitometry (AlphaImager 2000 software system). The position of rVCP (4 mg) was
then determined, using the same procedure as the markers, and the densitometric readings
superimposed with those of the markers. The whole process was performed in water and
in 100 mM NaCl to prevent unwanted interactions with the column.

Nuclear Magnetic Resonance (NMR):
NMR measurements were performed by Paul Barlow from the Edinburgh Center
for Protein Technology, University of Edinburgh, Edinburgh, UK, on a Varian (Palo Alto,
CA, U.S.A.) Inova NMR spectrometer operating at 600 MHz (proton frequency) in a 5
mm triple-resonance pulsed field gradient probe. The 1H spectra were acquired using a
pulse sequence with pulse field gradient water suppression using 0.3 mM sample (Hwang
and Shaka, 1998). Each of the spectra was acquired for 40 min at a range of temperatures
from 37°C to 53°C; an additional spectrum was measured at 37°C after the sample had
been heated to 90°C, as in the calorimetry measurement. Data were acquired, processed
and plotted using VNMR (Varian VNMR 6.1, Varian Associates, Inc.).

Differential Scanning Calorimetry (DSC):
DSC studies were conducted by Paul Barlow from the Edinburgh Center for
Protein Technology, University of Edinburgh, Edinburgh, UK, on a VP-DSC differential
scanning calorimeter (Microcal, Northampton, MA, U.S.A.) with the assistance of
Margaret Nutley (University of Glasgow, Glasgow, Scotland, U.K.). The cell volume
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was 1.5 ml, the rate of heating was 1°C per min, and excess pressure was kept equal to 80
bar (1 bar = 105 Pa). Samples were equilibrated at 10°C and then heated to 90°C. The
partial molar heat capacity and melting curve were analyzed using standard procedures
(Privalov and Potekhin, 1986). The collected data were processed using the software
ORIGIN.2 (Microcal). The protein concentration was 0.016 mM (0.46 mg/ml; molecular
mass 28.6 x 103 g/mol) as determined by measurements of absorbance at 280 nm
according to a calculated extinction coefficient (Gill and von Hippel, 1989) of 44.2 x 103
mol-1cm-1.
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Results
X-Ray Crystal Structure of rVCP:
In both the crystal forms of rVCP that were analyzed, the molecule has an
elongated structure with no intramolecular contacts between non-sequential modules –
see figure 47. Packing of the two molecules (A and B) in the asymmetric unit of form I
crystals (pH 7.5) is head-to-tail, with CCP module 4 of each molecule making contacts
with module 1 of the other. In form II crystals (pH 8.3) the three molecules (A, B and C)
in the asymmetric unit associate such that modules 3 and 4 of B interact with modules 1
and 2 of both A and C. Packing interactions within the asymmetric units of the two
crystal forms do not show evidence of specific oligomerization of rVCP molecules.
All five crystallographically independent molecules in the two structures are
highly similar in structure as reflected in root mean square (rms) deviations between Cα
atoms in the β-strands of molecule A and those of B, C, D and E being 0.28, 0.67, 0.68
and 0.69 Å, respectively – figure 48. At the module level, the originally observed 6 βstrand topology is closely resembled by all CCP modules of both copies of rVCP within
the asymmetric unit of form I crystals (Barlow et al., 1991; Barlow et al., 1992; Barlow
et al., 1993). Module 1 is remarkable for its prominent "hypervariable" loop of 10
residues, K14-A23, compared to 2, 4 and 5 residues in modules 2, 3 and 4, respectively,
projecting from rVCP near the N-terminal tip of the molecule. Also noteworthy in
module 1 is an unusual insertion, Q42, K43, that forms a prominent β-bulge close to the
interface with module 2. In addition, module 2 has a 5 residue insertion, L109-S114, that
forms a long loop near the interface with module 1.
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Figure 47. Packing in form I and form II crystals. A) The three molecules in the
asymmetric unit of form II crystals are shown with the domains color-coded as in panel
B. Molecules A, B and C are labeled. Side chains of residues making polar interactions
at intermolecular interfaces are shown. B) The two molecules in the asymmetric unit of
form I crystals are shown.

Domains 1-4 are colored red, blue, magenta and cyan

respectively. Side chains of residues that form polar interactions at the two ends of the
pair are also shown. Domains are marked D1-D4.

A.

B.
D
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E

Figure 48. Five independent molecules are similar. a) Stereo pair of superposed Cα
traces of all five crystallographically independent molecules in the two crystal forms are
shown. Molecule A in form I crystals is colored red, molecule B blue, and molecules C,
D and E in form II crystals are colored magenta, cyan and yellow respectively. CCP
domains are labeled mod1-mod4. b) A Cα trace of molecule A from Form I crystals is
shown in magenta in the same orientation as in panel a. Every 10th Cα has been colored
yellow and numbered. The N and C terminal residues are shown in cyan and labeled.
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VCP is a Monomer in Solution:
In order to shed light on how VCP functions in vivo to maintain a habitat
favorable to the virus, experiments were performed to determine whether it exists as a
monomer or an oligomer in solution. Initial gel filtration experiments did not
immediately determine whether rVCP was a monomer or multimer. As can be seen in
figure 49a, one large peak and one small peak (possibly due to non-specific attachment to
column matrix) can be seen in the rVCP densitometric profile. The presence of two
distinct peaks is even more evident for the hemolysis activity of the fractions – figure
49b. However, when gel filtration was performed on marker proteins with and without
NaCl, rVCP was found to exist solely as a monomer in solution - see figure 50a and b. In
both cases, rVCP emerged from the column in approximately the same fractions as
carbonic anhydrase, a 29 kDa molecular weight marker protein. No sign of rVCP was
found in the 60 or 90 kDa range, where it may have emerged if it had been a dimer or
trimer.

Shelf-life and Freeze-thawing Tolerance:
In order to test the shelf-life of rVCP, several 50 µl aliquots (2.75 µg/µl) of rVCP
(in 18 MΩ ultrapure water) were allowed to sit at room temperature for various periods
of time prior to assay of hemolysis inhibiting activity. As shown in figure 51b, rVCP
continued to remain fully active after 30 days, the longest time point tested. This
demonstrates that rVCP in solution has a long shelf-life. In addition, rVCP was tested to
determine its ability to resist irreversible denaturation caused by multiple freeze-thawing
events. A 0.5 ml sample (2.75 µg/µl) of rVCP was freeze-thawed fifty times. Figure 52a
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Figure 49.

Gel filtration chromatography of rVCP.

A)

Gel filtration fractions

containing rVCP (fractions 67-103) are visualized by SDS-PAGE and coomassie blue
staining.

Densitometry shows the existence of at least two peaks.

Gel filtration

chromatography was performed in water. B) Each fraction was tested for hemolysis
inhibiting activity in the hemolysis assay. Due to the sensitivity of this assay, the peaks
are easily visualized. The same fractions are shown from top to bottom of the figure.
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Figure 50.

Gel filtration chromatography of rVCP and marker proteins.

a)

Overlaid densitometric results of gel filtrations conducted on rVCP and marker proteins
ranging from 200 kDa to 12.4 kDa. Column and samples were equilibrated in water.
The second rVCP peak observed in figure 49 does not appear on this plot (smaller than
12 kDa) and is most likely an artifact. b) Overlaid desitometric results of gel filtrations
conducted on rVCP and marker proteins ranging from 66 kDa to 12.4 kDa. Column and
samples were equilibrated in 100 mM NaCl.
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Figure 51. rVCP tolerance to extreme temperature and shelf-life. a) Hemolysis
inhibiting activity of 11 µg rVCP taken from samples that were incubated for 30 min at
temperatures ranging from 37 to 115oC. b) Hemolysis inhibiting activity of 5.5 µg rVCP
taken from samples that were incubated at room temperature (~25oC) for 6 h, 12 h, 24 h,
48 h, 72 h, 1 week, or 1 month.
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Figure 52.

rVCP tolerance to freeze-thawing and pH.

a)

Hemolysis inhibiting

activity of serially diluted rVCP (2.75 µg/µl) that has been freeze-thawed 2, 5, 10, 25, or
50 times. Also shown is serially diluted rVCP (2.75 µg/µl) that was lyophilized and
resuspended to the original concentration. b) Hemolysis inhibiting activity of 12 µg
rVCP taken from samples that were adjusted to a wide range of pH for 30 min, and
returned to neutral.
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shows that rVCP is completely tolerant to freeze-thawing, maintaining complete activity
after fifty events. A slight enhancement in activity appears when rVCP was tested after
fifty freeze-thawing events. This is most likely due to evaporation taking place over the
course of the experiment. As also shown in figure 52a, rVCP was found to be completely
tolerant to lyophilization. The ability of this novel immunomodulating protein to tolerate
freeze-thawing, lyophilization, and long periods of time at room temperature, will prove
very valuable for shipping and storage purposes.

Temperature and pH Tolerance:
To assess the extent to which functional activity is to withstand high
temperatures, 50 µl samples of protein in water (2.75 µg/µl) were incubated at various
temperatures for 30 minutes prior to testing of their activity (at 37oC) using the hemolysis
assay. As can be seen in figure 51a, rVCP retains most of its activity after exposure to
temperatures up to the boiling point of water. At 100oC only a slight white precipitate
was evident. At 110oC, however, most of the protein was irreversibly denatured and was
seen to form a white precipitate. It may be possible that sample dilution during assaying
allowed for a small amount of aggregated protein to re-dissolve and regain functional
activity. Nonetheless, the results of these experiments reveal the high structural and
functional stability of rVCP.
To assess the ability of rVCP to tolerate extremes in pH, 100 µl aliquots of
protein were sealed in dialysis tubing and the pH of the sample changed. After returning
the pH of the sample to near neutrality, the hemolysis inhibiting activity of the protein
was tested, see figure 52b. Recombinant VCP was able to withstand exposure to a pH
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well below zero, at which point the dialysis tubing was destroyed (>5.0N HCl). rVCP,
however, was not quite as stable under basic conditions, becoming irreversibly denatured
and forming a heavy white precipitate at pH 12.5. The extreme acid stability of rVCP
may be very important for administration purposes. Since rVCP should easily be able to
tolerate the acidity of the stomach, oral administration of this complement inhibitor may
be possible.

Nuclear Magnetic Resonance (NMR) and Differential Scanning Calorimetry (DSC)
Studies:
The thermal stability of rVCP was studied using differential scanning calorimetry.
Figure 53a shows the calorimetric profile, which can be fitted with three, two-state, fully
reversible transitions. That the curve may be fitted in this way implies that van't Hoff and
calorimetric enthalpies are equal; attempts at fitting without this restraint produced an
order of magnitude difference between the enthalpies, which could not be explained by
any reasonable transition model (Privalov and Potekhin, 1986). The three fitted
transitions are characterized by midpoint temperature, Tm = 58.3 ± 0.07°C with enthalpy,
∆H, = 71.0 ± 0.7 kCal mol-1, Tm = 62.68 ± 0.09°C with ∆H = 84.2 ± 0.6 kCal mol-1 and
Tm = 68.46 ± 0.10°C with ∆H = 62.4e ± 7.1 kCal mol-1. As the protein consists of four
modules it is possible that more transitions could be invoked, however these three were
sufficient to represent the experimental profile. We are therefore unable to assign
discrete transitions to individual modules. The calorimetry indicates that the thermal
unfolding is to a large extent reversible as may be judged from the fitting but also from
the repeated scan - see figure 53b. Although in the repeated scan there is some loss of
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Figure 53. Differential scanning calorimetry profiles. A) The experimental data points
after baseline subtraction are shown as black dots. Solid thin line indicates reconstructed
profile using three fitted transitions represented as dotted lines. B) The experimental data
from following scan with data points represented as in A.
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enthalpy it is consistent with most of the protein molecules refolding and just a small
proportion of the population not reaching the lowest energy state. The current results
may be compared with previous data reported for rVCP~2,3, i.e. a protein fragment
containing just the two central modules of VCP (Kirkitadze et al., 1999). The
calorimetric profile of rVCP~2,3 showed a Tm = 57°C and ∆H = 86 kCal mol-1. The
curve for rVCP~2,3 had a distinct shoulder and could not be fitted to one or more twostate reversible transitions.
To further explore structural properties of this protein during heating and cooling,
a series of 1D 1H NMR spectra was acquired over a range of temperatures. These show
that no significant changes appear between the physiological temperature of 37°C and the
elevated temperature of 53°C (the maximum that could safely be achieved in the NMR
probe) - compare figure 54a and b. In contrast, NMR data obtained previously on
rVCP~2,3 showed that module 2 melted in the range 45-55°C, although module 3 was
more stable. The NMR data for rVCP~2,3 were consistent with its calorimetric profile.
Clearly, module 2 is more stable in the context of full-length rVCP than in the 2,3
fragment. To investigate the structural properties of the protein after the reversible
unfolding step, a spectrum at 37°C after heating to 90°C was acquired. The full 1H
spectrum is shown as an inset in figure 54c. All of the spectral lines in the methyl region
of the 1H NMR spectrum, which are sensitive to 3D structural integrity of the protein, are
retained after heating and cooling – see figure 54c.
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Figure 54. NMR spectroscopy. a) and b) 1H NMR spectra of VCP at 37°C and 53°C
respectively. c) Overlaid methyl regions of 1H NMR spectra of VCP as aquired before,
and after heating to 90°C showing evidence of folded protein. Inset shows entire 1H
spectrum of VCP as acquired after heating to 90°C.

NMR Spectroscopy
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Discussion
As suggested by the root mean square (rms) deviations between Cα atoms in the
β-strands shown in figure 48, the relative orientations of each of the four modules of
rVCP are remarkably similar among all five molecules in the two crystal forms (2 in I
and 3 in II) despite their being crystallographically independent. This suggests that this
conformation is strongly preferred of rVCP in solution under the conditions used to grow
the crystals, and that packing interactions are not responsible for the conformation
observed. The "tilt" angles (i.e. the rotation required to align the z-axis of the inertia
tensor of each module with its neighbor) between the long axes of the modules are 600,
630 and 990 at the 1-2, 2-3 and 3-4 module junctions, respectively. However, the tilts
between adjacent pairs of modules are in almost diametrically opposite directions, so that
module 3 is tilted by only 10° relative to module 1 and module 4 is tilted by 36° relative
to module 2, forming a "W" appearance. Thus, the molecule has an extended and
approximately linear part consisting of modules 1-3, then a kink between modules 1-3
and module 4. Interactions at the 1-2 interface in rVCP are between mostly hydrophilic
residues, those at the 2-3 interface are mixed, and those at the 3-4 interface are
predominantly hydrophobic.
Figure 55a superimposes the structures of VCP and MCP 1,2 (Casasnovas et al.,
1999). The arrangement of the N-terminal modules of MCP differs from that found in
rVCP, providing another example of the significant variation in inter-modular
orientations among this family of proteins. Knowing the crystal structure of rVCP,
comparisons between the structure of intact rVCP and the solution structures of rVCP
fragments, conducted previously, can be made – also shown in figure 55a. The angles
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Figure 55. Diverse orientations of modules in CCP containing proteins.

The four

modules of rVCP are shown in red and labeled. a) The first CCP module of MCP (gold)
is superimposed over module 1 of rVCP using the β sheet residues in each to calculate
the transformation. Similarly, module 2 of the solution structure of rVCP~2,3 (rose) is
superimposed over that of VCP2 and module 3 of the solution structure of VCP3,4
(purple) superimposed over module 3 of rVCP. b) The first CCP module of rVCP is
superimposed over module 1 of β2GPI (light blue). Modules 1-4 in each are labeled. Not
shown is an additional membrane association domain beyond domain 4 in β2GPI.
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between modules 3 and 4 of the NMR structure of rVCP~3,4 (tilt = 67°, twist = 81°, and
skew = 7°) are comparable to those seen in the crystal structure (tilt = 99°, twist = 74°
and skew = -20°) (Wiles et al., 1997). The 2-3 intermodular angles within the NMR
structure of rVCP~2,3, however, are dissimilar to those in the crystal structure of intact
rVCP. Moreover, approximately 281 Å2 of surface is buried between modules 2 and 3 in
the crystal form, while the junction between these two modules is not extensive in the
NMR rVCP~2,3 fragment (Kirkitadze et al., 1999). In addition, NMR indicates that this
pair is very flexible (Henderson et al., 2001). It is noticeable, however, that there are
significant differences in the structure of module 2 between intact and truncated forms of
rVCP, while modules 3 and 4 show only small insignificant differences. The notable
differences observed in module 2 may be the result of the lack of module 1, which could
destabilize module 2 in rVCP~2,3, and hence the 2,3 junction. For example, the L109S114 insertion in module 2 is a mobile loop in rVCP~2,3 but has moved by some 15 Å in
the crystal structure and contacts the Q42, K43 insertion of module 1. Modules 2 and 3
might also stabilize each other, which could explain the smaller differences between the
arrangement of modules 2 and 4 in intact rVCP compared to the rVCP~3,4 fragment. It
is clear from these comparisons that the structure of rVCP reported here, the first of an
intact complement control protein, represents a significant advance over previous
structural studies based on fragments. This structure's validity does not rely on the
assumption that CCP modules are structurally independent of the remainder of the
protein. Therefore, this structure may be considered the most reliable basis yet for the
design of mutagenesis experiments and homology modeling exercises.
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Previous data suggested that VCP might function as an oligomer in order to
increase its stability and life in solution (Kotwal et al., 1990). Furthermore, dimeric and
trimeric structures are observed in crystals. Current results suggest that rVCP may be
found as a monomer in its soluble state, where it is able to diffuse throughout the area of
viral infection, binding and destroying complement in the local surrounding tissue. rVCP
also exists in the cell bound state, where it remains bound to heparan sulfate found on the
infected cell, and neighboring cells' surfaces. In this state, rVCP is able to prevent
complement-mediated cell lysis, as well as chemotactic migration of monocytes, NK
cells and neutrophil-mediated cell killing, and antibody attachment. It is not known if
rVCP oligomerizes at the cell surface. Additional gel filtration experiments are needed to
determine whether rVCP can oligomerize in the presence of low molecular-weight
heparin.
The ability of rVCP to resist irreversible denaturation in extremes of heat and pH
can be attributed to its unusual architecture. The protein is composed of four modules
arranged in an extended head-to-tail fashion. Each module has an elongated shape and is
composed of extended regions of peptide running approximately parallel and antiparallel
with the long axis, with loops and turns formed at either end of the module. The main
chain makes a total of five passes up and down the module such that the N-terminus is at
one end of the long axis and the C-terminus is at the other. The extended regions are
connected by networks of hydrogen-bonds (H-bonds) and over much of their length
form β-strands that lie in antiparallel double or triple-stranded β-sheets – see figure 56a.
In addition to interstrand H-bonds, two disulphide bonds within each module provide
tethers, holding the module together. The disulphides involve the four absolutely
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Figure 56. Extensive H-bonding within VCP structure contributes to its stability. a)
Cα trace (shown in red) of the VCP molecule crystal forms I and II (13) with main-chain
H-bonds (shown in white). b) Residues 10Å around the center of each module interface
are shown with H-bonds (shown in red). The main-chain hydrogen bonds were shown in
white (b1) module 1 – module 2 interface (b2) module 2 – module 3 interface (b3)
module 3 – module 4 interface.

a)
CCP 1

CCP 2

CCP 3

CCP 4

209

b 1)

b 2)

CCP 1

CCP 2

CCP 3

CCP 2

b 3)

CCP 3

CCP 4

210

conserved C residues - the first C that is also the first residue of the CCP consensus
sequence is bonded to the third C, while the second C is bonded to the fourth C that is the
last residue of the consensus sequence – see figure 57 for disulphide bonding pattern.
The two disulphides lie as far apart as possible within the structure and form the lower
and upper boundaries of the hydrophobic core. It is likely these disulphides survive
elevated temperatures and their presence probably explains the reversibility of
denaturation. The core almost entirely buries the side-chain of the invariant W residue
and contains a number of highly conserved aromatic and L, I and V side-chains. Thus,
each module consists of a compact hydrophobic core, bounded by two disulphides and
wrapped in β-sheet. In the crystal structure (and in the average NMR structures), the
CCP modules of rVCP are arranged such that the eight disulphides form a twisted ladder
with roughly parallel and evenly spaced rungs.
From the crystal structure, we know that within rVCP, modules 1 and 2, and
(particularly) modules 3 and 4, touch against one another. The 1-2 junction within the
crystal structure exhibits many intermodular H-bonds and this could explain why module
2 is more stable (higher Tm) when module 1 is present (comparing the calorimetric
profiles obtained for rVCP and for rVCP~2,3) – see figure 56b. A similar effect is seen
amongst the CCP modules of CR1 (Kirkitadze et al., 1999). In the 3-4 junction, as seen
in both X-ray and NMR (Henderson et al., 2001) structures, modules make mainly
hydrophobic contacts with one another and these two modules are tilted to create a
significant interaction area. Module 3 may be more stable in full length rVCP than in
rVCP~2,3 but it is also possible that the melting of module 3 accounts for the first
transition in VCP’s calorimetric profile (Tm = 58°C) which compares well to the Tm
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Figure 57. Disulphide bonding pattern within CCP modules of VCP. Sequence of
the four CCP modules of VCP, following signal sequence cleavage, is shown. Invariant
W residue is shown in blue.

The highly conserved C residues are shown in red.

Disulphide bonding between CCP 1 (C21-C70 and C54-C81) CCP 2 (C86-C126 and
C112-C143) CCP 3 (C148-190 and C176-201) CCP 4 (C206-248 and C234-261) are
designated with brackets.

S–S

CCP 1

S–S

CCTIPSRPINMKFKNSVETDANANYNIGDTIEYLCLPGYRKQKMGPIYAKCTGTGWTLFNQCI

S–S
S–S

CCP 2

KRRCPSPRDIDNGQLDIGGVDFGSSITYSCNSGYHLIGESKSYCELGSTGSMVWNPEAPICE
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S–S
S–S

CCP 3

SVKCQSPPSISNGRHNGYEDFYTDGSVVTYSCNSGYSLIGNSGVLCSGGEWSDPPTCQ

S–S
S–S

CCP 4

IVKCPHPTISNGYLSSGFKRSYSYNDNVDFKCKYGYKLSGSSSSTCSPGNTWKPELPKCVR

(57°C) of rVCP~2,3. The 2-3 junction itself is the smallest one and NMR studies
indicate that this is a point of flexibility within the protein. Thus it is likely that module 2
derives little or no stabilization from module 3 and this would account for its poor
thermal stability in rVCP~2,3. A previous analysis of NMR relaxation times (Henderson
et al., 2001) showed the backbone of module 3 to be more flexible than module 2 –
despite module 3 undergoing melting at a higher temperature – so it is possible that some
of the stability of CCPs also derives from "give" in the structure that allows for local
motion without denaturation.
Overall, VCP is a protein that, unusually, combines three properties. First, it is
relatively small in terms of number of amino acid residues (and therefore is an
economically encoded protein in terms of the limited size of the viral genome). Second,
its highly elongated shape creates a large surface area that is available for binding to C3b,
C4b and proteoglycans. Lastly, as shown in the current study, it is both stable and robust,
able to tolerate a range of adverse circumstances.
The consensus sequence that defines CCP modules is found several thousand
times in the database (normally in tandem with other CCPs – solitary CCPs are rare). In
comparison to other module-types, there is an unusual degree of variation in the spacing
between the four consensus C residues, and in sequence apart from the consensus
residues themselves. This indicates that the CCP module consensus sequence provides a
highly versatile framework, tolerant of many insertions, deletions and substitutions, and it
is consistent with the observations recorded here showing the CCP scaffold to be robust.
Knowledge obtained from this study may be valuable in understanding the stability of
other CCPs. It would also be interesting to know if other non-CCP members of this large
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SCR containing family of proteins also possess the unusual ability to retain functional
activity after being subjected to extreme physical conditions. The question of whether
VCP is stable having been answered, the next question is why? One of the hallmarks of
the complement components is their heat stability up to 56°C. Our study indicates that
rVCP is at least as stable as the complement components. It is therefore possible that
their co-existence over an extensive evolutionary period has resulted in this comparable
stability. The importance of the disulfide bonds, for both stability and specific activity, is
currently being investigated.
Due to the many extraordinary activities exhibited by this protein, its use as a
novel immunomodulating agent is currently being investigated for treatment of many
complement-mediated diseases. Determining the stability of rVCP was crucial for
shipping, storage, administration, and dosage purposes as well as future proteinengineering efforts. rVCP has therapeutic potential as a means of ameliorating the
complement-mediated damage associated with many medical conditions. The findings
presented in this study may be important for future use of VCP in the treatment of many
complement mediated diseases, such as: Alzheimer's disease, restonosis, systemic lupus
erythematosus, and xenograft transplant rejections.
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CHAPTER 6
PHARMACOKINETICS OF VCP

Introduction
This chapter contains material adapted from the following manuscript:
Anderson J.B., Smith S.A., Wijk R.V., Chien S., and Kotwal G.J. Vaccinia virus
complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat
heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding
and complement pathway activation. Submitted to Transpl. Immunol., 2002.
Simply stated, pharmacokinetics is the study of the process by which a drug is
absorbed, distributed, metabolized, and eliminated by the body. Many routes of drug
administration exist, including intravenous, oral, buccal, sublingual, rectal, intramuscular,
transdermal, subcutaneous, inhalational, and topical. Ultimately, the goal of any
pharmacokinetic study is to develop a means to maintain a steady-state concentration of
the drug with rate of elimination equal to rate of administration, and the dosing rate must
equal the clearance rate times the desired plasma concentration (Carson and Jones, 1979).
Until recently, the use of proteins as potential therapeutic agents had not received much
attention. However, due to the recent advances in protein purification and recombinant
DNA techniques, pharmacokinetic studies of proteins are becoming much more common.
The most common, by far, mode of administration used in these studies is intravenous.
Unfortunately, proteins are often cleared from the blood very rapidly. This occurs most
commonly via glomerular filtration in the kidneys, and the protein is excreted in the

urine. The tendency for a protein to be eliminated from circulation by glomerular
filtration depends mainly on two factors, the size of the protein and its electrostatic
charge. Small proteins, less than 40 kDa, are often removed very rapidly. Likewise, the
glomerular barrier also discriminates according to a protein's charge (Brenner et al.,
1978). Negative charge seems to have the effect of reducing clearance of a protein via
filtration. Therefore, in order to increase the half-life of a therapeutic protein in the
blood, one must increase its size and/or negative charge. Many strategies have been
developed to accomplish this, including: addition of polyethylene glycol (PEG) chains
(PEGylation), covalent cross-linking, immunoglobulin domain fusion, and covalent
fusion with albumin.
Most of the therapeutic studies that have been published in the area of CCPs
involve the use of soluble complement receptor one (sCR1). sCR1 has been studied for
its therapeutic use in, among other things, graft rejection, arthritis, allergic
encephalomyelitis, and antigen-induced bronchoconstriction (Pratt et al., 1997; Mizuno et
al., 2000; Piddlesden et al., 1994; Regal et al., 1993). These studies used different
dosages and different routes of delivery. Early studies indicated that the effective
intraperitoneal dose, as determined by the serum CH50, was 20 mg/kg/day (Piddlesden et
al., 1994). In addition, the plasma sCR1 concentration was found to remain relatively
constant from day to day. These results indicate that this dosage would result in a
complement CH50 hemolytic activity below 5 for at least 6 days. For the transplantation
studies using sCR1, an intravenous dosage of 25 mg/kg/day was used throughout the
experimental time course (Pratt et al., 1996). Studies testing the ability of sCR1 to
reduce the severity of experimentally induced arthritis found that, in addition to a direct
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intraarticular dose, an intravenous dose of 15 mg/kg/12h was very effective (Goodfellow
et al., 2000). Taken together, it would seem that the half-life of sCR1 is relatively long;
glomerular filtration of sCR1, therefore, would appear to be low. This is most likely due
to the protein's size; possessing 20 SCRs (60-70 amino acids each), it is much too large to
be easily excreted in the urine.
Several other CCPs have been used as therapeutic agents. Soluble versions of
CD59 (sCD59), DAF (sDAF), and MCP (sMCP) have been investigated for use in
treatment of complement-mediated disease. In addition, various chimeric fusion proteins
have been created in an attempt to lengthen the serum half-life of a complement
inhibiting protein. One such experiment used a chimeric protein created by fusing the
active domains of MCP with a recombinant soluble form of the immunoglobulin
receptor, FcγRII (Lanteri et al., 2000). Results indicated that this chimera possessed a
much greater serum half-life than either of its components acting alone. Moreover, when
less than 0.5 mg of the protein was injected intravenously, it was found to block
hyperacute rejection in a mouse (wt) to mouse (Gal o/o) heterotopic xenograft model.
Until this time, there has been no data determining the pharmacokinetics of VCP
in vivo. Knowing the size and the charge of VCP, one might predict that it would very
easily be filtered by the kidneys, eliminated rapidly from the blood, and excreted in the
urine. Initial in vivo experiments utilized FITC-labeled VCP injected intravenously to
attempt to determine its localization. As expected, VCP was found to localize along the
endothelium, near to the site of injection, most likely binding to heparan sulfate present
on the endothelial cell surfaces. However, the results of this experiment did not
demonstrate the intense staining that was anticipated. The cause of this was later
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revealed when FITC rVCP was found to bind heparin much less effectively than
unlabeled rVCP – see figure 16. It seems clear that the label or the labeling process
results in a dramatic reduction in VCP's ability to bind strongly to heparin, possibly by
masking the binding sites or preventing proper folding and alignment of the sites. Using
unlabeled rVCP and staining with anti-rVCP and labeled secondary antibodies solved this
problem.
Single bolus injection studies were then conducted on live anesthetized rats.
Various dosages and delivery locations were attempted while the pharmacokinetics was
monitored by periodic collection of serum, for CH50 analysis, and urine, for CH50 and
SDS-PAGE analysis. In addition, to understand how delivery could be optimized for use
in long-term experiments, multiple or continuous injection strategies would be required.
Therefore, various multiple and continuous intravenous dosages were attempted while
serum was periodically collected for CH50 analysis. Finally, in an attempt to increase the
serum half-life of rVCP, various strategies of protein modification were attempted.
Efforts were made to covalently oligomerize rVCP, and to covalently link it to albumin,
thus, in each case making the protein larger and less likely to be eliminated by glomerular
filtration. Unfortunately, both attempts failed, either resulting in an inactive modified
protein, or an inadequate amount of dimerized rVCP.
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Materials and Methods
Single Injection Strategies:
Pharmacokinetic studies were done with the surgical help of Jaime Anderson. In
order to insure that the desired quantity of rVCP was entering the bloodstream, rVCP was
injected directly into the jugular vein of anesthetized rats (anesthetized using 55 mg/kg,
I.P., sodium pentobarbital). A small incision was made in the neck of each rat, and the
dose of rVCP was injected directly into the jugular vein making sure no leakage resulted.
The small lesion was then closed with superglue and the animal was allowed to awaken.
Blood was taken before the injection and periodically afterwards by cutting off the
extreme tip (2 mm) of the tail using a fresh scalpel blade. After the experiment was
complete, the rats made a full recovery and were used in other unrelated experiments.

Multiple and Continuous Injection Strategies:
Several methods were attempted in order to administer rVCP over an extended
time period. The first was to use an external syringe pump and inject rVCP into the
jugular vein while the rat remained anesthetized. This method, using a Harvard
Apparatus 22 syringe pump, was not practical due to the length of time the rat needed to
be anesthetized. The second method that was attempted used an implantable rodent
pump. This Harvard Apparatus implantable infusion pump was powered by an elastomer
spring and delivered a constant rate of drug delivery. The pump was implanted
subcutaneously in the rat's back, with the line running subcutaneously to the jugular vein.
Although the pump allowed the rats to awaken while being studied, because this pump
supplied a steady flow rate of only 0.12 ml/day, it was also unpractical. In order to
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deliver the amount of rVCP needed to maintain the desired level in the blood, the protein
concentration was much too high and resulted in a clogged line. Finally, an intermittent
strategy of administration was attempted. A small I.V. port was superglued externally to
the back of the rat, while the line ran subcutaneously to the jugular vein. With the rat
awake, any amount of rVCP could very easily be injected as often as desired. This
strategy was most effective, but required continuous attention.

CH50 Hemolytic Activity Assay:
To determine the complement activity of a serum sample, the complement
hemolytic activity at 50% (CH50) assay was employed. This assay greatly resembles the
hemolysis assay, however it tests the serum complement activity as opposed to testing the
ability of a protein to inhibit serum complement. Both assays use sSRBCs to accurately
quantify complement activity, or the inhibition thereof. The CH50 assay determines the
serum complement activity by identifying the quantity of a given serum needed to lyse
50% of the sSRBCs in the assay. Therefore, serially diluted serum samples were
incubated with a known concentration of sSRBCs, and the % lyses was determined by
comparing the sample to a positive control, usually water lysed sSRBCs.

Detection of rVCP in Urine:
Urine samples were collected by a 25 G urinary catheter before and after rVCP
injection. All samples were then concentrated and dialyzed against water to the same
final volume. First, the urine sample was centrifuged at 10,000 rpm, in order to pellet
contaminating bacteria and epithelial cells. Next, each sample was filtered through a 0.2
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µm syringe filter. The samples were then placed in separate centricon concentrators and
centrifuged at 7,000 rpm at 4oC. After the samples were concentrated to the same
volume (~100 µl), they were dialyzed by addition of 2 ml sterile water. Finally, the urine
samples were analyzed by hemolysis assay and visualized by SDS-PAGE and Coomassie
blue staining.

Oligomerization and Modification of rVCP:
In order to couple rVCP to BSA or to itself, standard amine coupling procedures
were used. To couple rVCP to BSA, 5 mg of BSA was suspended in 5 ml activation
buffer: 100 mM MES, 500 mM NaCl, pH 6.0. Next, 2 mg of N-ethyl-N'(dimethylaminopropyl)-carbodiimine (EDC) and 3 mg of N-hydroxysuccinimide (NHS)
were added to the solution. The solution was then allowed to incubate at room
temperature for 15 min. In order to quench the EDC, 7 µl of β-mercaptoethanol was
added to the mixture. Finally, 4 mg of rVCP was added to the solution and allowed to
incubate at room temperature for 2 hours. After the incubation period, 0.4 g of
hydroxylamine was added to reform the uncoupled carboxyl groups on the BSA. The
mixture was then concentrated and dialyzed to eliminate all remaining chemicals. The
same protocol was used to form rVCP dimers.

222

Results
Single Bolus Injection Studies:
In order to determine the half-life of rVCP in the serum of rats, various routes of
admission and dosage strategies were investigated. Starting with a relatively high dose of
3 mg (0.5 ml total bolus), preliminary intravenous (I.V.) and intraperitoneal (I.P.)
injections were attempted while the serum CH50 was monitored. As can be seem in
figure 58a, clear complement depletion is observed by 15 min following I.V. injection of
rVCP. This activity rapidly starts to decrease and the serum complement approaches
normal levels. This decrease (lack of complement activity) is not observed when rVCP is
injected into the peritoneum of the rat – see figure 58b. Only a very small amount of the
protein makes it to the serum and is detected. The inability of rVCP to enter the blood
from the tissue was also observed when a rat was injected subcutaneously with a large 24
mg/kg bolus. Very little serum complement depletion is observed by the CH50 of this
rat. The results of the above experiments determined that rVCP must be injected
intravenously to work most effectively. Therefore, in order to establish the most
effective I.V. dose, rats were injected with various bolus amounts of rVCP. The averaged
results (2 rats each) of a single dose of 3 mg/kg, 6 mg/kg, or 12 mg/kg are shown in
figure 59. A clear difference can be seen between the slopes of the CH50s for the various
doses. Thus, the rate of clearance can be effectively predicted from this data. See the
appendix for figures showing additional preliminary results of single animal studies.
The ability of rVCP to deplete serum complement was also investigated in
baboons. Due to the extreme size of this animal, large quantities of the protein must be
made and purified. Therefore, the kinetics of rVCP in baboons must be worked out using
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Figure 58. CH50 following I.V. and I.P. injection of 3 mg rVCP. A) Complement
depletion in rat injected intravenously with 3 mg rVCP. Serum complement activity at
15 min, 30 min, and 60 min is shown. Significant depletion of complement activity can
be observed. B) Complement depletion in rat injected intraperitoneally with 3 mg rVCP.
Serum complement activity at 15 min, 30 min, 60 min, and 12 hours is shown. No
depletion of complement activity is evident.
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Figure 59. Serum CH50 of I.V. injected rVCP at 3, 6 and 12 mg/kg. Two rats in each
group were administered either 3, 6 or 12 mg/kg IV of rVCP and the serum was collected
at 15 minutes intervals and assayed for CH50 as compared to serum control prior to
rVCP administration. The pharmacokinetics of rVCP in rats can be accurately deduced
by this data.
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only a few experimental animals and by comparing their data with that obtained in the rat
studies. The first baboon in the study (University of Cape Town, Cape Town, SA) was
injected intravenously with 45 mg rVCP bolus and the serum and urine were collected for
analysis. Due to the extreme size and the small amount of rVCP that was injected (~3
mg/kg), no complement activity depletion was observed at any time point, even 15 min.
The size of the I.V. dose was then increased to 9 mg/kg in hopes of seeing even a slight
decrease in CH50. Baboon 479 (15.8 kg) showed a slight drop in serum CH50 at the 15
min time point. The CH50 was reduced to 37 (37% lysis using the pre-treatment serum
dilution that resulted in 50% lysis) by 15 min, but returned to normal by the next time
point, 30 min. An additional baboon was injected with the same dose, 9 mg/kg, but was
injected using an I.V. drip. Baboon 397 (17.1 kg) received rVCP over 15 minutes in an
I.V. drip, as opposed to baboon 479 who got a single bolus. As can be seen in figure 60,
the serum CH50 of baboon 397 was much higher than that observed in baboon 479 at the
5 min time point. Baboon 397 had a CH50 of 30, while baboon 479 had a CH50 of only
5, after 5 min. This does not suggest that the single bolus injection strategy of
administration was more effective in depletion of serum complement activity, because the
drip was not completed until the 15 min time point. More animals would have to be
tested in order to confirm these results. However, the data obtained by these experiments
may be sufficient for determining the approximate clearance rate of rVCP in the baboon.
See the appendix for figures showing additional preliminary results of single animal
studies.
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Figure 60. Baboon 479 and 397 CH50 following 9 mg/kg I.V. rVCP. Serum samples
taken from baboon 397, which received rVCP in an I.V. drip, and 479, which received
rVCP as a bolus, were tested for complement activity with the CH50 assay. The CH50
was tested at time 0 and 5 min following completion of the injection. The verticle lines
represent the CH50s for pre-treatment sera.
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Multiple and Continuous Injection Studies:
To further exploit rVCP's therapeutic potential, it would have to be administered
over an extended period of time. Therefore, preliminary attempts were made to inject
rVCP I.V. continuously or intermittently for an extended time. The initial experiments
were attempted using an external syringe pump. With the rat sedated, rVCP was pumped
into the jugular vein at a continuous controlled rate, 16 mg/kg/hr was injected and blood
samples were taken 15, 30, and 60 min. This method worked well, controlling the
complement activity by maintaining the CH50 below 10. Next, an implantable pump was
used in order to allow the rat to awaken. With the pump implanted subcutaneously in the
back of the rat, the small injection line was sutured to the jugular vein. The type of pump
used had a fixed rate of drug administration. With the injection rate of the pump in mind,
rVCP was added to the pump such that a steady concentration of rVCP would be present
in the blood. First, rVCP was added to the pump such that a continuous dose of 3
mg/kg/hr would be given, following an initial bolus of 6 mg/kg. Complement activity
was initially depleted but very slowly increased over the 6-hour time course. Although
the CH50 never returned to normal levels, this demonstrates that an insufficient amount
of rVCP was being injected. Therefore, a higher dose was attempted, trying a
concentration of rVCP high enough to deliver 6 mg/kg/hr. Unfortunately, this
concentration was too high and resulted in a clogged pump line. Thus, less rVCP was
detected in the serum and resulted in a more rapid return of complement activity, as
detected by the increase in CH50 to near normal levels. Because of these experiments,
the continuous method of injection, via an implantable pump, has been set aside. A
different strategy for long-term delivery had to be worked out in order to administer large
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amounts of rVCP continuously. See the appendix for figures showing preliminary results
of single animal studies.
To deliver rVCP over extended periods of time without the aid of an implantable
pump, a catheter technique was developed. A small I.V. catheter port was fixed to the
back of the rat by superglue, and a small injection line was run subcutaneously and
sutured to the jugular vein. After an initial 6 mg/kg bolus was given, 2 mg/kg was
injected through the I.V. catheter every 20 min to sustain a concentration of 6 mg/kg/hr.
The complement activity was depleted to below a CH50 of 5 after 15 min and was held to
the same level at 6 hours. This strategy of long-term injection works well, however, it is
very time consuming and not very practical. See the appendix for figures showing
preliminary results of single animal studies.

Presence of rVCP in Urine:
In order to investigate the mannor by which rVCP is cleared from the blood,
various urine samples were taken and studied. Early animal experiments were conducted
using rVCP that was unknowingly contaminated with endotoxin, approximately 30,000
EU/ml. Urine samples obtained from the animals injected intravenously with this rVCP
revealed extremely high levels of the protein excreted into the urine. As can be seen in
figure 61a, large concentrations of rVCP can be seen in two samples taken from rats
injected with rVCP (endotoxin contaminated), but cannot be seen in the sample taken
before injection. In addition, figure 61a shows urine samples taken (taken over several
hours following injection) from rats and a baboon that received rVCP that was endotoxin
free (<10 EU/ml). There is no visible sign of rVCP in the rat samples or the baboon
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Figure 61. Presence of rVCP in urine. A) SDS-PAGE analysis of rat urine and a
baboon urine samples taken before and after administration of rVCP, contaminated with
endotoxin (lanes 1-4), or endotoxin free (lanes 5-8). rVCP marker can be seen in lanes 1
and 5. Lane 2 represents urine before rVCP was injected while lanes 3 and 4 represent
urine samples taken over 2 hours from two different rats following rVCP administration.
Again, lane 6 represents urine before rVCP was injected while lane 7 represents urine
taken for 2 hours following rVCP administration. Lane 8 shows a baboon urine sample
following rVCP administration. B) Hemolysis inhibiting activity of rat urine samples
taken before and after (for 2 hours) rVCP injection.

Also shown is the hemolysis

inhibiting activity of baboon urine after injection of rVCP. As can be seen, a significant
increase in hemolysis inhibition occurs after rVCP is injected, due to its presence in the
urine.
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sample. Finally, the rat and baboon sample were tested for hemolysis inhibiting activity.
Figure 61b shows that rat urine after rVCP (endotoxin free) was injected showed a
significantly greater degree of hemolysis inhibiting activity. This can only be attributed
to a small amount of active rVCP being present in the urine sample. The baboon urine
sample showed no sign of rVCP by SDS-PAGE analysis or hemolysis assay.

Attempts to Oligomerize and Modify rVCP:
Due to the rapid rate at which rVCP is eliminated from the blood, most likely
through glomerular filtration, attempts were made to extend the proteins half-life by
modification or multimerization of rVCP. Using standard amine coupling procedures,
rVCP was covalently conjugated to bovine serum albumin (BSA). As can be seen in
figure 62, rVCP coupled to BSA was purified away from uncoupled rVCP and uncoupled
BSA by heparin affinity purification. Coupled rVCP-BSA bound heparin with less
affinity than rVCP alone, allowing for complete separation from the unconjugated
protein. Unfortunately, when rVCP-BSA was tested for hemolysis inhibiting activity it
was found to be inactivated. Next, rVCP was coupled to itself by standard amine
coupling procedures. As can be seen in figure 62, only a slight degree of dimerization
took place. Not enough rVCP dimers were created to purify away from the uncoupled
rVCP. Therefore, dimers of rVCP could not be tested for their ability to inhibit
hemolysis in the hemolysis assay or if they could effectively increase the half-life of
rVCP in the serum.
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Figure 62.

Modification of rVCP using standard amine coupling.
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purification following the coupling of rVCP to BSA and rVCP to itself is shown by SDSPAGE analysis. Following rVCP coupling to BSA, heparin chromatography provides a
way to purify out rVCP-BSA from both uncoupled rVCP and BSA. This is due to rVCPBSA having a lesser affinity for heparin than rVCP. However, rVCP coupled to itself
can not be purified away from rVCP by this method. Thus, heparin chromatography is
ineffective and gel filtration would be the most likely alternative.
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Discussion
Initial experiments employed single bolus doses of rVCP delivered by various
routes to try to determine the best dosage and location of delivery. It was determined that
the intravenous (I.V.) route of injection was the most effective. Intraperitoneal and
subcutaneous injection strategies were attempted with poor results. It is possible that the
strong affinity that VCP possesses for heparin and heparan sulfate contributes to these
findings. When rVCP is injected into these locations, it may bind to heparan sulfate
proteoglycans on the surface of cells or to heparin containing mast cells. This could
effectively prevent rVCP from entering the blood, even at a slow rate. Although nothing
is known about what happens following rVCP binding to heparan sulfate on the surface
of cells, studies are underway using electron microscopy. If the protein is internalized,
and possibly degraded, it would result in the effect seen in the above experiments, where
it is injected into the tissue and does not affect serum complement.
Using single bolus, continuous, and intermittent strategies of I.V. injection, the
rate at which rVCP leaves the blood can be calculated relatively accurately. Using the
data presented in figure 59, for example, when 3 mg/kg is injected, the CH50 returns to
around 20 at 30 min post injection. When 12 mg/kg is injected, it takes twice the amount
of time before the CH50 reaches 20. Therefore, it takes 4 times the amount of rVCP to
double the time the protein effectively depletes serum complement activity. This data
tells us a lot about the pharmacokinetics of rVCP. Obviously, rVCP is being eliminated
from the blood at a very fast rate. By studying figure 59, it seems that half of the protein
activity is eliminated, CH50 of 25, somewhere between 6 and 12 mg/kg, closer to 6
mg/kg. Using this data one would predict that rVCP is eliminated from the blood at a
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rate of approximately 8 mg/kg/hr. Thus, rVCP would need to be administered
continuously to be effective in sustaining a low serum CH50.
The studies where rVCP was injected I.V. continuously or intermittently also give
us clues about the elimination rate of rVCP. Preliminary data shows that while the CH50
is immediately reduced by the 6 mg/kg bolus, it continues to rise despite a continuous
infusion of 3 mg/kg rVCP. This demonstrates that 3 mg/kg is not sufficient for
controlling complement levels in the blood. The study using a continuous infusion of 16
mg/kg I.V. showed extremely reduced complement activity sustained for up to an hour.
This dose was most likely "overkill" because of what was found when 6 mg/kg was
injected intermittently following a 6 mg/kg bolus. Priliminary data shows that the serum
CH50 was not only depleted at the early 15 min time point, but also at the latest time
point of 6 hours. This study indicates that in order to maintain a CH50 below 5, one
needs to continuously inject 6 mg/kg rVCP intravenously. This supports the conclusions
drawn by the bolus dose experiments, that rVCP is eliminated from the blood at a very
high rate, somewhere between 6 and 12 mg/kg/hr. It also seems likely that the level of
complement activity in the blood slowly decreases over time as rVCP is continuously
administered. Therefore, it is quite possible that lower levels of rVCP would be needed
at later time points and the dosage could be dropped.
The initial data collected from baboons injected intravenously with large bolus
doses of rVCP shows that the protein is clearly not as effective as in rodents. This data
supports conclusions drawn in chapter 4, hypothesizing that rVCP is specific for the rat
and therefore works most effectively against rat complement. Figure 60 shows the CH50
of a baboon injected with a 9 mg/kg bolus. After 15 min, the CH50 was reduced to only
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37. The same dose if it were injected into a rat, would have eliminated complement
activity, reducing the CH50 to 0 after 15 min. It takes 45 min for the complement
activity of a rat injected with only 3 mg/kg to reach CH50 of 37. This clearly
demonstrates the drastic in vivo difference in complement inhibiting activity possessed by
rVCP between rat and baboon, and probably human. To achieve the same level of
complement inhibition, one would have to inject approximately 5 times as much rVCP in
a baboon as a rat. That means to sustain a CH50 of below 5 in a baboon, one would need
to inject 30 mg/kg/hr following a 30 mg/kg bolus.
To determine the means to which rVCP is eliminated from the blood and
ultimately from the body, urine samples were collected and analyzed for traces of the
protein. Knowing that the most likely mode of elimination of a protein of this size and
charge is via glomerular filtration, large amounts of rVCP could likely be found in the
urine. Early studies of rat urine revealed that very large concentrations of rVCP was
present and could be clearly visualized by SDS-PAGE analysis. Although Western
blotting would have more conclusively proven that this was in fact rVCP, the absence of
the band in the urine before injection makes a strong case. These rats, however, received
rVCP that possessed high concentrations of endotoxin. Interestingly, urine samples
obtained from rats that received rVCP that contained no endotoxin showed very small
traces of rVCP, as detected by hemolysis assay but not by SDS-PAGE analysis. The
presence of the protein was determined, however, by testing the urine samples in the
hemolysis assay. The urine sample after injection of rVCP possessed a significant ability
to inhibit complement, when compared to a sample taken before rVCP was injected. This
not only demonstrates the presence of rVCP in the urine, but also shows that at least
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some of the protein is eliminated in an active, fully functional form. It seems however,
that the presence of endotoxin greatly increases the amount of rVCP being excreted in the
urine. This may therefore result in a decreased half-life in the serum. Fortunately, this
does not discredit the pharmacokinetic studies described above, because almost all of the
studies were performed using aliquots of the same batch of protein (16 mg/kg continuous
infusion used a different batch that was not tested, figure 65 in appendix), which was
tested and found to be nearly endotoxin free.
Due to the rapid elimination of rVCP from the blood, presumably via glomerular
filtration, attempts were made to modify the protein to increase its serum half-life. Using
standard amine coupling procedures, rVCP was covalently linked to BSA and to itself.
Unfortunately, neither attempt proved fruitful. When rVCP was linked to BSA, it was
easily purified, but possessed no activity and was thus useless. When rVCP was linked to
itself, forming rVCP dimers in only low relative amounts, the protein resembled the
monomeric protein too closely and could not be purified away from the uncoupled rVCP.
In addition, the amount of rVCP dimers created was very low relative to the
concentration of rVCP monomers. Theoretically, creating rVCP dimers should greatly
increase the protein's half-life, by making the protein near to the size of albumin, if a
method of purification could be devised, possibly using gel filtration chromatography.
Despite these failed attempts at modifying rVCP, if rVCP were to be seriously considered
for use as a therapeutic agent, efforts would have to be made to increase the protein's
serum half-life. Other than gene therapy, which could theoretically deliver a constant
dose of rVCP where it is needed, protein modification may be the best solution. As
discussed in the introduction, many methods of protein modification have been employed
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to increase a proteins half-life in the serum. One effective method that was not
investigated, although it has great potential, for use on rVCP, is PEGylation. This
method of modification is growing in popularity due to its ability to not only result in a
favorable size and charge, but also reduce the protein's antigenicity (Reddy, 2000;
Mehvar, 2000). The procedure for PEG modification of proteins is relatively
straightforward and has been described for many other proteins (Reddy et al., 2001;
Wang et al., 2000; Hershfield et al., 1987). This procedure has significantly increased
the half-life of many proteins, including several in clinical use, without affecting their
activities, although, this does not necessarily mean it will work effectively for rVCP.
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CHAPTER 7
FUTURE STUDIES OF VCP

Species Specificity Studies of rVCP and the Variola Virus Homologue
In order to investigate the species specificity of rVCP and the variola virus
homologue of VCP using Biacore and in vitro hemolysis assays, the variola virus gene
must be cloned from the viral DNA. Sergei N. Shchelkunov, a collaborator from the
Department of Molecular Biology of Genomes, State Research Center of Virology and
Biotechnology "Vector" Koltsovo, Novosibirsk Region, Russia, will PCR amplify the
gene for cloning. The primers that will be used to amplify the variola homologue of VCP
are: (sense) 5' GTA TCT CTC GAG AAA AGA TGC TGT ACT ATT CCG TCA 3'
making a Xho I restriction site and (anti-sense) 5' TTA ATT CGC GGC CGC TTA GCG
TAC ACA TTT TGG 3' making a Not I restriction site. Following gene amplification by
PCR, the amplified product will be cloned into the Pichia pastoris yeast expression
system. The same procedures and plasmids used to express rVCP (described in chapter
2) will be used for expression of variola virus VCP.
Once the variola virus homologue of VCP is in hand, the hemolysis assay will be
performed to determine whether this protein possesses greater activity against human and
baboon complement than rVCP. The hemolysis assay will also be used to determine
whether the variola virus homologue of VCP possesses less activity against rat and
mouse complement than exhibited by rVCP. The Biacore will also be used to evaluate

the strength of binding between rVCP and rat C3b or human C3b (purification and
trypsinization described in chapter 4) and evaluate the strength of binding between the
variola virus homologue of VCP and rat C3b or human C3b. The results obtained using
the hemolysis assay and Biacore binding analysis will determine whether these proteins
interact with complement in a species-specific mannor.
It has already been shown that rVCP is much more effective in blocking
rat/mouse complement than human/baboon, using the hemolysis assay (results presented
in chapter 4). It is possible that the variola virus homologue possesses greater activity
(possibly binding affinity) against human/baboon complement than rVCP. If the data
obtained from this study matches that of the preliminary data, it will not only bring up
interesting questions about host specificity but also lend valuable information for
structure-function determination of the complement binding residues. If a difference in
the proteins' binding kinetics to human or rat C3b is found, then the only twelve amino
acid dissimilarity between rVCP and the variola virus homologue of VCP will help
narrow down the important residues involved in this interaction.
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rVCP Cell Binding and Kinetic Studies Using Electron Microscopy
In order to investigate the cell binding and kinetics of rVCP, electron microscopy
(EM) will be used. Brendon Price, a collaborator from the Electron Microscope Unit,
University of Cape Town, Rondebosch, South Africa, will carry out the EM experiments.
Recombinant VCP, expressed from the Pichia pastoris yeast expression system, will be
purified by heparin affinity chromatography as described in chapter 2. Using HUVECs
grown to confluency in 6-well plates, various concentrations of rVCP will be incubated
with the cells for various time points. Following incubation, the cells will be fixed,
embedded, processed and viewed by EM. The cells will be treated with chicken antiVCP IgY primary antibody, followed by biotinylated goat anti-chicken IgG secondary
antibody and finally visualized using conjugated streptavidin-5 nm gold. The position of
the gold particles will be tracked to determine the location of rVCP, initially on the cell
surface, and possibly within the cell at a later time point. The data obtained from this
study will greatly increase our understanding of the kinetics and intracellular localization
of rVCP following its binding to cell surface heparan sulfate. This data may be useful for
increasing the serum half-life of rVCP in vivo as well as providing a basic understanding
of how the protein behaves after it is secreted from the vaccinia virus-infected cell during
the natural infection process.
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Pharmacokinetic and Xenotransplantation Studies in Baboons
To determine the pharmacokinetics of rVCP in baboons, several baboons will
receive large bolus I.V. injections and the serum CH50 will be monitored over time. The
baboons and technical assistance will be provided by Professor Del Kahn, head of the
Surgical Transplant Service, University of Cape Town, Rondebosch, South Africa. As
described in chapter 2, rVCP will be expressed and purified by heparin affinity
chromatography. The kinetics of rVCP in the serum, determined by CH50, will be
compared to that observed in the rat studies (see chapter 6). The dosage of rVCP
required to maintain a serum CH50 below 10 for an extended time (possibly several
weeks) will be determined using the data collected. The dosage of the variola virus
homologue of VCP required to maintain a serum CH50 below 10 will also be evaluated,
once it is cloned and produced. An internal I.V. pump will be purchased and used to
continuously deliver the required quantity of VCP for the desired time. Once a
satisfactory rVCP regimen and delivery strategy is achieved, pig to baboon
xenotransplants can be attempted. Pig livers will be transplanted into baboons, with and
without rVCP. Organ survival, histology and immunohistochemistry (for VCP, C3, and
IgM) will be used to evaluate the efficacy of rVCP in blocking hyperacute rejection.
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C3b/rVCP and Heparin/rVCP Co-crystallization Studies
Dr. Jamie Rossjohn, St. Vincent's Institute of Medical Research, Fitzroy,
Australia will perform the co-crystallization of rVCP and C3b. C3 will be purified from
human serum and partially trypsinized to form C3b, as described in chapter 4.
Recombinant VCP will be produced using the Pichia pastoris yeast expression system
and purified to nearly 100% by repeated heparin affinity chromatography (described in
chapter 2). The resulting crystal structure will provide conclusive results about the
residues involved in rVCP binding to C3b. These results will determine whether the
complement binding residues defined by the hemolysis assay, SPR binding analysis, and
homology with MCP, do in fact play a role in this interaction.
Dr. Krishna Murthy from the Center for Biophysical Science and Engineering,
University of Alabama at Birmingham, who performed the X-ray crystallography of
rVCP, will conduct the co-crystallization of rVCP and heparin. Again, rVCP will be
expressed using the Pichia pastoris yeast expression system and purified to nearly 100%
repeated heparin affinity chromatography (described in chapter 2). Using low molecular
weight heparin, approximately 5 kDa molecular size (Sigma), rVCP will be cocrystallized with heparin. The resulting structure will provide conclusive results about
the residues involved in rVCP binding to heparin. This will determine whether the
heparin binding sites defined by chromatography, SPR binding analysis, and homology
with FGF, do in fact play a role in this interaction.
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C3b/rVCP and Heparin/rVCP Binding Kinetics Using Biacore
Biacore kinetics analyses between C3b and rVCP, as well as Heparin and rVCP
will be performed in collaboration with Dr. Shrihari Arjunwadkar, from the Department
of Microbiology, Division of Virology, University of Cape Town, South Africa. With
C3b immobilized to the surface of a CM5 sensor chip, various concentrations (0.5 - 50
nM) of rVCP will be passed over the surface and binding will be measured. The binding
plots will be overlaid and fit using the BIAevaluation software package. The software
will determine the Ka and Kd of this interaction automatically. Similarly, with low
molecular weight heparin immobilized to the surface of a sensor chip, various
concentrations (0.5 - 50 nM) of rVCP will be injected and binding will be measured.
Again, the binding plots will be overlaid and fit using the BIAevaluation software
system. Again, the software will determine the Ka and Kd of this interaction
automatically. The association and disassociation constants for rVCP binding to
complement and heparin may provide very useful insights into these interactions. By
studying the kinetics of mammalian complement control proteins, knowledge about the
evolutionary history and the potency of VCP can be learned.
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Identification of C3 Fragments Involved in rVCP Binding Using Biacore
In collaboration with Dr. Seppo Meri from the Haartman Institute, University of
Helsinki, Finland, surface plasmon resonance analysis will be used to identify the regions
of C3 involved in binding rVCP. Human C3 will be purified from human serum as
described in chapter 4. The C3b fragment of C3 will be produced from partial
trypsinization, as described in chapter 4. The C3c fragment will be purified using C3 and
Activated Thiol Sepharose 4B (Pharmacia) as described previously (Jokiranta et al.,
2001). Lastly, the C3d fragment of C3 will be generated and purified from C3 using a
procedure described previously (Jokiranta et al., 2000). SPR binding studies will be
performed using a Biacore 2000 instrument and the data will be analyzed using the
BIAevaluation software package. C3 and each of the C3 fragments, C3b, C3c, and C3d
will be immobilized to the surface of a CM5 sensor chip using standard amine coupling
procedures described in chapter 4. Various concentrations of rVCP, expressed and
purified by heparin affinity chromatography, will be injected over the surface of each
sensor chip to determine whether binding occurs. The ability of rVCP to bind, as well as
the relative strength of the binding, to C3 or the fragments of C3 will help identify the
region(s) within C3 required for this interaction to occur.
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Protein Engineering and Use of VCP as an Immunomodulatory Agent
Complement has been shown to play an important role in many inflammatory
conditions, such as Alzheimer's disease, rheumatoid arthritis, CNS injury and
xenotransplant rejection. In hopes of developing a therapeutic agent for use in treating
such conditions, various complement-inhibiting proteins have been studied extensively
for many years. There have been proteins identified that are capable of blocking the
complement cascade at nearly every step, from C1 (C1-Inhibitor) to the assembly of the
membrane attack complex (sCD59), and a few proteins that can block at multiple steps
(sCR1). Many of these are membrane bound mammalian proteins used to prevent
unwanted complement activation and tissue destruction in the absence of an invading
microorganism. In order to use them as a therapeutic agent, however, their
transmembrane domain is removed and the protein expressed in a soluble form. These
soluble proteins are often very affective in blocking complement, both in vitro as well as
in vivo. However, the soluble mammalian complement control proteins are very large,
generally consisting of 20 SCRs or more (>150 kDa molecular size). VCP is the smallest
known complement regulatory protein, possessing a similar function as exhibited by
sCR1. In addition, VCP expands its repertoire of functions by including heparin binding
sites, making it both small and multifunctional.
It has been shown previously that VCP exhibits greater potency in inhibiting
complement than an equal concentration of C4b-BP (Kotwal, 1994). This shows that the
small structure of VCP may improve its ability to bind the complement components C3b
and C4b, thus improving its ability to block complement. By determining the residues
involved in this interaction with complement, a better understanding of the structural
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basis for this potency may be acquired. With the residues involved in both binding
complement and facilitating its cleavage to an inactivated form by factor I determined,
the structure of a complement inhibitor even smaller and possibly more potent than VCP
may be created by protein engineering. A short protein backbone can be created to
display these critical residues in the specific spatial orientation displayed in VCP,
required for complement binding. With the size of the complement inhibitor reduced,
absorption into the blood may become possible, allowing for I.P., SubQ, or I.M.
administration to be effective. In addition, if the synthetic protein can be made small
enough, it may be able to pass across the blood brain barrier into the cerebral spinal fluid.
With this being possible, damaging inflammation mediated by complement activation
shortly following CNS injury may be modulated, perhaps resulting in significant neuronal
sparing and return of neurological function.
The heparin binding ability of VCP endows it with many extremely novel
functions, including the ability to block chemokine induced monocyte migration and
preventing molecular and cellular interactions with cells. Knowing the amino acids and
their spatial orientations involved in VCP's ability to bind heparin may someday allow for
the development of a short synthetic peptide, able to retain the novel functions displayed
by VCP. This synthetic peptide may be ten amino acids or less, and still maintain the
ability to bind heparin and heparan sulfate proteoglycans, allowing for steric interference
with unwanted molecular and cellular interactions with cells. A synthetic peptide with
this immunomodulatory ability could have therapeutic uses for preventing molecular and
cellular mechanisms of graft rejection or even autoimmune diseases. It could prove
valuable in prolonging survival of xenografted organs by inhibiting cellular mechanisms
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of graft rejection associated with accelerated rejection and acute cellular rejection
processes. The immune modulating ability that would be displayed by this peptide may
be able to suppress an autoimmune reaction in diseases such as rheumatoid arthritis,
systemic lupus erythematosus, and multiple sclerosis. However, there is no indication of
how long the peptide would be effective or if any side effects would result from extended
use.
By using the complement and heparin binding regions identified within VCP,
small synthetic therapeutic proteins, created by protein engineering, may be developed
for use against many complement-mediated conditions. This strategy would be less
complex when designing a synthetic heparin binding peptide, and much more
complicated when creating a synthetic complement binding protein. Due to the fact that
residues involved in binding complement are spread throughout nearly the entire length
of VCP, it seems very likely that the vaccinia virus has already reduce the protein to its
smallest functional unit. It would therefore be exceedingly difficult to further reduce the
number of amino acids making up the protein. Spatially, four SCRs may be the minimal
requirement for binding C3b and C4b, and facilitating their cleavage by factor I. If this
were in fact the case, VCP would remain a likely candidate for therapeutic use in
blocking the harmful effects of complement seen in many inflammatory diseases.
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Figure 63.

Rat serum CH50 following 24 mg/kg SubQ bolus.

Following a

subcutaneous bolus dose of 24 mg/kg, the complement activity was monitored
periodically by CH50 assay. The CH50 was measured every half-hour for four hours.
As can be seen, no evident change in complement activity is evident. The verticle black
line represents CH50.
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Figure 64. Baboon 479 CH50 following 9 mg/kg I.V. bolus. Serum samples were
tested for complement activity by CH50 assay. CH50 activity was determined for 15
min, 30 min, 60 min, and 120 min. As can be seen, only a slight decrease in complement
activity can be seen after 15 min. The verticle black line represents CH50 for pretreatment serum.
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Figure 65. Rat serum CH50 following continuous 16 mg/kg/hr via catheter. A rat
was administered rVCP at 16 mg/kg/hr by continual infussion and the serum CH50 was
evaluated at 15 minute intervals for one hour. The verticle black line represents CH50
for pre-treatment serum.
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Figure 66.

Rat serum CH50 following 6 mg/kg I.V. + 3 mg/kg/hr via pump.

Following the bolus injection, serum CH50 was assayed at 15 min and every hour for 6
hours. As can be seen, the initial CH50 was reduced to near 0, but slowly returned
toward normal levels. The verticle black line represents CH50 for pre-treatment serum.
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Figure 67.

Rat Serum CH50 following 6 mg/kg I.V. + 6 mg/kg/hr via pump.

Following the bolus injection, serum CH50 was assayed at 15 min and every hour for 3
hours. The initial CH50 was reduced to near 0, but quickly returned toward normal
levels.

This was attributed to clogging of the injection line from using too high a

concentration of rVCP. The verticle black line represents CH50 for pre-treatment serum.
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Figure 68. Rat Serum CH50 following 6 mg/kg I.V. + 6 mg/kg/hr via catheter.
Following the bolus injection, serum CH50 was assayed at 15 min and at 6 hours. The
CH50 was reduced to near 0, and remained that way for at least 6 hours. The verticle
black line represents CH50 for pre-treatment serum.
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